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E-cigarettes are popular and effective smoking cessation aids, but there are concerns 
about the consequences of their use. Specifically, young people who have never smoked 
before may use e-cigarettes and this may lead to smoking initiation. Additionally, there 
are fears that long-term e-cigarette use may cause health issues.  
To fully understand the potential impact of e-cigarette use and to inform policy, it is vital 
to understand who uses e-cigarettes, why, and what the potential consequences of use 
are – questions which are explored in this thesis. To investigate the likely harms of 
e-cigarette use, I have used novel methods to explore whether e-cigarettes may act as a 
gateway to smoking and explore what the health consequences of e-cigarette use may 
be.   
First, I conducted a meta-analysis of studies exploring whether e-cigarette use acts as a 
gateway to smoking among young people. Second, I explored which young adults are 
most likely to vape and whether different reasons for vaping are associated with 
continued smoking. Third, I explored whether there is a shared genetic liability for 
smoking initiation and e-cigarette use in a cohort of young adults. Fourth, I investigated 
whether nicotine use without exposure to cigarette smoke (e.g., via e-cigarettes) may 
cause smoking-related poor health outcomes using a variety of Mendelian 
randomisation methods in a cohort of adults. Finally, I began to explore the relationship 
between nicotine and BMI in an experimental study of adults. 
Overall, I found little evidence that e-cigarettes act as a gateway to smoking, however, 
smokers and vapers share common characteristics and may share a genetic 
predisposition to risk-taking. There was little evidence of nicotine use causing poor 
health outcomes without tobacco smoke exposure. The evidence suggests policies 
should encourage smokers to switch to vaping. Further research is needed to explore 
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Chapter 1 Introduction  
1.1 Chapter Overview 
Over the past decade, e-cigarettes have become extremely popular; in the UK alone 
there are currently an estimated 3.6 million users (Action on Smoking and Health, 
2019a). Alongside this growing popularity, concerns about the safety and unintended 
consequences of use (particularly among young people) have also grown (Besaratinia & 
Tommasi, 2019). Despite evidence indicating that e-cigarettes are less harmful than 
cigarettes (Public Health England, 2015) and evidence suggesting they can aid smoking 
cessation (Hajek et al., 2019; Hartmann-Boyce et al., 2020), fears have arisen regarding 
the use of e-cigarettes by young people who have never smoked before.  
E-cigarette users who have never smoked before appear to be at increased likelihood of 
subsequently smoking at least once in the future (Soneji, Barrington-Trimis, Wills, 
Leventhal, et al., 2017). However, it is unclear whether this association is causal. 
Furthermore, the extent to which these individuals are at greater risk is unclear due to 
heterogeneity between study effect estimates, low sample sizes, measurement 
limitations and inadequate control for potential confounders within the available studies 
(Glasser, Abudayyeh, Cantrell, & Niaura, 2018). It is important to understand which 
individuals use e-cigarettes, why, and how this may impact on behaviour in order to 
assess the potential consequences of use, such as smoking initiation, smoking 
continuation, or poor health outcomes. This understanding is necessary to determine 
whether cautious policy approaches (e.g., bans) are appropriate and could also help to 
inform public health strategies. 
Although e-cigarettes contain far fewer, and lower levels of, the harmful toxicants and 
chemicals found in cigarettes (Goniewicz et al., 2014), the long-term health 
consequences of using e-cigarettes are currently unknown. As e-cigarettes are a 
relatively new product, it is impossible to observe the long-term effects of e-cigarette 
use. Instead, innovative methods are needed to explore the long-term effects without 
waiting decades for health outcome data to become available. Understanding the 
potential health effects of long-term e-cigarette use could help guide public health 





that e-cigarettes are equally or more harmful than cigarettes (Action on Smoking and 
Health, 2019a; Gravely et al., 2020). 
The aim of this thesis is to understand which individuals are more likely to use 
e-cigarettes, why they use e-cigarettes, and what are the potential implications of 
e-cigarette use both in terms of continued use, the effect on smoking and health 
effects? I apply novel methods in the context of e-cigarette research – including using 
multivariable Mendelian randomisation and negative controls – to address these aims. 
Where possible, I focus on the association and effects among young adults (up to and 
including 30 years of age). 
1.2 E-cigarettes 
1.2.1 E-cigarette Terminology and Basic Function  
E-cigarettes are known by a variety of names (e.g., electronic cigarettes, e-cigs, vapes, 
vape pens, vaporisers, mods, pods, JUULs, Electronic Nicotine Delivery Systems [ENDS], 
Alternative Nicotine Delivery Systems [ANDS]). The use of e-cigarettes can also be 
referred to as vaping or Juuling (among other terms). E-cigarettes are electronic devices 
which were introduced onto the UK market in 2007 (House of Commons Science and 
Technology Committee, 2018). They operate by heating a solution, often referred to as 
e-liquid or e-juice, which creates a vapour that can be inhaled via a mouthpiece. For the 
purposes of this thesis, I refer to these products as e-cigarettes, describe the use of 
these products as ‘e-cigarette use’ or ‘vaping’, and I refer to the solution as e-liquid.  
1.2.2 Constituents of E-cigarette Vapour 
E-cigarettes were originally marketed as a smoking cessation device because 
e-cigarettes can contain nicotine (the addictive component of cigarettes), but contain far 
fewer chemicals and toxicants (Goniewicz et al., 2014; Goniewicz et al., 2018). The 
chemicals and toxicants that are included in e-cigarettes are generally found at much 
lower levels than are found in cigarettes (Goniewicz et al., 2014). E-cigarettes are filled 
with e-liquid, which usually contains nicotine, flavours, and vegetable glycerin or 
propylene glycol (or a mixture of both), however, nicotine-free and unflavoured options 
are available. Nicotine can be in the form of a freebase solution or in the form of salts; 





chemical substance, such as ammonia, to free the nicotine base and create a purer form 
of nicotine – freebase nicotine (Gholap, Heyder, Kosmider, & Halquist, 2020). In 
e-cigarettes, nicotine salts can deliver high concentrations of nicotine to the user with 
less irritation than a freebase solution (Bowen & Xing, 2015). The flavourings included in 
e-liquids vary between products, and consequently the extent to which the resulting 
e-cigarette vapours are potentially harmful also varies; although the flavours are safe for 
oral consumption, there is often little evidence on the safety of these ingredients when 
heated and inhaled. In particular, cinnamon flavouring (created by adding 
cinnamaldehyde) has been shown to act as a respiratory irritant and is toxic when 
inhaled (Behar et al., 2016).  
1.2.3 Generations of E-cigarettes 
Over the past decade or so, e-cigarettes have developed rapidly in order to adapt to the 
needs of the consumer, resulting in four generations of e-cigarette (Figure 1.1). The first 
generation of e-cigarettes (also known as “cigalikes”) are similar in appearance to 
cigarettes but, for many users, deliver insufficient nicotine compared to cigarettes 
(Farsalinos et al., 2014). These devices can be disposable or rechargeable and can be 
refilled with prefilled cartridges. The second generation of e-cigarettes are pen-style – 
they deliver nicotine slightly better than first generation e-cigarettes. These devices are 
rechargeable and can be refilled with e-liquid. The third generation include ‘mods’ 
(modifiable devices), tank-style devices, and rebuildable dripping atomisers which allow 
users to modify their devices (e.g., by modifying the voltage) to suit their needs. These 
devices are also rechargeable and can be refilled with e-liquid. The latest devices are 
known as ‘pods’; pods are small (sometimes similar in appearance to a USB) but 
powerful devices that deliver nicotine as effectively as cigarettes using salt-based 
nicotine rather than freebase nicotine (Bowen & Xing, 2015). Nicotine delivery can also 
differ within each generation of e-cigarettes due to a range of factors, including the 
concentration of nicotine in the e-liquids used, atomiser resistance, wattage and user 












Figure 1.1. Appearance of varying e-cigarette types. 
 
  





1.2.4 E-cigarette Policy 
Due to safety concerns, e-cigarettes have been banned in a number of countries, 
including Australia and India (Chakma, Kumar, Bhargava, & Khanna, 2020; Gartner & 
Bromberg, 2019). In countries where e-cigarettes are not banned (e.g., the UK), there 
are often restrictions placed on the design and marketing of products. In the UK, 
e-cigarettes are currently regulated under the European Union Tobacco Products 
Directive (TPD). However, with the UK’s exit from the European Union and the transition 
period ending soon, these regulations could be subject to change in the near future. At 
present, e-cigarettes have to be registered prior to sale (with a full list of ingredients and 
safety profile), e-liquid bottles must be child-proof and not exceed 10 ml, and nicotine 
concentrations cannot exceed 20 mg/ml of nicotine (Tobacco Products Directive, 2014). 
These regulations are stricter than in the US. Many countries have age restrictions on 
purchasing e-cigarettes – in the UK the minimum age of sale is 18 years of age, and 
federal law in the US prohibits the sale of tobacco products (including e-cigarettes) to 
those under 21 years of age. 
Although e-cigarettes were originally marketed as a smoking cessation device, many 
countries now prohibit or restrict the advertising of e-cigarettes as cessation products. 
For example, the UK have placed restrictions on which devices can claim they are 
smoking cessation aids; only devices which are licensed as medicines by the Medicines 
and Healthcare products Regulatory Agency (MHRA) can make claims about smoking 
cessation. Currently, there are no available devices which are medically licensed. 
1.3 E-cigarette Use and Smoking 
1.3.1 Smoking Cessation 
In a meta-analysis which aimed to evaluate the safety and effectiveness of using 
e-cigarettes to quit smoking (Hartmann-Boyce et al., 2020), there was 
moderate-certainty evidence to suggest that e-cigarettes can aid long-term smoking 
cessation (more than 6 months) compared with nicotine replacement therapy (N = 1,498 
participants, risk ratio = 1.69, 95% CI 1.25 to 2.27) by Grading of Recommendations, 





(https://gdt.gradepro.org/app/handbook/handbook.html). This equates to an additional 
four successful quitters per 100 attempts. 
Of the three randomised controlled trials included in the meta-analysis (all of which 
were low risk of bias), only one was conducted in the UK. In a randomised controlled 
trial of 886 attendees of UK NHS stop smoking services, Hajek and colleagues (2019) 
found that when combined with behavioural support, e-cigarettes were more effective 
for smoking cessation than nicotine replacement therapy. Of those randomly assigned 
to the e-cigarette arm of the study (who received an e-cigarette starter kit), 18% were 
abstinent at 1 year follow-up, whereas only 9.9% of those assigned to the nicotine 
replacement therapy group (who received a 3-month supply of nicotine replacement 
therapy as per standard treatment) were abstinent at 1 year follow-up. 
A partially double-blind randomised controlled trial comparing nicotine containing 
e-cigarette use, nicotine-free e-cigarette use or no e-cigarette use (all in combination 
with individual counselling) is also in progress in Canada, and was due to complete data 
collection (with a target sample of 376 smokers who are willing to quit) in September 
2020 (Hébert-Losier, Filion, Windle, & Eisenberg, 2020). Double-blinding was only 
possible for treatment allocation in the e-cigarette groups. Another double-blind 
randomised controlled trial comparing nicotine containing e-cigarettes to e-cigarettes 
without nicotine, and varenicline – a prescription drug which reduces cravings for 
nicotine and blocks the rewarding and reinforcing effects of smoking (West, Baker, 
Cappelleri, & Bushmakin, 2008) – is being conducted in France with 635 smokers who 
are willing to quit (Berlin et al., 2019). The growing evidence base should provide a 
clearer indication of the extent to which e-cigarettes are effective as a smoking 
cessation aid, but the current evidence suggests that nicotine containing e-cigarettes are 
an effective smoking cessation tool. 
1.3.2 Observed Longitudinal Associations between Smoking and Vaping 
With the potential e-cigarettes have to act as a smoking cessation tool, it would be 
logical to assume there is a strong association between smoking and later vaping. As 
expected, East and colleagues (2018) found that ever smoking young people in the UK 
are 3.54 times more likely to subsequently vape than never smokers. Biochemically 





subsequently vape in young adulthood (Khouja, Munafò, et al., 2020). However, there 
also appears to be a strong association between vaping and later smoking; young people 
who were ever vapers but never smokers were found to be approximately 12 times 
more likely to subsequently smoke (East et al., 2018). 
A meta-analysis exploring the association between vaping among never smokers and 
subsequent smoking also found a strong positive association; adolescents and young 
adults were 3.5 times more likely to subsequently smoke (Soneji, Barrington-Trimis, 
Wills, Leventhal, et al., 2017). This suggests that there may be a causal influence of 
e-cigarette use on later smoking among never smokers. However, in their review of the 
impact of e-cigarette use on smoking, Glasser and colleagues (2018) highlighted that 
many of the studies included in the meta-analysis were at risk of bias, and there was 
also moderate heterogeneity between study estimates. Many of the included studies 
were based on a small number of e-cigarette users (Primack, Soneji, Stoolmiller, Fine, & 
Sargent, 2015) and used inappropriate methods (i.e., assessed experimental smoking 
rather than established smoking and did not adequately control for potential 
confounding). Therefore, it is misleading to draw any clear conclusions regarding 
causality from the findings of Soneji and colleagues (2017). There has been considerable 
discussion of potential explanations for the observed associations between e-cigarette 
use and smoking; for example, it has been proposed that vaping may normalise smoking, 
act as a gateway to smoking, or share a common liability with smoking (Chapman, 
Bareham, & Maziak, 2019; Etter, 2018; Sæbø & Scheffels, 2017). Each of these are 







Figure 1.2. Diagrams to show the potential mechanisms (normalisation [a], gateway 
effect [b] or common liability [c]) of the association between e-cigarette use among 
never vapers and later smoking. 
 
1.3.3 Normalisation  
Concerns have been raised over the potential implications of e-cigarette use on an 
individual and societal scale (Sæbø & Scheffels, 2017). One such concern is that the 
presence of e-cigarettes in public areas, particularly where it is illegal to smoke but not 
to vape, may encourage smoking by normalising the behaviour (Fairchild, Bayer, & 
Colgrove, 2013; Stanwick, 2015). Arguably, seeing individuals vape in public may 
normalise nicotine addiction and frame smoking as a socially acceptable behaviour 
because the behaviours are similar in appearance (i.e., a hand to mouth action followed 
by a visible exhalation of smoke/vapour). On an individual level, if a non-smoker sees 
vaping or nicotine addiction as normal and acceptable, they may be more likely to start 
vaping; they may also see the act of smoking as more normal due to the similarities with 
vaping and thus be more likely to experiment with smoking too (Sæbø & Scheffels, 
2017). However, there is little evidence to support the normalisation of smoking among 
young people in Great Britain; smoking rates continued to decline after the introduction 
of e-cigarettes despite a marginal slowing in the rate of decline for regular smoking 
between 2010 and 2015, when e-cigarettes were widely available but unregulated 
(Hallingberg et al., 2020). Furthermore, over the same time period there was an 
acceleration in decline of acceptability with regards to smoking (i.e., young people were 
increasingly less likely to believe it was OK to smoke). Additionally, qualitative evidence 
suggests there is limited support for e-cigarette use renormalising smoking among 
young people in Great Britain (Brown et al., 2020). Given the current evidence suggests 
that it is unlikely that normalisation of smoking can explain the relationship between 
e-cigarette use and later smoking, I focus on alternative theories in this thesis. 
1.3.4 The Gateway Hypothesis 
Another theory which has been proposed as a potential explanation for the strong 
association between vaping among never smokers and subsequent smoking is that 
vaping acts as a gateway to smoking (Bell & Keane, 2014; Chapman et al., 2019; Etter, 





explain patterns of recreational drug use (Vanyukov et al., 2012). The original hypothesis 
referred to the use of a ‘soft’ drug (e.g., cannabis) leading to the use of a ‘hard’ drug 
(e.g., heroin), with three main principles; 1) the ‘soft’ drug exposure occurs prior to the 
use of the ‘hard’ drug, 2) there is an increased risk of subsequent ‘hard’ drug use among 
‘soft’ drug users compared to non-users, and 3) there is a dose-response relationship 
whereby the more an individual uses the ‘soft drug’, the more likely they are to use the 
‘hard’ drug (Vanyukov et al., 2012). Many have applied this hypothesis to the 
relationship between e-cigarette use and later smoking whereby e-cigarette use is 
considered to be the ‘soft’ drug and cigarettes are considered to be the ‘hard’ drug. 
Although both products (can) deliver nicotine, cigarettes are considered ‘hard’ due to 
the other constituents of tobacco smoke which are not present in e-cigarettes and due 
to the known harms of smoking. 
Proponents of the gateway effect often claim that the effect is attributable to nicotine 
addiction (Bell & Keane, 2014). Historically (i.e., among older generation devices), 
e-cigarettes have not delivered nicotine as effectively as cigarettes (Farsalinos et al., 
2014); therefore, some e-cigarettes may not be adequate to satisfy users who become 
more heavily addicted to nicotine. Consequently, addicted users may transition to 
smoking in order to satisfy their needs. However, newer generations of e-cigarettes can 
deliver similar levels of nicotine (Bowen & Xing, 2015), so this hypothesis may not be 
sufficient to explain why users of newer devices may transition to smoking. 
Alternatively, these newer generation devices may increase the likelihood of developing 
nicotine dependence (as they deliver such high doses of nicotine), which may increase 
the likelihood of users smoking if users need to satisfy their nicotine addiction by any 
means but cigarettes are more available than e-cigarettes. 
Despite a lack of consideration of nicotine contents in the studies included in Soneji and 
colleagues’ (2017) meta-analysis, Soneji and colleagues concluded that there were 
several aspects of the association between e-cigarette use and later smoking that 
suggested a causal effect (e.g., a gateway effect). However, Soneji and colleagues (2017) 
did not stratify by risk of study bias, which was high for many of the included studies 
(Glasser et al., 2018). This is important because the preconceptions of study authors 
may also consciously or unconsciously influence how studies are designed and 
conducted, and this may be reflected in a study’s conclusions. For example, two studies 





the pooled odds ratios not differing substantially from each other; Leventhal and 
colleagues (2015) concluded there was insufficient evidence to support the gateway 
hypothesis, whereas Miech and colleagues (2017) concluded that there was a one-way 
bridge from e-cigarette use to smoking. 
1.3.5 The Common Liability Theory 
An alternative theory which is sometimes used to explain the association seen between 
e-cigarette use (among never smokers) and subsequent smoking is the common or 
shared liability theory (Etter, 2018). Proponents of the common liability theory suggest 
that people who use multiple drugs (or in the case of e-cigarettes and cigarettes, 
different delivery methods of the same drug – nicotine) share the same predisposing 
factors (Chapman et al., 2019). When considering a causal relationship between 
e-cigarette use and later smoking (e.g., the gateway hypothesis), these shared 
factors/confounders (i.e., common liabilities) should be taken into account. Often the 
studies included in the Soneji and colleagues (2017) meta-analysis, failed to sufficiently 
adjust for potential confounders (Glasser et al., 2018) meaning the association found 
may be due to shared factors which influence the likelihood of engaging in both 
behaviours. I explore this further in Chapter 2. 
1.4 Demographics of E-cigarette Users 
Given that the relationship between e-cigarette use and smoking could be due to a 
shared liability, it is vital to observe the demographics of e-cigarette users. Previous 
evidence indeed suggests that e-cigarette users differ in terms of sex, income, 
socioeconomic position, smoking history, and age compared to non-users. 
1.4.1 Sex 
Using nationally representative data from the Tobacco Use Supplement of the Current 
Population Survey for the United States (US), Levy and colleagues (2017) found a higher 
proportion of men in the US have ever used e-cigarettes compared with women (8.6% 
and 7.0% respectively). Men are also more likely to currently (in the past 30 days) and 
regularly (20 or more times in the past 30 days) use e-cigarettes than women in the US 
(current use: 2.3% and 1.9% respectively; regular use: 1.1% and 0.8% respectively). 





males in the European Union are also more likely to ever use e-cigarettes than females 
(Filippidis, Laverty, Gerovasili, & Vardavas, 2017), and in a cross-sectional study in 
Malaysia, sex differences are observable to a greater degree, where 18.1% of male 
respondents were e-cigarette users compared to 0.4% of female respondents 
(Perialathan et al., 2018).  
In a systematic review observing differences in e-cigarette use between 
sociodemographic groups, there were no clear differences between males and females 
in terms of ever use in two high-quality studies – one observing children in Wales and 
one observing adults in the US (Hartwell, Thomas, Egan, Gilmore, & Petticrew, 2017). 
However, four out of five medium-quality studies (conducted in Poland and the US) 
showed that men were more likely to have ever used e-cigarettes than women and 
three out of four studies (conducted in the US, Poland and South Korea) showed men 
were more likely to currently use e-cigarettes (Hartwell et al., 2017). Combined, these 
results suggest that men may be more likely to vape than women. 
1.4.2 Income and Socioeconomic Position 
The association between e-cigarette use and income is less clear. For example, US adults 
who quit smoking more than 3 years ago or have never smoked are more likely to have a 
lower income if they regularly vape, whereas those who have smoked within the past 3 
years are more likely to regularly vape if they have a higher income (Levy et al., 2017). 
Among Europeans in the adult Special Eurobarometer for Tobacco survey, there is weak 
evidence to suggest that ever e-cigarette users are more likely to experience financial 
difficulties; however, there is no clear evidence to suggest that regular users are more 
likely to experience financial difficulties (Filippidis et al., 2017). Data from the 
International Tobacco Control (ITC) Four-Country Survey of adults in the US, Canada, 
Australia, and the UK showed that higher income was associated with ever vaping 
(particularly in the US and UK), but not current vaping (Adkison et al., 2013).  
Income is often used as a proxy for socioeconomic position, alongside education and 
occupation (Galobardes, Shaw, Lawlor, & Lynch, 2006a, 2006b). A systematic review 
observing differences in e-cigarette use by sociodemographic groups found that levels of 
association between socioeconomic factors and e-cigarette use vary between and within 





occupation and e-cigarette use, but ever e-cigarette use was frequently associated with 
higher educational levels (Hartwell et al., 2017). Data from the US Legacy Longitudinal 
Smoker Cohort Study suggest that those in higher socioeconomic groups (i.e., higher 
educational level) in the US are more likely to vape, but there was no clear evidence of 
this association in an online survey (Pearson, Richardson, Niaura, Vallone, & Abrams, 
2012).  
Socioeconomic disadvantage (i.e., lower socioeconomic position based on educational 
level, occupational status and net income), is associated with increased likelihood of 
current vaping among never smoking youth and adult ex-smokers but not adult never or 
current smokers in the UK (Green, Gray, Sweeting, & Benzeval, 2020). Additionally, 
evidence from a national cross-sectional UK survey of current adult smokers and adult 
smokers that recently quit (within the past year) suggests that higher socioeconomic 
position (assessed using the occupation-based National Statistics Socio-Economic 
Classification) is associated with higher likelihood of current e-cigarette use among 
current smokers only (Brown et al., 2014). Where smoking history is taken into account 
in studies exploring the association between socioeconomic position and vaping, the 
association appears to be mediated by smoking history (Brown et al., 2014; Green et al., 
2020; Levy et al., 2017). 
1.4.3 Smoking History 
In a cross-sectional study, Levy and colleagues (2017) found that US smokers and 
ex-smokers who had quit in the last 3 years were more likely to have ever vaped than 
non-smokers or ex-smokers of more than 3 years. Current and regular vapers were also 
less likely to be current smokers compared with ever vapers (Levy et al., 2017). Using ITC 
study data, Adkinson and colleagues (2013) found that non-daily smokers in the US, UK, 
Australia and Canada were more likely to have tried e-cigarettes, and long-term 
ex-smokers were less likely to have tried e-cigarettes than daily smokers (≤ 20 cigarettes 
per day). Heavy smokers (who smoked 20 or more cigarettes per day) and non-daily 
smokers were more likely to currently vape than respondents who were daily smokers 
(≤ 20 cigarettes per day). Similarly, in the UK, Brown and colleagues (2014) found that 
smoking a higher number of cigarettes per day and having attempted to quit smoking in 





As previously discussed, young people in the UK who are ever smokers are also more 
likely to subsequently vape than never smokers (East et al., 2018). In a longitudinal, 
3-wave study of Canadian youth, infrequent and frequent smokers at wave 1 were more 
likely to be dual users (using both cigarettes and e-cigarettes) at waves 2 and 3 
compared to non-smokers (Aleyan, Hitchman, Ferro, & Leatherdale, 2020). Yet Bold and 
colleagues (2018) used autoregressive cross-lagged models to explore the relationship 
between current smoking and current e-cigarette use and found no clear evidence that 
smoking is associated with later e-cigarette use among high school students in 
Connecticut (US). Importantly, this model did not account for regular use of either 
product (prior to wave 1 or between waves), which could be problematic if there are age 
specific factors which influence use of each product differently (i.e., if smoking initiation 
is more likely to occur at a younger age than vaping and consequently was not captured 
in this data).  
1.4.4 Age 
A systematic review observing differences in e-cigarette use by sociodemographic 
groups found that all high-quality studies showed greater ever and current use of 
e-cigarettes among older adolescents (17-18 years) and/or young adults (18-24 years) 
compared with younger children (12-13 years) or older adults (25-39 years) (Hartwell et 
al., 2017). Similarly, ITC data of adults in the US, Canada, Australia, and the UK also 
suggested that 18-24 year olds were most likely to try e-cigarettes but there was no 
clear association between age and current use of e-cigarettes (Adkison et al., 2013). In 
Great Britain in 2019, current e-cigarette use was most prevalent among 35-44 year olds 
(9.5%) followed by 45-54 year olds (9.3%), and then 25-34 year olds (7.8%), but only 
4.3% of young adults aged 18-24, and 5.6% of those over 55 years currently used 
e-cigarettes (Action on Smoking and Health, 2019a). Among young people in Great 
Britain (11-18 years), current vaping has increased from 2.4% in 2015 to 4.9% in 2019 
(Action on Smoking and Health, 2019b).  
1.5 Reasons for Vaping 
There are clear differences in e-cigarette usage patterns across age groups which could 





may differ between adolescents, older adults, and young adults, and these reasons may 
impact smoking and vaping behaviour.  
1.5.1 Adolescents 
In a study of South Korean adolescents (13-18 years), Lee, Lee, and Cho (2017) found 
that the most common reason for vaping among infrequent monthly users was out of 
curiosity (0-2 days a month = 28.8%), but the most common reasons for more frequent 
monthly vaping were to quit smoking (3-9 days a month = 18.7%; ≥10 days a month = 
21.0%) and to vape indoors (3-9 days a month = 17%; ≥ 10 days a month = 19.5%). 
Among US middle and high school students, vaping ‘out of curiosity’ was the most 
common reason for use (57.1%), followed by ‘good flavours’ (41.8%) and ‘friends use’ 
(32.6%), but using e-cigarettes to quit smoking was the strongest predictor of continued 
e-cigarette use as these users were 13 times more likely to continue vaping than those 
who did not use e-cigarettes to quit smoking (Bold, Kong, Cavallo, Camenga, & Krishnan-
Sarin, 2016). 
1.5.2 Adults  
In contrast to the majority of research on adolescents, the primary reasons for vaping 
among adults (18+ years) in Great Britain are related to smoking cessation (Action on 
Smoking and Health, 2019a); 21% of respondents to a national survey stated they use 
e-cigarettes to cut down their smoking, 14% stated they vape to quit smoking, and 12% 
stated they vape to prevent relapse. Among American Indian adult (18+ years) dual 
users in Oklahoma, a much larger proportion (79%) vaped to quit smoking (Rhoades et 
al., 2019).  
In the nationally representative Population Assessment of Tobacco and Health survey in 
the US, use of e-cigarettes as an alternative to cigarettes (a factor created using multiple 
reasons such as ‘using them help people to quit smoking’) was found to be associated 
with current vaping and former regular vaping (Nicksic, Snell, & Barnes, 2019). Similarly, 
Yong and colleagues (2019) reported results from the ITC study which showed that 
smokers were more likely to currently vape if they vaped to cut down their smoking 
(86%), thought it was less harmful to others (78%) or vaped to help them quit smoking 
(77%). Current smokers who vaped daily were also found to be more likely than 





of enjoyment, due to affordability or because they thought it was more acceptable than 
smoking (Yong et al., 2019). Ex-smokers were more likely to currently use e-cigarettes 
out of enjoyment (91%), because they thought they were less harmful to others (90%), 
due to affordability (90%) or to help to stay quit (88%), and were more likely to vape out 
of enjoyment or due to affordability if they vaped daily rather than weekly (Yong et al., 
2019).  
1.5.3 Young Adults 
Yong and colleagues (2019) also reported some differences between reasons for use and 
associated behaviour among younger adults (18-24 years); compared with older adults, 
younger people appeared to be more motivated to regularly vape for reasons other than 
quitting smoking. Similar to the findings among adolescents, evidence from the US 
suggests that young adults vape primarily out of curiosity (Kong, Morean, Cavallo, 
Camenga, & Krishnan-Sarin, 2015), enjoyment (Saddleson et al., 2016) or because their 
friends or family vape (Tsai et al., 2018). 
Although some of the studies described here have explored associations between 
reasons for vaping and continuation/discontinuation of vaping and smoking, there is 
limited evidence from young adults in the UK specifically. Understanding why young 
adults vape, and how this influences their later vaping and smoking behaviour, is 
necessary to determine whether cautious policy approaches (e.g., bans) are appropriate 
and could also help to inform public health strategies. I explore this in Chapter 3. 
1.6 Genetics and E-cigarette Use 
Aside from the subjective reasons given for e-cigarette use, there may be other 
underlying factors influencing peoples’ use of e-cigarettes, such as their genetics.  
1.6.1 Genetics 
Some people are genetically predisposed to develop certain diseases or engage in 
certain behaviours (i.e., phenotypes). For example, people with specific mutations in the 
BRCA1 and BRCA2 gene are more likely to develop breast cancer than those without 
such mutations (Kuchenbaecker et al., 2017). However, most traits are polygenic, 





Kichaev, & Pasaniuc, 2016). For example, 378 genetic variants have been found to be 
associated with liability for smoking initiation (Liu et al., 2019).  
Nucleotides are chemical bases which lie on the DNA strand (Alberts et al., 2002). There 
are four types of base, Thymine (T), Adenine (A), Cytosine (C), and Guanine (G). Due to 
their chemical structure, A always pairs with T, and C always pairs with G. In humans, 
the order of these bases on the DNA strand is 99.9% identical, but 0.1% of these bases 
can vary. Some of this variation occurs due to substitutions of one base for another (e.g., 
an A is substituted for a T) at a single base pair. Common genetic variants of this type 
are called single nucleotide polymorphisms (SNPs). These SNPs can result in differences 
between humans for a variety of traits, including eye colour, height, disease risk, 
smoking behaviours, and so on. 
1.6.2 Genome-Wide Association Studies 
To discover whether individuals are genetically predisposed to display a phenotype, 
researchers first need to know which SNPs are associated with that phenotype. 
Genome-wide association studies are designed to discover which genetic variants 
influence a specific trait and therefore can be used to identify these SNPs. A 
genome-wide association study can explore the association between over 8 million 
genetic variants across the genome and a specific phenotype such as eye colour or 
smoking initiation (Bush & Moore, 2012). The results of a genome-wide association 
study are often displayed in a Manhattan plot with SNP position along the x-axis, 
significance level along the y-axis, and a significance line indicating that all values lying 
above this threshold are considered to be clearly associated with the phenotype, 
although some influential SNPs may be missed at this highly stringent threshold (Reed et 
al., 2015). This threshold is usually p < 510-8 (known as the genome wide significant 
threshold) to account for multiple testing of the likely number of functional units in the 
human genome (Hoggart, Clark, De Iorio, Whittaker, & Balding, 2008; Panagiotou, 
Ioannidis, & the Genome-Wide Significance Project, 2011). 
1.6.3 Polygenic Risk Scores 
Individual SNPs identified in genome-wide association studies as associated with traits of 
interest can be combined into polygenic risk scores. Polygenic risk scores are weighted 





study and weighted by the effect size of each variant on the trait of interest from that 
genome-wide association study) each individual possesses (Lewis & Vassos, 2020). 
Polygenic risk scores can be calculated using software such as PRSice (Choi & O'Reilly, 
2019; Euesden, Lewis, & O'Reilly, 2015) and PLINK (Chang et al., 2015; Purcell et al., 
2007). Higher polygenic risk scores are indicative of greater genetic predisposition to the 
given phenotype. Once calculated, polygenic risk scores can be used to predict 
individuals’ predisposition to a given phenotype and observe the association between 
predisposition to a phenotype and outcomes of interest (Lewis & Vassos, 2020).  
1.6.4 Genome Wide Association Studies of E-cigarette Use and Smoking 
Initiation 
At present, there are no large-scale genome-wide association studies which could be 
used to create an e-cigarette use polygenic risk score. Ideally, I would conduct a 
genome-wide association study to identify SNPs which are associated with vaping, but I 
do not have access to data with a large enough sample of vapers with available genetic 
data. Therefore, I am currently unable to observe the association between genetic 
predisposition to vaping and outcomes such as smoking. However, it is biologically 
plausible that there could be a genetic overlap between vaping and smoking initiation as 
both cigarettes and e-cigarettes (can) contain nicotine; a predisposition to smoking 
initiation could be in part due to an individuals’ response to nicotine or their nicotine 
metabolism. 
Allegrini and colleagues (2019) have investigated this overlap; using independently 
associated SNPs from the Tobacco and Genetic Consortium (TAG) genome-wide 
association study to create polygenic risk scores for smoking initiation and smoking 
heaviness, they found that a predisposition to be a heavier smoker was associated with 
an increased likelihood to ever use e-cigarettes. They concluded that this association 
may be due to a genetic predisposition to use nicotine or that it could reflect a more 
general personality trait, such as impulsivity or risk-taking.  
Since Allegrini and colleagues (2019) published these findings, a larger genome-wide 
association study of smoking initiation and smoking heaviness has been published using 
data from the Genome-Wide Association Study and Sequencing Consortium of Alcohol 





2019). The TAG genome-wide association study identified 8 SNPs associated with 
smoking initiation and 3 SNPs associated with smoking heaviness, whereas the GSCAN 
genome-wide association study identified 378 and 55 respectively. Thus, using the SNPs 
identified in the GSCAN genome-wide association study (rather than the SNPs identified 
in the TAG genome-wide association study) should allow for greater statistical power to 
detect associations as the polygenic risk scores should explain a greater proportion of 
variance in the phenotype. In Chapter 4, I have explored the association between 
smoking initiation polygenic risk scores identified in GSCAN and later e-cigarette use. I 
focussed on smoking initiation rather than smoking heaviness due to the potential for 
collider bias and reduced statistical power that would result from stratifying by smoking 
status in order to explore the associations with smoking heaviness. 
1.6.5 Positive and Negative Controls 
Allegrini and colleagues (2019) suggested that the association found between smoking 
polygenic risk scores and e-cigarette use could be due to personality traits such as 
risk-taking. One way to explore this hypothesis would be to look at the association 
between smoking initiation polygenic risk and e-cigarette use and compare it with the 
association between the polygenic risk scores and selected control outcomes.  
Control outcomes, which can either be positive or negative, are often used in genetic 
research and are useful for a variety of reasons. Positive controls can be used to check 
that polygenic risk scores are indeed associated with the phenotype of interest they 
should be predicting. The magnitude of association between the polygenic risk score and 
phenotype of interest (e.g., smoking initiation) can also be compared with the 
association between the polygenic risk score and the outcome of interest (e.g., 
e-cigarette use) to explore potential mechanisms underlying the associations. An 
example of a positive control would be looking at the association between alcohol 
consumption polygenic risk scores and self-reported alcohol consumption. If there is no 
clear evidence of association, it would suggest that the polygenic risk score is not 
adequately predicting predisposition to alcohol consumption in the chosen sample. 
Negative control outcomes are outcomes for which there is no plausible biological route 
to the exposure. They can inform the overall evaluation of whether an association is 
causal via a hypothesised route. For example, smoking is associated with risk of dying by 





by homicide (which is not), casting doubt on the causal nature of the former association 
(Davey Smith, Phillips, & Neaton, 1992). Therefore, associations with negative controls 
suggest there is another factor explaining the association between polygenic risk score 
and the outcome (i.e., confounding). The association between the polygenic risk score 
and the outcome may still be causal, but this is less likely if it has a similar confounding 
structure to the negative control association. 
Comparing associations between smoking initiation polygenic risk scores and e-cigarette 
use with associations between smoking initiation polygenic risk scores and biologically 
unrelated risky behaviours, such as risky sexual behaviour, could indicate whether it is 
possible that the association found by Allegrini and colleagues (2019) could be explained 
by a general risk-taking disposition. I explore this possibility in Chapter 4.  
1.7 Predicting Health Outcomes of E-cigarette Use 
Novel methods and supplementary analyses, such as the use of negative control 
outcomes, are required to aid understanding of the factors influencing e-cigarette use 
and the possible consequences of use. As e-cigarettes are relatively new, little is known 
about the long-term health effects of vaping and the effects will not be observable for 
many years to come. Even when these effects are eventually observable, a high 
proportion of e-cigarette users have also smoked, meaning any observable effects will 
be heavily confounded by smoke exposure – a known cause of many poor health 
outcomes. Despite this issue, some research has attempted to explore the potential 
health consequences of e-cigarette use. 
1.7.1 Potential Health Consequences of E-cigarette Use 
E-cigarette users may be exposed to levels of aldehydes (e.g., formaldehyde) which are 
equal to or surpass levels resulting from smoke exposure (Gillman, Kistler, Stewart, & 
Paolantonio, 2016; Jensen, Luo, Pankow, Strongin, & Peyton, 2015); levels at which 
exposure is associated with an increased risk of cancer among current smokers (Godish, 
1989). However, these studies are based on chemical analysis of artificial puffing 
behaviour (i.e., using a smoking machine) and consequently there has been considerable 
debate about the extent to which e-cigarette users are exposed to formaldehyde. Some 





are unpleasant to users; Farsalinos and colleagues (2015) state that the voltages 
necessary to produce vapours containing harmful levels of formaldehyde create an 
unpleasant ‘dry puff’ sensation. Users of new generation e-cigarettes (which are more 
powerful than earlier generation e-cigarettes) can adjust the voltage of their e-cigarette, 
but quickly learn to avoid ‘dry puff’ sensations caused by excessively high voltages 
(Farsalinos et al., 2015). However, Salamanca and colleagues (2018) claim that 
dangerous levels of formaldehyde can be produced at voltages which are non-aversive 
to users. 
Smokers are exposed to numerous carcinogens, but e-cigarette users have been shown 
to have lower levels of carcinogens in their saliva and urine compared with smokers 
(Shahab, Dobbie, Hiscock, McNeill, & Bauld, 2017). Although this suggests that smokers 
who switch to e-cigarettes will be at lower risk of developing cancer, never-smoking 
e-cigarette users could be exposing themselves to low levels of carcinogens which could 
have negative effects following repeated exposure (Glantz & Bareham, 2018). However, 
low levels of carcinogens can be detected at levels unlikely to have any biological 
effects, so the measurable presence of carcinogens alone is not sufficient to suggest 
harmful outcomes; it is important to also consider the level of carcinogen exposure 
(Nohmi, 2018).   
Smokers and e-cigarette users are also exposed to ultrafine particles in the 
smoke/vapour which they inhale. Although inhaling ultrafine particles is associated with 
poor pulmonary and cardiovascular outcomes (Glantz & Bareham, 2018), many of these 
associations are evidenced in smokers, and there is no clear evidence that ultrafine 
particles in e-cigarette vapour will have the same health effects as cigarette smoke. 
Crucially, the e-cigarette vapour in which the ultrafine particles are carried is chemically 
and physically different to cigarette smoke, and the ultrafine particles may differ in size, 
composition and toxicity (Grana, Benowitz, & Glantz, 2014). Therefore, it is unclear 
whether ultrafine particle exposure via e-cigarette use will impact pulmonary or 
cardiovascular health. 
Chronic obstructive pulmonary disease (COPD) is strongly associated with smoking and 
evidence suggests that it may also be strongly associated with vaping (Osei et al., 2020; 
Xie, Ossip, Rahman, & Li, 2019). The NHS claim that 9 out of 10 COPD cases are likely to 





dust, air pollution and genetics, but there is no discussion of e-cigarette use as a 
potential cause (NHS, 2019a). Osei and colleagues (2020) reported a strong association 
between current e-cigarette use and COPD, particularly among never smokers (less than 
100 cigarettes in their lifetime) who used an e-cigarette daily (OR = 2.64, 95% CI = 1.43 
to 4.89). However, the study did not adequately take into account the extent of tobacco 
exposure; never smokers self-reported smoking less than 100 cigarettes in a lifetime but 
may have been exposed to tobacco from other sources (e.g., cigars, shisha). 
Furthermore, due to the cross-sectional nature of the study, direction of causality 
cannot be inferred, and COPD diagnosis may lead to e-cigarette use. It is unlikely that 
COPD causes never-smokers to start using an e-cigarette, however, misreporting of 
smoking behaviour can introduce bias in studies that rely on self-reports (Khouja, 
Munafò, et al., 2020), and misreporting is a common issue among populations with 
COPD (Shahab, Jarvis, Britton, & West, 2006). If self-reported never smokers misreport 
their behaviour (i.e., they have actually smoked more than 100 cigarettes in their 
lifetime), the wrong direction of causality could be inferred; the observed relationship 
would indicate that vaping caused the COPD diagnosis, however, smoke exposure may 
have caused the COPD diagnosis, which in turn caused the individual to switch from 
smoking to vaping. Xie and colleagues (2019) also showed a positive cross-sectional 
association between e-cigarette use and self-reported COPD compared with never 
smokers, but compared with smokers and dual users there was evidence of a lower 
likelihood of self-reported COPD. Longitudinal evidence, albeit with a small sample size 
and short follow up, does not suggest that e-cigarette use is associated with respiratory 
symptoms among never smokers who have vaped for at least 3.5 years (Polosa et al., 
2017). 
Bronchiolitis obliterans (also known as popcorn lung) is a lung disease that is similar to 
COPD, and associated with inhalation of diacetyl in popcorn factory workers after ~12 
months of repeated, short-term, intense exposure (Kanwal et al., 2006; Kreiss et al., 
2002). Diacetyl was found in a majority of tested e-cigarettes (39 out of 51 products) in 
2016 (Allen et al., 2016). However, there are a lack of cases found in e-cigarette users. 
Furthermore, the studies which have found associations between diacetyl inhalation and 
popcorn lung among popcorn factory workers have been heavily criticised for failing to 
take into account the smoking history of the cohort or the disproportionately high rates 





(Pierce, Abelmann, & Finley, 2014; Pierce, Abelmann, Spicer, Adams, & Finley, 2014). In 
fact, diacetyl exposure due to smoking far exceeds that of occupational exposure, yet 
smoking has not been found to be associated with bronchiolitis obliterans (Pierce, 
Abelmann, Spicer, et al., 2014). Despite the weak evidence for a causal effect of diacetyl 
on popcorn lung among e-cigarette users, diacetyl was banned from e-cigarettes sold in 
the UK and Europe with the enforcement of the European Tobacco Products Directive in 
2016. However, diacetyl remains in products in other areas of the world such as Canada 
and the US. 
The European Tobacco Products Directive also prevents the inclusion of vitamins such as 
vitamin E acetate in e-cigarettes. Vitamin E acetate, an ingredient added to 
tetrahydrocannabinol (THC) products as a thickener, has been identified as the probable 
cause of e-cigarette or vaping product use associated lung injury (EVALI) (Blount et al., 
2019). In the US, 68 individuals have died due to EVALI, and more than 2,500 have been 
hospitalised (as of February 2020), yet there have been no cases of EVALI in the UK 
(CDC, 2020). Although the harmful products were primarily acquired from informal, 
unregulated sources (e.g., friends, acquaintances and unlicenced retailers) rather than 
licenced vaping shops or online stores (Heinzerling et al., 2020), and no cases were 
identified in the UK, the EVALI outbreak coincides with an increase in people in the UK 
believing that e-cigarettes are as harmful as, or more harmful than, smoking (Tattan-
Birch, Brown, Shahab, & Jackson, 2020).  
Evidence published in 2019 suggesting that e-cigarette use is associated with increased 
risk of myocardial infarction (i.e., heart attacks) could also have contributed to the 
increase in harm perception of e-cigarettes (Bhatta & Glantz, 2019). Bhatta and Glantz 
(2019) explored the association between e-cigarette use and myocardial infarction 
cross-sectionally and longitudinally but found only a cross-sectional association whereby 
e-cigarette use increased the risk of myocardial infarction. However, this analysis does 
not rule out reverse causality as an explanation for the association. To explore whether 
the association was due to reverse causality, the authors explored whether myocardial 
infarction predicted daily e-cigarette use at follow up – it did not. However, the study 
was heavily criticised for not adequately accounting for the order of the exposure and 
outcome by excluding those who had experienced a myocardial infarction prior to 
e-cigarette use (which was possible using the available dataset). Following calls for the 





to data access issues. Consequently, the paper was retracted less than a year later. A 
reanalysis of the study, which adequately accounted for the order of exposure, showed 
no clear evidence of an association between e-cigarette use and myocardial infarction 
among never smokers (Rodu & Plurphanswat, 2020). In line with the reanalysis, a review 
exploring the relationship between electronic cigarette use and cardiovascular health 
stated there was inconclusive evidence to support a long-term effect on cardiovascular 
health (MacDonald & Middlekauff, 2019). 
1.7.2 Health Effects of Nicotine 
Nicotine is an addictive drug which is naturally found in tobacco leaves (Benowitz, 
Hukkanen, & Jacob, 2009) and is often implicated as a plausible potential cause of poor 
cardiovascular health related to e-cigarette use (Benowitz & Fraiman, 2017; Kennedy, 
van Schalkwyk, McKee, & Pisinger, 2019). When nicotine is inhaled via tobacco smoke, it 
travels from the users lungs to the brain where it binds to nicotinic cholinergic 
receptors, leading to the release of neurotransmitters and resulting in psychoactive 
effects (Benowitz, 2010). Exposure to nicotine induces acute effects, including increased 
heart rate, blood pressure and sympathetic nerve activity to muscle circulation (Najem 
et al., 2006). Evidence also suggest there may be longer term effects of nicotine 
exposure; alongside the acute effects on heart rate, nicotine exposure may increase 
resting heart rate (Linneberg et al., 2015). While multiple reviews have explored the 
cardiovascular effects of e-cigarette use on cardiovascular health, there is limited 
evidence to suggest that nicotine is the mechanism by which e-cigarette use may impact 
cardiovascular health (Benowitz & Fraiman, 2017; Kennedy et al., 2019; Qasim, Karim, 
Rivera, Khasawneh, & Alshbool, 2017).  
At present, there is limited evidence of long-term effects of nicotine use in humans 
without exposure to the other constituents of tobacco smoke, because other forms of 
nicotine that were available prior to the introduction of e-cigarettes (e.g., nicotine 
replacement therapy) were rarely used for long periods of time. Only 6% of those who 
used nicotine replacement therapy during a quit attempt were still using nicotine 
replacement therapy one year later (Shahab, Dobbie, et al., 2017). Hajek and colleagues 
(2019) similarly found low rates of nicotine replacement therapy use at 1 year post-quit 
date among those assigned to use nicotine replacement therapy in a randomised 





an e-cigarette. In a UK adult sample of never smokers (i.e., those without exposure to 
other constituents of tobacco smoke), long-term use of nicotine is even more rare; less 
than 0.1% of respondents had used nicotine replacement therapy for 12 months or 
more and only 0.1% had used e-cigarettes for 12 months or more (Jackson et al., 2019). 
Therefore, it is difficult to observe the long-term health effects of nicotine use without 
tobacco smoke exposure in humans.  
1.7.3 Univariable Mendelian Randomisation  
It is difficult to conclude that e-cigarettes cause any health effects with the current 
available evidence for multiple reasons. In addition to the lack of observational evidence 
and high potential for confounding, conducting a randomised controlled trial (the 
gold-standard method for causal inference) would be unethical; exposing nicotine-naïve 
individuals to e-cigarettes over a long period of time in order to assess whether they 
develop poor health outcomes would mean knowingly exposing individuals to toxicants 
and chemicals which they may not otherwise have been exposed to. Thus, methods 
which have not previously been applied to this research area, such as Mendelian 
randomisation, are needed to explore potential health outcomes.  
Mendelian randomisation is a method often used to infer causality, particularly where a 
randomised controlled trial would be unethical or impossible to conduct (Davey Smith & 
Ebrahim, 2003). It is based on the laws of Mendelian genetics: segregation and 
independent assortment. The law of segregation states that each individual possesses 
pairs of alleles for each trait and each parent passes only one of those alleles from each 
pair onto their offspring (Griffiths, Miller, Suzuki, Lewontin, & William, 2000). Mendel’s 
law of independent assortment states alleles are independently assorted at meiosis so 
that each allele passed down from a parent to their offspring is independent of the 
other alleles which are passed down (Griffiths et al., 2000). Mendelian randomisation 
assumes that these laws are held at a population level (i.e., a random assortment of 
genes are transferred from parents to their offspring) (Nitsch et al., 2006). Although this 
is not strictly true for the inheritance of genes in homologous chromosomes where 
linkage disequilibrium (the non-random assortment of genes in close proximity) may 
occur, it is generally true with respect to the inheritance of genes in non-homologous 





In Mendelian randomisation, an individual’s genotype or genetic liability – which should 
not be associated with the confounding factors that often distort observational evidence 
– is used as an instrumental variable to assign them to a phenotype group (e.g., smoker 
or non-smoker). Consequently, the instrumental variable used as the exposure (i.e., an 
individual’s genotype or genetic liability) always precedes the outcome as it is 
determined at conception. This genetic variation mimics the randomisation process in a 
randomised controlled trial, reducing issues of both confounding and reverse causality 
(Nitsch et al., 2006; Swanson, Tiemeier, Ikram, & Hernán, 2017). The relationship 
between the genotype and the outcome is then assessed to estimate the total causal 
effect of one exposure on one outcome using one or two datasets. Mendelian 
randomisation often uses one dataset with individual-level data (i.e., a dataset which 
contains genetic variants, exposure and outcome data for all participants), but 
summary-level data can also be used on random subsets of the same sample (Lawlor, 
2016). Summary-level data contain only the summarised genetic associations with the 
exposure and outcome. Mendelian randomisation can also be conducted using 
summary-level data from two separate datasets (Lawlor, 2016). 
As shown in Figure 1.3, the basic Mendelian randomisation method is reliant on the 
instrumental variables (G) included in the model being valid. For an instrumental 
variable to be valid, there are three key assumptions (Martens, Pestman, de Boer, 
Belitser, & Klungel, 2006):  
Assumption 1 (relevance) – The genetic variant (G) is associated with the exposure (X). 
Assumption 2 (exchangeability) – The genetic variant (G) is independent of any 
measured and unmeasured confounders of the exposure-outcome relationship (U).  
Assumption 3 (exclusion restriction) – The genetic variant (G) is only associated with the 






Figure 1.3. A directed acyclic graph depicting the relationship between genetic variant(s) 
(G), a phenotypic exposure (X), outcome (Y) and confounders (U) in a Mendelian 
randomisation analysis. 
Note: Numbers indicate the three assumptions which valid instrumental variables 
satisfy. The dashed lines indicate the absence of an association.   
 
Assumptions 2 and 3 can pose an issue in Mendelian randomisation analysis because 
genetic variants can be pleiotropic – one genetic variant may affect multiple 
phenotypes. Pleiotropy can be vertical (affecting a phenotype on the causal pathway 
from exposure to outcome) or horizontal (affecting a different phenotype which affects 
the outcome through a pathway other than through the exposure or directly affecting 
the outcome). Although vertical pleiotropy is not problematic for Mendelian 
randomisation, horizontal pleiotropy can violate assumptions 2 and 3 (Davies, Holmes, & 
Davey Smith, 2018). Confounding by population structure (i.e., common sub-population 
differences in allele frequencies) can also violate assumption 2. Various Mendelian 
randomisation methods have been developed which make different assumptions about 
pleiotropy and are often used in parallel and compared; consistent estimates across 
multiple Mendelian randomisation methods (which make different assumptions) 
provides stronger evidence for a causal effect (Bowden, Davey Smith, Haycock, & 
Burgess, 2016). For example, the inverse variance weighted method is well-powered but 
cannot handle any invalid instruments (i.e., violation of assumptions 1, 2 or 3), whereas 
the weighted median approach can handle violation of assumptions 2 and 3 provided at 





100% of the SNPs used to be invalid due to violation of assumption 3, but an additional 
and untestable assumption has to be met: the Instrument Strength Independent of 
Direct Effect (InSIDE) assumption. The InSIDE assumption is a relaxed version of the 
exclusion restriction assumption (assumption 3) whereby the SNP-exposure effect 
should not be correlated with any horizontal pleiotropic effect (Bowden, Davey Smith, & 
Burgess, 2015). 
1.7.4 Mendelian Randomisation Studies of Smoking and Health 
Although there are no Mendelian randomisation studies exploring the causal effects of 
vaping, previous Mendelian randomisation studies have found that increased smoking 
heaviness causes poor lung function, increased risk of COPD (Millard, Munafò, Tilling, 
Wootton, & Smith, 2018), and increased resting heart rate (Åsvold et al., 2014) as well as 
increased risk of all-cause mortality, circulatory diseases, and respiratory diseases (Vie et 
al., 2019). Heavier smoking also appears to cause lower body mass index (BMI) (Åsvold 
et al., 2014; Taylor et al., 2019). In fact, bidirectional effects of smoking and BMI have 
been observed; heavier smoking decreases BMI and higher BMI causally increases 
smoking heaviness (Taylor et al., 2019). However, increased BMI does not appear to 
causally influence cotinine levels (a highly specific direct metabolite of nicotine), which 
indicates a more complex relationship between nicotine and BMI. 
Although these univariable Mendelian randomisation studies provide evidence for a 
causal effect of smoking, they cannot determine which constituent of tobacco smoke 
causes these effects. On the one hand, if nicotine is the constituent driving these effects, 
I could infer that long-term nicotine use via e-cigarettes would also lead to these poor 
health outcomes. On the other hand, if nicotine is not driving these effects, I could infer 
that long-term use of nicotine via e-cigarettes may not lead to these poor health 
outcomes. Using a multivariable Mendelian randomisation approach, the direct causal 
effects of nicotine exposure can potentially be determined. 
1.7.5 Multivariable Mendelian Randomisation 
Multivariable Mendelian randomisation is an extension of the inverse variance weighted 
Mendelian randomisation method. Rather than calculating the total effect of one 
exposure on one outcome (which includes indirect effects that mediate the effect of the 





the direct causal effect of two or more exposures on an outcome (Lawlor et al., 2019; 
Sanderson, Davey Smith, Windmeijer, & Bowden, 2019). When two exposures are 
related, multivariable Mendelian randomisation can estimate the effect of one exposure 
on an outcome while accounting for the effect of the other exposure on the outcome. 
Figure 1.4 demonstrates the inclusion of genetic variants (G1 and G2) as instrumental 
variables for two exposures (X1 and X2), including those variants which predict both 
exposures (G12), in a multivariable Mendelian randomisation analysis.  
 
 
Figure 1.4. A directed acyclic graph to show the relationship between genetic 
instruments (G1, G12, and G2), exposures (X1 and X2), confounding factors (U) and 
outcome (Y) in a multivariable Mendelian randomisation analysis.  






1.7.6 Total Versus Direct Effects of Nicotine and Smoking Heaviness 
Multivariable Mendelian randomisation could prove particularly useful when 
investigating the potential health impact of long-term e-cigarette use. As previously 
discussed, one constituent of particular concern in e-cigarette vapour is nicotine, which 
is also found in cigarette smoke, but e-cigarettes contain far fewer toxicants which can 
cause harm. Genetic variants associated with cotinine (a direct metabolite of nicotine) 
and smoking heaviness have previously been identified in genome-wide association 
studies (Liu et al., 2019; Ware et al., 2016) which could be utilised in Mendelian 
randomisation analyses.  
Evidence of the health effects of long-term nicotine use is often based on tobacco 
smoke exposure, but multivariable Mendelian randomisation methods can be used to 
explore the direct effect of nicotine while taking into account the effect of smoke 
exposure and vice versa. The total effects of smoking heaviness on health outcomes 
includes the effect of nicotine on health outcomes, but by exploring the direct effect of 
smoking heaviness while controlling for the direct effect of nicotine (and confounding 
factors), it may be possible, in theory, to observe the effect of the remaining 
constituents of tobacco smoke aside from nicotine. Therefore, among smokers it may be 
possible to identify the health effects directly caused by nicotine and compare these 
with the health effects directly caused by the other constituents of tobacco smoke 
exposure (aside from nicotine) which are less likely to be found in e-cigarette vapour. 
However, large sample sizes are needed to explore genetic effects and older samples are 
required to explore long-term health effects. Using the summary results of a 
genome-wide association study of cotinine levels (as a proxy for nicotine exposure) and 
another genome-wide association study of smoking heaviness (Liu et al., 2019; Ware et 
al., 2016), I explore this in UK Biobank (a population-based health research resource 
consisting of approximately 500,000 people, aged between 38 years and 73 years) in 
Chapter 5. 
1.8 Exploring the Acute Effects of Nicotine 
Potential health effects of nicotine use via e-cigarettes can be further explored using 
experimental methods. Before e-cigarettes became widely available, the short-term 





using nicotine replacement therapy. Exploring short-term effects can provide an insight 
into the mechanisms by which nicotine could impact long-term health. 
1.8.1 Nicotine Use without Exposure to Other Constituents of Tobacco Smoke 
Experimental studies have been used to explore the short-term effects of nicotine use. 
For example, exposure to nicotine replacement therapy acutely increases heart rate by 
10 to 15 beats per minute and increases blood pressure by 5 to 10 mm Hg (Benowitz & 
Gourlay, 1997). These effects can lead to reduced blood flow and oxygen to the heart 
and result in poor cardiovascular outcomes (Benowitz & Gourlay, 1997), therefore 
understanding these short term outcomes gives an indication of the potential long-term 
outcomes. 
1.8.2 BMI, Appetite and Nicotine 
As previously discussed, evidence suggests there is a complex relationship between BMI 
and nicotine exposure (Taylor et al., 2019). Observationally, there is a clear association 
between smoking and BMI; the average BMI of an adult smoker in the US was found to 
be 2 kg/m2 lower than the average BMI of a non-smoker, and smoking cessation was 
associated with 3 to 4 kg of weight gain (Audrain-McGovern & Benowitz, 2011; 
Williamson et al., 1991). However, Mendelian randomisation studies suggest a 
bidirectional effect, whereby heavier smoking decreases BMI, but higher BMI increases 
the likelihood of someone smoking and the number of cigarettes they smoke (Taylor et 
al., 2019). This could be due to those with higher BMI choosing to smoke due to the 
known (and frequently cited) association between smoking and lower BMI. There is also 
some evidence to suggest that e-cigarette use is associated with BMI, but the evidence 
is limited and the direction of this association is unclear; sole use of either e-cigarettes 
or cigarettes was found to be associated with high body mass index, but dual use was 
associated with lower body mass index among adolescents (Jacobs, 2018). One 
commonly proposed mechanism by which smoking (and potentially e-cigarette use) may 
impact BMI is through changes in appetite; the NHS website, for example, states that 
smoking suppresses your appetite, and explains that this effect causes smokers to put 
on weight when they quit (NHS, 2019b). There is considerable evidence from animal 





2002; Mineur et al., 2011), however, there is limited and conflicting evidence from 
human studies.  
Pilhatsch and colleagues (2014) explored the effect of nicotine versus placebo gum 
administration on subjective ratings of appetite (measured via visual analogue scale) 
among human non-smokers after a 30 minute absorption period. Following nicotine 
administration, non-smokers’ subjective ratings of appetite declined by 17.5%. In 
contrast, non-smokers’ appetite ratings increased by 18% following placebo 
administration. Similarly, Perkins and colleagues (1991) found that male participants 
consumed less food following nicotine administration compared with placebo 
administration via nasal spray. Although there was no overall difference in food 
consumption between smokers and non-smokers, further investigation revealed that 
nicotine administration only clearly reduced food consumption among non-smokers, not 
among daily smokers. Perkins and colleagues (1992) further explored this effect in 
another study of male and female daily smokers (using similar methods). Among male 
and female smokers, caloric intake increased following nicotine administration 
compared with placebo administration. These contrasting results suggest that the effect 
of nicotine on appetite and food consumption is not as straightforward as it is 
sometimes claimed to be. 
1.8.3 Improving Experimental Designs to Explore Nicotine and Eating Behaviour 
There are clear limitations in the existing literature exploring nicotine and eating 
behaviour. The few available studies in the area are likely to be statistically 
underpowered; the sample sizes for the studies were small, with as few as 20 
participants (Perkins et al., 1992; Perkins et al., 1991). Also, the dose and delivery 
method of nicotine may not have been appropriate; the studies provided little evidence 
that the dose was sufficient to induce a biological response among smokers (who are 
tolerant to nicotine), or whether the method of administration (i.e., nasal spray or gum) 
led to any side effects, such as changes in taste or sensation, which could affect eating 
behaviour. Additionally, the contrasting results between smokers and non-smokers 
suggest that confounding factors were not adequately addressed in the experimental 
design. For example, nicotine-naïve non-smokers are likely to experience adverse effects 
of nicotine which could impact their eating behaviour; non-smokers have not developed 





nicotine. This could result in an effect of nicotine administration on appetite and food 
consumption which is not seen among those who are experienced with nicotine. As well 
as developing a tolerance to nicotine, daily smokers become dependent on nicotine, 
thus daily smokers may experience withdrawal symptoms when asked to refrain from 
smoking. In these studies, smokers were asked to abstain from smoking before the study 
(in order to standardise nicotine exposure) which could have led to withdrawal 
symptoms which affected their appetite and eating behaviour (e.g., increased appetite) 
(Jorenby et al., 1996).  
With these limitations in mind, improved experimental studies exploring the effect of 
nicotine on eating behaviour are necessary before concluding that a nicotine-induced 
reduction in appetite can explain the relationship between nicotine exposure and BMI. 
For example, exploring the effects of nicotine on eating topography among 
non-dependent smokers could avoid the confounding effects of withdrawal seen among 
dependent smokers and aversion seen among non-smokers; non-dependent smokers 
are experienced with nicotine and therefore should not experience adverse effects 
when exposed to nicotine and should also not experience any withdrawal symptoms 
when asked to refrain from smoking. I explore this further in Chapter 6. If the resulting 
evidence from such studies supports a nicotine-induced reduction in appetite and eating 
behaviour, this would support evidence that e-cigarettes may prevent post-cessation 
weight gain (Russo et al., 2016; Russo et al., 2018). As weight gain following smoking 
cessation often leads to relapses in smoking (Mizes et al., 1998), smoking cessation 
services need to understand if there are mechanisms by which e-cigarettes could 
prevent this, particularly as e-cigarettes are available with and without nicotine. 
1.9 Thesis Aims, Methods and Original Contribution 
1.9.1 Aims 
The aims of this thesis are three-fold, namely to: 
1. Identify which young adults are more likely to use e-cigarettes by describing the 
demographics and profiles of young e-cigarette users in a UK sample; 
2. Explore why young adults use e-cigarettes, including the subjective reasons 





3. Investigate the potential consequences of e-cigarette use on smoking behaviour 
and health outcomes. 
Where possible, I focus on young adults (18 to 30 years), a subgroup who are often 
understudied despite apparent differences in their motivation and behaviour compared 
with adolescents and older adults. 
1.9.2 Methods 
This thesis begins with a systematic review and meta-analysis exploring whether 
e-cigarettes act as a gateway to smoking (Chapter 2). This review highlights the 
importance of understanding who uses e-cigarettes, why, and what the potential 
consequences of use are. In Chapter 3, I first explore the demographics and profiles of 
young adult vapers in the UK. I go on to explore how young adults’ reasons for vaping 
associate with their later smoking and vaping behaviour using logistic regression. In 
Chapter 4, I further explore why young adults use e-cigarettes by looking at how 
smoking initiation polygenic risk scores associate with e-cigarette use, risk-taking and 
impulsivity in a series of logistic regressions. In Chapter 5, I use univariable and 
multivariable Mendelian randomisation methods to begin to explore the potential 
health effects of long-term e-cigarette use by separating the effects of long-term 
nicotine use from the effects of other constituents of cigarette smoke in UK Biobank. In 
Chapter 6, I employ an experimental design to further explore the potential health 
effects of nicotine without exposure to the other constituents of tobacco smoke. 
Specifically, I explore the effects of nicotine on eating behaviour. 
1.9.3 Original Contribution 
At present very little is known about which young adults in the UK use e-cigarettes and 
why, and even less is known about the potential implications of vaping. Using traditional 
methods, such as randomised controlled trials, to address these research questions 
would be unethical, therefore alternative methods are required. This thesis contributes 
a necessary update to existing reviews – which are fast outdated in this rapidly evolving 
field – and provides a rare insight into the motivations for vaping and self-reported 
smoking and vaping behaviour of young adults in the UK. Additionally, I have employed 
novel and innovative methods (e.g., negative control analyses and multivariable 





assess observationally at present due to confounding and a lack of longitudinal data. 
Finally, I provide an outline for experimental research to explore the mechanisms 
underlying the relationship between nicotine and BMI which is needed to confirm the 
often cited (but not sufficiently evidenced) claim that nicotine suppresses appetite and 





Chapter 2 Do e-cigarettes act as a gateway 
to smoking? 
This chapter closely resembles sections from the following publication, pre-print and 
pre-registered study protocol: 
Khouja, J. N., Suddell, S. F., Peters, S. E., Taylor, A. E., & Munafò, M. R. (2020). Is 
e-cigarette use in non-smoking young adults associated with later smoking? A 
systematic review and meta-analysis. Tobacco Control, Published Online First: 10 March 
2020. doi: 10.1136/tobaccocontrol-2019-055433. 
Khouja, J. N., Suddell, S. F., Peters, S. E., Taylor, A. E., & Munafò, M. R. (2020). Is 
e-cigarette use in non-smoking young adults associated with later smoking? A 
systematic review and meta-analysis. MedRxiv; doi:10.1101/19007005 %J.  
Khouja, J. N., Suddell, S., Peters, S. E., Taylor, A., & Munafò, M. R. (2019). Does 
e-cigarette use in non-smoking young adults act as a gateway to smoking? A systematic 
review and meta-analysis. OSF; https://doi.org/10.17605/OSF.IO/3GC2Y. 
I took the lead in designing, implementing and interpreting the systematic review and 
meta-analysis with the support of my co-authors. Specifically, MM and AT provided 
feedback on the design of the study. Co-authors SS and SP assisted me with study 
selection and data extraction by independently checking 100% of my selection and 
extraction (50% each). I was responsible for the data analysis and was responsible for 
writing the first draft of the manuscript and editing the manuscript in response to 
comments from co-authors and reviewers. All co-authors provided feedback during the 
manuscript preparation. 
2.1 Chapter Overview 
In this Chapter, I describe a systematic review and meta-analysis of the studies 
investigating the association between e-cigarette use among non-smokers and later 
smoking. As discussed in Chapter 1, this is not the first review or meta-analysis to 
address this research question (Glasser et al., 2018; Soneji, Barrington-Trimis, Wills, 





that this is a fast-moving area of research, I expected to identify a substantial number of 
studies that had been published since the previous reviews. As well as providing an 
update to the currently available reviews, I outline the key areas in which future studies 
could focus in order to better address the research question. Outlining these areas for 
improvement helped to shape the design of the studies in the subsequent chapters of 
my thesis.  
2.2 Introduction 
There are concerns, shared by the public and policy makers alike, that e-cigarettes may 
act as a gateway to smoking cigarettes among young people (Chapman et al., 2019). If 
e-cigarettes act as a gateway to smoking, rather than seeing a decline in smoking rates 
due to smokers using e-cigarettes for smoking cessation, we may see smoking rates 
remaining stable or even increasing due to a new generation of smokers for whom 
e-cigarettes have acted as a route into smoking. This hypothesis is sometimes referred 
to as the ‘gateway hypothesis’ or ‘catalyst model’ and has been widely debated among 
researchers and public health officials (Etter, 2018). Some argue that rather than 
e-cigarette use acting as a gateway to smoking, an association between e-cigarette use 
and later smoking may be explained by a common liability between vaping and later 
smoking, whereby the same genetic or environmental factors that increase the 
likelihood of someone vaping also increase the likelihood of someone smoking (Etter, 
2018). Such factors should be accounted for when exploring the association between 
e-cigarette use and later smoking. Furthermore, as many people use e-cigarettes to help 
them stop smoking (Action on Smoking and Health, 2017), it would also be logical to 
assume the opposite direction of causality with smoking causing people to vape 
(Eastwood et al., 2015). The lack of consensus on the issue demonstrates the need for 
the current available evidence to be synthesised.  
As discussed in Chapter 1, a recent meta-analysis concluded that e-cigarette use is 
associated with a nearly 4-fold increase in the likelihood of smoking at follow up (Soneji, 
Barrington-Trimis, Wills, Levanthal, et al., 2017). Given this is a fast-moving field, and the 
topic is of great interest to researchers and policy makers, regular updates to 
meta-analyses in this area are likely to be necessary. Moreover, in the previous 
meta-analysis (Soneji, Barrington-Trimis, Wills, Levanthal, et al., 2017), moderate 





of heterogeneity could include the age range of the participants in the studies, cultural 
and regulatory differences between study locations, and risk of bias among the studies. 
Soneji and colleagues (2017) addressed one of these potential sources of bias by 
stratifying by average age, finding that there was greater heterogeneity between studies 
of adolescents (under the age of 18 years) compared with studies of young adults. 
However, they did not stratify by risk of bias. This is important because the 
preconceptions of study authors may also influence how studies are designed and 
conducted, and this may be reflected in a study’s conclusions (as described in Chapter 
1).  
In this systematic review and meta-analysis, I have updated and extended previous 
reviews in which e-cigarette use and later smoking have been explored. My aim was to 
investigate whether e-cigarette use, compared with non-use, in young non-smokers is 
associated with subsequent cigarette use. I combined evidence from studies 
investigating this relationship where an odds ratio (OR) could be calculated. Additionally, 
I explored potential sources of heterogeneity and bias by reviewing the details of 
included studies, as well as subgrouping, and stratifying the data.  
 
2.3 Methods 
The protocol for this systematic review and meta-analysis was pre-registered and 
published online prior to initiating the systematic search. The pre-registration can be 
found on the Open Science Framework (https://osf.io/3gc2y/). Where appropriate, I 
followed PRISMA and MOOSE reporting guidelines. 
2.3.1 Eligibility Criteria 
In my systematic search of the literature, I included randomised controlled trials, 
longitudinal studies, cross-sectional studies, and case-control studies and I only included 
studies investigating young people aged up to 30 years old (inclusive). I selected this 
cut-off to include studies of both youth and young adults. As a requirement for 
inclusion, all studies had to have a baseline or retrospective measure of e-cigarette use 
(including but not limited to ever, occasional, heavy, recent, regular or frequent use) 





limited to ever, occasional, heavy, recent, regular, frequent or escalated smoking) as an 
outcome. Studies also had to include a comparison group (i.e., group which the exposed 
group is compared to), which could include young people who were never users, trial 
users (i.e., vaping once/a couple of times or less than 100 times) or not recent 
e-cigarette users or smokers, dependent on the study. Review articles and animal 
studies were excluded. 
2.3.2 Information Sources 
My search strategy was a replication and extension of a strategy used by Soneji and 
colleagues (2017); I added a search term to the original search criteria, and widened the 
search by including studies for which an OR could be calculated (rather than where an 
OR was reported). I conducted an electronic search of the PubMed, Embase, Web of 
Science and Wiley Cochrane Library databases and also searched the conference 
abstract books for the Society for Research on Nicotine and Tobacco and the Society for 
Behavioural Medicine conferences. Due to member restricted access, I was unable to 
search the NIH Tobacco Regulatory Science Conference abstracts as stated in my 
pre-registered protocol. I compared the list of studies to be included to those included in 
previous similar reviews to ensure the amended search strategy had not omitted any 
relevant studies. Studies written in languages other than English were translated using 
Google translate where translations were not already available. The search strategy was 
conducted up to 24th November 2018. E-cigarettes are a relatively new product on the 
consumer market; therefore, no date restrictions were placed on the search strategy. 
2.3.3 Search Strategy 
Studies were initially selected for screening using the following search terms within the 
titles, abstracts or keywords: Cigar* OR Tobacco OR Smok* AND Electronic Cigarette* 
OR E-Cig* OR Electronic Nicotine Delivery System* OR Vape OR Vaping OR Alternative 
Nicotine Delivery System*. Boolean operators and truncations differed depending on 
the database. Relevant medical subject headings (MeSH) terms were included when 
searching the PubMed database. The search dates and terms used for each platform can 
be found in Appendix 1. The most notable difference between the search strategy of 





‘Alternative Nicotine Delivery System’. This term was being frequently used at 
conferences and in research articles, so I thought it relevant to include in the search. 
2.3.4 Study Selection and Data Collection Process 
Study selection and data extraction took place over three stages. Stage 1 consisted of 
title and abstract screening; Stage 2 consisted of a full text screening; Stage 3 consisted 
of data extraction from selected studies. For each paper, my review team (SS and SP) 
and I extracted administrative details, study details and participant characteristics. 
Specifically, these included: author names; year of publication; country of the study; 
study design; study name (if applicable); sex of included participants, percentage of 
males included in the total sample and in the case and control groups; number of cases, 
controls and the size of the cohort; year(s) of data collection; age of the total sample, 
cases and controls; follow up length (if applicable); comparison group; exposure; 
outcome; covariates; definition of e-cigarette use and smoking; and type of assessment 
of e-cigarette use and smoking. We also extracted exposure and control details, 
outcome details, and results and conclusions. Specifically, these included: stratification 
information; direction of effect; effect estimate reported; number of individuals 
included in specific analyses; number of individuals exposed and unexposed in the 
analysis and number of subsequent smokers for each group; effect size, confidence 
intervals, standard errors and p-values for both unadjusted and adjusted analyses; and 
the conclusion regarding support for the gateway hypothesis. Titles, abstracts and full 
text articles were double screened and then double extracted by the review team 
(myself [100%], SS [50%] and SP [50%]). Discrepancies between myself and the second 
reviewer were resolved by the third reviewer where necessary. Covidence 
(www.covidence.org), an online systematic review tool which is in partnership with 
Cochrane, was used to streamline and document this process.  
When insufficient information was available to determine eligibility, I contacted study 
authors directly via email. Contacting study authors proved challenging, with some 
authors changing institutions – and consequently changing email addresses – and some 
being slow to reply or failing to reply at all. Where insufficient information was provided 





2.3.5 Risk of Bias Assessment 
Risk of bias within studies was assessed using the Newcastle-Ottawa Scale (NOS) (Wells 
et al., 2012). The selection, comparability and outcome domains of the tool were used 
to assess the risk of bias in all full texts included in the review (Appendix 2). The studies 
were rated as good, fair or poor quality based on the star system of the tool (maximum 
of 9 stars). Thresholds were applied to convert the NOS for study quality to Agency for 
Health Research and Quality standards (McDonagh, Peterson, Raina, Chang, & Shekelle, 
2013) (whereby a good quality rating indicates low risk of bias and a poor rating 
indicates high risk of bias). Good quality ratings were determined by 3 or 4 stars in the 
selection domain and 1 or 2 stars in the comparability domain and 2 or 3 stars in the 
outcome/exposure domain. Fair quality was determined by 2 stars in the selection 
domain and 1 or 2 stars in the comparability domain and 2 or 3 stars in the 
outcome/exposure domain. Poor quality was determined by 0 or 1 star in the selection 
domain or 0 stars in the comparability domain or 0 or 1 stars in outcome/exposure 
domain. Quality/risk was double assessed by the review team. Studies were not 
excluded based on their risk of bias, but this information was used to explore 
heterogeneity by subgrouping. 
Risk of bias across studies was assessed using the symmetry and 95% confidence region 
of a funnel plot (Higgins, Green, & Cochrane Collaboration, 2008). Asymmetry and more 
than 5% of points lying above the 95% confidence region may indicate some bias across 
studies. 
2.3.6 Causality Assessment 
Nine Bradford-Hill criteria are often used to assess causality (Hill, 1965). I selected four 
of these criteria to indicate the strength of evidence of a possible causal relationship 
between our exposure and outcome: strength of association, specificity, temporality and 
dose responsivity. I chose these criteria because they are particularly relevant to studies 
assessing whether e-cigarettes may act as a gateway to smoking (Etter, 2018) and could 
be measured on a study-by-study basis (unlike consistency). A strong association was 
defined as having an adjusted OR of two or more. Studies were considered specific if 
they adjusted for relevant covariates (e.g., peer smoking/vaping and impulsivity) in 





criterion was met if studies were assessed longitudinally (i.e., e-cigarette use was 
measured at time point 1 with a measure of smoking prior to measuring later smoking at 
time point 2) – retrospective measures did not meet this criterion. Studies which 
measured and took into account frequency of e-cigarette use, length of time the 
product was used for, or how much nicotine was in the e-liquid used, were considered 
to meet the dose responsivity criterion.  
2.3.7 Summary Measures 
Effect estimates were reported as ORs (and converted where necessary). ORs of the 
association between e-cigarette use and later cigarette use were combined using a 
random-effects model. I chose a random-effects model to account for potential 
variations in the true effect between studies (e.g., the effect may vary by age thus the 
true effect may be greater in studies with younger participants). All unadjusted ORs 
were calculated using observed data points which were obtained from the original study 
or directly from the author if insufficient information was provided in the original study. 
Calculated effect sizes were double checked by the review team.  
As I did not have access to the original data sets, the adjusted ORs were reported as they 
were in the original study. Where adjusted risk ratios had been reported, they were 
converted to ORs using a modified version of a formula published in Section 12.5.4.4 of 
the Cochrane Handbook (Higgins et al., 2008): OR = (-RR + RR × ACR) / (RR × ACR - 1), 
where OR = odds ratio; RR = risk ratio; ACR = assumed control risk. I calculated ACR on a 
per study basis as the risk of later smoking among controls. Sufficient information was 
available to calculate the ACR for each of the included studies. 
2.3.8 Synthesis of Results 
I identified five subgroups of interest to explore the data by exposure and outcome 
definition:  
1) ever versus never e-cigarette use at baseline and ever versus never smoking at follow 
up. 
2) ever versus never e-cigarette use at baseline and current (past 30-day) versus 





3) current versus non-current e-cigarette use at baseline and ever versus never smoking 
at follow up.  
4) current versus non-current e-cigarette use and current versus non-current use of 
cigarettes at follow up.  
5) regular (at least monthly for more than 6 months) versus non-regular e-cigarette use 
at baseline and regular cigarette use versus non-regular cigarette use at follow up.  
In retrospective studies, measures of e-cigarette use prior to smoking were treated as 
baseline and smoking status at the time of the study was treated as the follow up.  
For the main analysis, I focussed on subgroup 1; I compared ever e-cigarette users with 
never e-cigarette users at baseline and calculated the pooled ORs (from unadjusted and 
adjusted ORs) for ever (versus never) cigarette use at follow up. Where multiple results 
were reported in the original study using varying definitions of the exposure or outcome 
(e.g., where the results for both subgroup 1 and subgroup 2 were reported), the 
estimate relating to the comparison of ever versus never e-cigarette use at baseline 
(subgroup 1) was used in the main analysis. However, if ever use of e-cigarettes 
(subgroup 1) was not reported, the main effect reported in the study (e.g., subgroup 2) 
was included in my main analyses.  
Pooling estimates from studies with different definitions of e-cigarette use (as I have in 
the main pooled estimate) can increase risk of bias (Haidich, 2010). Where possible (i.e., 
where more than one study was available), I also analysed the results of each exposure 
and outcome definition subgroup. I originally aimed to pool the results of subgroup 5 
(comparing regular use); however, insufficient data were available to do so. 
Heterogeneity of study effect estimates can be indicated by an I2 statistic (Higgins et al., 
2008). Sources of heterogeneity were explored through subgroup analysis. Specifically, I 
grouped the studies by risk of bias (poor, fair or high quality), age of participants 
(including versus excluding participants under the age of 18 years), and location of study 








2.4.1 Study Selection 
Figure 2.1 shows the PRISMA study selection flow chart. A total of 15,519 studies were 
selected for title and abstract screening, 9,199 remained after exclusion of duplicates. 
After title and abstract screening, 133 studies were selected for full text screening. Of 
these, 24 studies were initially selected for inclusion; however, 7 studies were not 
included in the meta-analysis because the data overlapped with other included studies. 
Where data overlapped, the most relevant study was selected based on aims (i.e., 
studies where the primary aim addressed the question of interest were selected above 
those which addressed the question in secondary analysis) and sample size (i.e., larger 
sample sizes were included where both studies were relevant based on aims). In the 
meta-analysis, 16 studies were included in the main pooled unadjusted analysis and 17 
studies were included in the pooled adjusted analysis. One study was excluded from the 
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2.4.2 Study Characteristics 
Full details of the study characteristics are shown in Appendix 3. All but one of the 
studies included were longitudinal. One study was cross-sectional in which participants 
were asked questions regarding their product use retrospectively (Auf et al., 2018). Total 
study sizes varied considerably, ranging from 347 to 39,718 and the number of 
participants included in the final analyses were often substantially smaller. Participants 
were mostly under 18 years of age and many of the studies were school-based. Where 
the numbers of males and females were reported, approximately 50% of the 
participants were male in most studies. However, only 33% were male in one study 
(Loukas, Marti, Cooper, Pasch, & Perry, 2018). Few studies reported the numbers of 
males and females by e-cigarette exposure, but for those that did, there were 
consistently a higher percentage of males in the exposed group compared with the 
unexposed group (Leventhal et al., 2015; Primack et al., 2018; Primack et al., 2015). The 
majority of the studies (10 out of 17) were conducted in the US, three studies took place 
in the UK (Best et al., 2018; Conner et al., 2018; East et al., 2018), one was based in 
Canada (Hammond, Reid, Cole, & Leatherdale, 2017), one in Mexico (Lozano et al., 
2017), one in Germany (Morgenstern, Nies, Goecke, & Hanewinkel, 2018) and one in the 
Netherlands (Treur, Rozema, Mathijssen, van Oers, & Vink, 2018). Follow up periods in 
the longitudinal studies ranged from 4 to 24 months. 
In terms of observed exposures, most studies explored ever e-cigarette use with never 
e-cigarette users as a comparator. Two studies looked at current e-cigarette users with 
not current users as the comparator (Hammond et al., 2017; Miech et al., 2017) and two 
looked at both current and ever e-cigarette use (Spindle et al., 2017; Watkins, Glantz, & 
Chaffee, 2018). Only one study considered the amount of exposure to nicotine (Treur et 
al., 2018), and one study looked at frequency of e-cigarette use (Wills et al., 2017). In 
the one study that took nicotine use into account (Treur et al., 2018), two separate 
analyses were conducted for: 1) ever use of nicotine containing e-cigarettes (OR = 11.90, 
95% CI 3.36 to 42.11); and 2) ever use of non-nicotine containing e-cigarettes (OR= 5.36, 
95% CI 2.73 to 10.52). However, the analysis groups were not mutually exclusive (i.e., an 
individual would have been in both analysis groups if they had tried both nicotine 
containing and nicotine free e-cigarettes). No analysis was reported using subgroups of 





e-cigarette use (Wills et al., 2017) found that those who had used e-cigarettes at varying 
frequencies from once or twice (OR = 2.88, 95% CI 1.96 to 4.22) to weekly/daily (OR = 
4.09, 95% CI 2.43 to 6.88) were more likely than those who had not used e-cigarettes to 
have smoked at least once at follow up.  
Most of the included studies used ever smoking as an outcome. One study explored 
experimentation with smoking, as well as frequent and infrequent smoking (Barrington-
Trimis et al., 2018), and three looked at recent/current smoking at follow up (Leventhal 
et al., 2015; Spindle et al., 2017; Watkins et al., 2018).  
There was considerable variation between the covariates included in each study analysis 
(Appendix 3). One study only adjusted for four covariates (Best et al., 2018) while 
another adjusted for over 20 covariates (Morgenstern et al., 2018). All studies adjusted 
for sex and most adjusted for age and race/ethnicity. Other frequently included 
covariates were peer smoking, sensation seeking (and related factors), and drug and 
alcohol use.  
2.4.3 Quality/Risk of Bias Within Studies and Causality 
The quality of studies (or inversely, risk of bias) was good in most cases when rated 
using the NOS (Table 2.1). One study was rated as fair quality (Lozano et al., 2017), and 
three were rated as poor quality (Auf et al., 2018; Primack et al., 2018; Treur et al., 
2018). Of the four Bradford-Hill criteria for causality deemed relevant to this research, 
the majority (11 studies) met three criteria (usually strength of evidence, temporality 
and specificity), four studies only met two criteria (Auf et al., 2018; Hammond et al., 
2017; Leventhal et al., 2015; Loukas et al., 2018) and two met four criteria (Treur et al., 
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out of 4 
Auf et al. (2018) Poor  Strong Yes No No 2 
Barrington-Trimis et al. (2018) Good Strong Yes Yes No 3 
Best et al. (2018) Good  Strong Yes Yes No 3 
Conner et al. (2018) Good  Strong Yes Yes No 3 
East et al. (2018) Good  Strong Yes Yes No 3 
Hammond et al. (2017) Good  Strong No Yes No 2 
Leventhal et al. (2015) Good  Weak Yes Yes No 2 
Loukas et al. (2018) Good  Weak Yes Yes No 2 
Lozano et al. (2017) Fair  Strong Yes Yes No 3 
Miech et al. (2017) Good Strong Yes Yes No 3 
Morgenstern et al. (2018) Good Strong Yes Yes No 3 
Primack et al. (2015) Good  Strong Yes Yes No 3 
Primack et al. (2018) Poor  Strong Yes Yes No 3 
Spindle et al. (2017) Good  Strong Yes Yes No 3 
Treur et al. (2018) Poor Strong Yes Yes Yes 4 
Watkins et al. (2018) Good  Strong Yes Yes No 3 
Wills et al. (2017) Good  Strong Yes Yes Yes 4 
Note: Thresholds were applied to convert the Newcastle-Ottawa scales to Agency for Health Research and Quality standards (whereby a good quality rating 
indicates low risk of bias and a poor rating indicates high risk of bias). Good quality = 3/4 stars in selection domain AND 1/2 stars in comparability domain 
AND 2/3 stars in outcome/exposure domain. Fair quality = 2 stars in selection domain AND 1/2 stars in comparability domain AND 2/3 stars in 
outcome/exposure domain. Poor quality = 0/1 star in selection domain OR 0 stars in comparability domain OR 0/1 stars in outcome/exposure domain. ORs 






2.4.4 Results of Individual Studies 
The results of individual studies included in the main meta-analysis can be found in 
Table 2.2 and within forest plots in Figures 2.2 (unadjusted) and 2.3 (adjusted). Effect 
sizes (ORs) ranged from 2.46 to 12.31 (unadjusted). All estimates were considered to 
show strong evidence of a positive association between e-cigarette use among 
non-smokers and later smoking in unadjusted analyses. Covariates included in the 
adjusted analyses varied on a study-by-study basis. After adjustment, effect estimates in 
all but three studies (Leventhal et al., 2015; Loukas et al., 2018; Lozano et al., 2017) 
remained strong (i.e., OR > 2). These studies included relatively rigorous adjustment for 
covariates (i.e., adjusting for peer use, impulsivity, susceptibility etc.). The inclusion of 
covariates in the model attenuated most results towards the null (although none 
crossed the null). Effect sizes were strengthened after adjustment in four studies 







Table 2.2. Individual results of studies included in the meta-analysis. 
 Initiated cigarette smoking (n)/ 
not initiated cigarette smoking (n) 
Odds of initiating smoking 
Study E-cigarette users Never/not current 
e-cigarette users 
Unadjusted odds ratio  
(95% CI) 
Adjusted odds ratio (95% CI) 
Auf et al. (2018) * * * 3.7 (3.1, 4.5)* 
Barrington-Trimis et al. (2018) 184/857 280/4,171 3.80 (3.10, 4.66) 4.57 (3.56, 5.87) 
Best et al. (2018) 74/183 249/1,942 4.62 (3.34, 6.38) 2.42 (1.63, 3.60) 
Conner et al. (2018) 118/343 124/1,383 5.32 (3.99, 7.11) 4.06 (2.94, 5.60) 
East et al. (2018) 11/21 74/902 12.31 (5.06, 29.94) 10.57 (3.33, 33.50) 
Hammond et al. (2017) 136/487 1,313/16,831 4.58 (3.73, 5.63) 2.12 (1.68, 2.66) 
Leventhal et al. (2015) 19/222 71/2,308 2.95 (1.74, 4.99) 1.75 (1.10, 2.77) 
Loukas et al. (2018) 114/568 168/1,190 2.72 (2.10, 3.53) 1.36 (1.01, 1.83) 
Lozano et al. (2017) 86/216 950/4,479 2.46 (1.85, 3.26) 1.60 (1.31, 1.97)** 
Miech et al. (2017) 4/13 14/213 6.32 (1.73, 23.10) 6.58 (2.04, 57.88)** 
Morgenstern et al. (2018) 93/312 175/1,867 4.11 (3.08, 5.48) 2.50 (1.82, 3.54)** 
Primack et al. (2015) 6/16 65/678 5.66 (1.99, 16.07) 8.30 (1.20, 58.60) 
Primack et al. (2018) 6/16 81/889 6.06 (2.15, 17.10) 6.82 (1.65, 28.25) 
Spindle et al. (2017) 45/153 230/2,163 3.50 (2.41, 5.09) 3.37 (1.91, 5.94) 
Treur et al. (2018) 432/740 235/2,049 10.83 (8.87, 13.22) 11.9 (3.36, 42.11) 
Watkins et al. (2018) 81/425 387/9,923 5.80 (4.46, 7.54) 2.53 (1.80, 3.56) 
Wills et al. (2017) 42/215 50/926 4.25 (2.74, 6.61) 2.87 (2.03, 4.05) 
Overall 1,451/4,787 4,340/52,727 4.59 (3.60, 5.85) 2.92 (2.30, 3.71) 
*Raw data were not available or insufficient information was provided to calculate an accurate unadjusted odds ratio. Adjusted results were reported to 














Figure 2.3. Forest plot for the adjusted association between e-cigarette use and 





2.4.5 Synthesis of Results 
When pooled in a random effects meta-analysis, e-cigarette use in non-smoking young 
people was associated with a 4-and-a-half-fold increase in the odds of subsequent 
smoking (unadjusted; OR = 4.59, 95% CI 3.60 to 5.85). Pooling the adjusted estimates, 
the association was still strong but somewhat weaker (adjusted; OR = 2.92, 95% CI 2.30 
to 3.71). Heterogeneity statistics indicated there was high heterogeneity in both the 
unadjusted (I² = 88%) and adjusted (I² = 85%) analyses. 
Of the 16 studies included in the unadjusted meta-analysis, 13 provided results which 
explored ever e-cigarette use and ever smoking and three studies provided results for 
ever e-cigarette use and current smoking. Three studies explored past 30-day e-cigarette 
use and ever smoking. Further studies explored: past 30-day use of e-cigarettes and past 
30-day smoking (one study), frequency of e-cigarette use (one study) and frequency of 
smoking (one study). Pooled analyses require at least two studies to be available, thus 
pooled analyses were not possible for these subgroups. Forest plots of the analyses 
sub-grouped by varying exposure and outcome definitions (adjusted estimates) can be 
found in Figures 2.4-2.7. The number of studies included in the adjusted analyses were 
slightly higher in some cases than the unadjusted results due to the availability of raw 







Figure 2.4. Forest plot for the adjusted association between ever e-cigarette use and 
later ever smoking. 
 
2.4.5.1 Ever e-cigarette use and ever smoking (subgroup 1). Pooled analyses of studies 
exploring ever vaping among never smokers and subsequent ever smoking resulted in a 
pooled unadjusted OR of 4.17 (95% CI 3.53 to 6.29). Heterogeneity between included 
studies in this analysis was high (I² = 90%). The results of the pooled adjusted analysis 
(Figure 2.4) were similar with a slightly lower odds ratio (OR = 3.13, 95% CI 2.35 to 4.16). 






Figure 2.5. Forest plot for the adjusted association between ever e-cigarette use and 
later current smoking. 
 
2.4.5.2 Ever e-cigarette use and current smoking (subgroup 2). Among never smokers, 
pooled unadjusted analyses indicated ever e-cigarette users had increased odds of 
subsequently becoming a current smoker (OR = 4.35, 95% CI 2.95 to 6.42) compared 
with never e-cigarette users. Heterogeneity estimates indicated low heterogeneity (I² = 
41%). Adjusted analyses (Figure 2.5) showed similar but weakened results when pooled 
(OR = 2.21, 95% CI 1.72 to 2.84). Heterogeneity was indicated as low in the adjusted 







Figure 2.6. Forest plot for the adjusted association between past 30-day e-cigarette use 
and later ever smoking. 
 
2.4.5.3 Current e-cigarette use and ever smoking (subgroup 3). Past 30-day use of 
e-cigarettes among never smokers was associated with increased odds of ever 
subsequently smoking (OR = 5.64, 95% CI 3.75 to 8.50) in pooled unadjusted analysis. 
Heterogeneity estimates indicated moderate heterogeneity (I² = 49%). The pooled 
adjusted analysis (Figure 2.6) also indicated increased odds of ever subsequently 
smoking (OR = 2.33, 95% CI 1.84 to 2.96). Heterogeneity estimates also indicated low 







Figure 2.7. Forest plot for the adjusted association between current e-cigarette use and 
later current smoking. 
 
2.4.5.4  Current e-cigarette use and current smoking (subgroup 4). There was 
insufficient data available to calculate unadjusted estimates for one of the two studies 
which reported adjusted estimates for past 30-day use of e-cigarette and past 30-day 
smoking. Consequently, I was only able to pool the adjusted estimates. There was no 
clear evidence of an association between current e-cigarette use and current smoking at 







Figure 2.8. Forest plot for the adjusted association between e-cigarette use and later 
smoking among studies including and excluding those under the age of 18 years. 
 
2.4.5.5 Stratification by age. When the unadjusted main analyses were stratified by age 
(including versus excluding those under the age of 18 year olds) the pooled OR among 
studies including those under the age of 18 years was slightly higher (OR = 4.87, 95% CI 
3.73 to 6.35) than the pooled OR of studies excluding those under 18 (OR = 3.17, 95% CI 
2.37 to 4.25). Heterogeneity estimates indicated that there was low heterogeneity 
between studies excluding under 18’s (I² = 32%) but high heterogeneity between studies 
including under 18’s (I² = 88%). Adjusted pooled analyses including and excluding those 
under the age of 18 years are reported in Figure 2.8. The pattern of the results is similar 
in the adjusted and unadjusted analysis, but there was more evidence of heterogeneity 
in the adjusted analysis excluding those under 18 than in the unadjusted analysis. Of 








Figure 2.9. Forest plot for the adjusted association between e-cigarette use and later 
smoking among studies of fair/poor quality and good quality. 
 
2.4.5.6 Stratification by study quality/risk of bias. Due to limited variation in quality 
rating of studies using the NOS, fair and poor quality studies were pooled and compared 
with good quality studies. The pooled unadjusted OR for studies rated as good quality (n 
= 13 studies; OR = 4.29, 95% CI 3.67 to 5.01) was lower than the pooled ORs for 
fair/poor quality studies (n = 3 studies; OR = 5.41, 95% CI 1.67 to 17.51), but the 
confidence intervals overlap. Heterogeneity measures indicated that high quality studies 
were less heterogeneous than fair/poor quality studies (I² = 60% and I² = 97% 
respectively). Adjusted pooled analyses are shown in Figure 2.9. The pattern of the 
results is similar in the adjusted and unadjusted analysis, but there was more evidence 





2.4.5.7 Stratification by support for the gateway hypothesis. During the review process 
it became apparent that many studies did not draw clear conclusions regarding the 
gateway hypothesis or made balanced conclusions. This made it difficult to categorise 
studies and as such I was unable to stratify based on this criterion. This is encouraging as 
it suggests that authors are somewhat acknowledging the limitations of their findings, 
however, it could equally be a result of authors avoiding discussing the gateway 
hypothesis as it is such a charged topic. In hindsight, clearer criterion for determining a 
study to be supporting or refuting the hypothesis should have been outlined in my study 
protocol to allow my review team and I to more effectively judge the level of support for 
the gateway hypothesis that was present in each study conclusion. However, the use of 
strict criteria could distort the strength of the authors’ conclusions and inflate the 








Figure 2.10. Forest plot for the adjusted association between e-cigarette use and later 
smoking among US studies, UK studies, and studies outside of the US and UK. 
 
2.4.5.8 Stratification by location of study. There were only two countries in which more 
than one included study was conducted; 10 studies took place in the US and three took 
place in the UK. The pooled estimate for unadjusted odds of studies conducted in the US 
was 3.95 (95% CI 3.17 to 4.92) and in the UK was 5.55 (95% CI 3.94 to 7.82). 
Heterogeneity for studies conducted was high in the US (I² = 93%) and moderate in the 
UK (I² = 52%). The remaining studies were located in the Netherlands, Germany, Canada 
and Mexico. Pooling the results of these four studies, the odds of subsequent smoking 
was 4.75 (95% CI 2.54 to 8.89) with high heterogeneity between studies (I² = 96%). 





2.4.6 Risk of Bias Across Studies 
The risk of bias across studies is shown in a funnel plot in Figure 2.11. The figure is 
somewhat asymmetrical and some points (25%) lie above the superimposed funnel 
limits (95% confidence region) suggesting that there may be some publication bias and 
indicating there may be heterogeneity (as supported by the I2 statistics) or selection bias 
across the included studies (Sterne & Harbord, 2004).  
 
Figure 2.11. Funnel plot to assess risk of bias across studies. 
 
2.5 Discussion 
I have provided an update to the previous meta-analysis by identifying an additional 11 
studies which were not included in Soneji and colleagues’ (2017) meta-analysis and 6 
studies which were not included in the systematic review by Glasser and colleagues 
(2018). One study which was included in the previous meta-analysis was not included in 
this meta-analysis; it was substituted for more recent evidence using an overlapping 





longer accessible was substituted for the published article (Primack et al., 2016). The 
pooled adjusted estimate indicated a strong association, reflecting a nearly 3-fold 
increased odds of later smoking among young people who have used e-cigarettes. 
Subgrouping and stratification revealed some differences between groups, but 
consistently indicated a strong positive association. The main findings were consistent 
with the findings of Soneji and colleagues (2017), whereby there was a strong positive 
association between e-cigarette use among non-smokers and subsequent smoking and a 
high degree of heterogeneity between studies. Similar to Soneji and colleagues (2017), 
stratification by age revealed slightly lower pooled estimates for the odds of smoking in 
studies which excluded those under the age of 18 years compared with studies including 
them. Stratification by location indicated stronger associations in the UK compared with 
the US and other countries.  
Three of the four pre-selected Bradford-Hill criteria for causality (strength of association, 
temporality and specificity) were commonly rated as having been met in the included 
studies. Although not assessed on a study-by-study basis, the consistency and 
plausibility criteria were also met; the included study estimates are consistently in the 
same direction and plausible causal pathways were considered or discussed in some 
studies (e.g., nicotine addiction or similar hand-to-mouth actions for both behaviours). 
Although meeting these criteria provides some support for a possible causal relationship 
between e-cigarette use and later smoking, which is in line with the theory that 
e-cigarettes act as a gateway to smoking (Bell & Keane, 2014; Etter, 2018), meeting 
these criteria does not rule out other potential explanations of the association (e.g., a 
genetic or common liability).  
Commonly in the literature, the claim is that the gateway effect is attributable to 
nicotine addiction (Bell & Keane, 2014). E-cigarettes have historically not delivered 
nicotine as effectively as cigarettes (Farsalinos et al., 2014), so that e-cigarettes may not 
be adequate to satisfy users who become more heavily addicted to nicotine (Vanyukov 
et al., 2012). In contrast, the common liability theory proposes that people who use 
multiple drugs (or in this case different delivery methods of the same drug) share the 
same predisposing factors (Chapman et al., 2019). When considering a causal 
relationship between e-cigarette use and later smoking (e.g., the gateway hypothesis), 
these shared factors/confounders (i.e., the common liability theory) should be taken 





have strong reservations about inferring a causal relationship from my findings. I discuss 
my reservations below with respect to the Bradford-Hill criteria for causality, while 
highlighting the additional research which may help to strengthen the evidence for a 
causal relationship. I have also described how identifying areas for improvement in the 
field helped to inform my research questions and study designs in the subsequent 
chapters of this thesis. 
The majority of studies included in the meta-analysis satisfied the temporality criterion. 
All studies except one were longitudinal and measured exposure prior to smoking and 
smoking at follow up; therefore, the observed association between earlier e-cigarette 
use and later smoking is unlikely to be due to reverse causality (i.e., smoking leading to 
e-cigarette use). However, smoking status is sometimes misreported by young people 
(Khouja, Munafò, et al., 2020) meaning that some self-reported non-smokers at baseline 
may in fact have smoked previously. If ever smokers are more likely to use e-cigarettes 
and are more likely to misreport their smoking history at baseline compared with never 
smokers, but accurately report that they are ever smokers at follow up, the association 
could be biased away from the null. Self-reports were validated in one study (Conner et 
al., 2018) using breath carbon monoxide levels; however, with the short half-life of 
breath carbon monoxide (4-6 hours) this measure is not suitable to validate self-reports 
of ever smoking. Other methods of biochemical verification of smoking, such as 
assessments of cotinine levels, are unsuitable for validation in this research; cotinine is a 
metabolite of nicotine and will therefore be affected by both smoking and using 
nicotine-containing e-cigarettes, so it cannot be used to distinguish between products. 
In future research, the use of biomarkers which can identify long-term smoke exposure 
could help researchers to objectively confirm self-reported smoking status at baseline. 
Differential DNA methylation signals have been observed among smokers compared 
with non-smokers (Lee et al., 2015; Zeilinger et al., 2013) and it is plausible that different 
signals would be observed among e-cigarette users (Richmond et al., 2018). Eventually, 
researchers may be able to use these differential methylation signatures to exclude 
people who misreport their behaviour. Consequently, researchers could more 
confidently dismiss reverse causation as an explanation for the association.  
It is also worth noting that the measure I used to determine specificity was relatively 
liberal. The review team and I rated studies as specific if they adjusted for more than 





fully explained the relationship between e-cigarette use and current smoking, 
demonstrating the importance of adjusting for potential confounders such as alcohol 
and drug use, peer smoking and risk-taking behaviour (Kim & Selya, 2019). In addition, 
some potential confounders, like impulsivity, are difficult to fully capture via self-report 
and are often assessed relatively crudely. Had we considered only studies adjusting for 
behavioural risk factors (e.g., alcohol and marijuana use) to meet this criterion, only six 
studies would have been rated as specific. Adjusting for these factors reduced the OR 
and/or widened the confidence interval compared with the unadjusted analysis (ORs 
reduced by 1.40 on average), however, I found no clear difference in OR reduction when 
compared with studies not adjusting for behavioural risk factors (p = 0.19). Further 
research is needed to investigate the demographic, behavioural, and lifestyle factors 
which are associated with the use of e-cigarettes among specific populations. In Chapter 
3, I have explored these factors among young adults in the UK.  
Since statistical adjustment can never fully remove the risk of confounding, other 
approaches to exploring the potential for a common liability (e.g., to risk-taking) 
explaining the observed association between e-cigarette use and smoking are also 
warranted. One way of exploring the specificity of this relationship more thoroughly 
(which none of the included studies did) would be the use of negative control outcomes 
(i.e., outcomes which have similar confounding structures to smoking but for which 
there is no biologically plausible mechanism for e-cigarette use being a causal factor). 
For example, behaviours like smoking or using an e-cigarette are unlikely to cause other 
risk-taking behaviour such as increasing the number of sexual partners a person has; if 
similar associations are seen between e-cigarette use, smoking and number of sexual 
partners, it would indicate that the link may be caused by common underlying factors. 
Furthermore, exploring the genetic aetiology of e-cigarette use may help in 
understanding whether e-cigarette use and smoking share a common liability. If 
e-cigarette use has a shared genetic aetiology with negative control outcomes for which 
there are no plausible pathways through which e-cigarette use would be a causal factor 
(e.g., gambling) this would suggest that the association is due to the two behaviours 
sharing a common genetic liability for risk-taking. I have begun to explore this in Chapter 
4 using polygenic risk scores of smoking initiation and utilising negative control 
outcomes, but the triangulation of evidence obtained using different methods will be 





To meet the final pre-selected Bradford-Hill criterion, dose-response, increased 
e-cigarette use should lead to greater risk of later smoking. Despite the most likely 
causal pathway from e-cigarette use to later smoking being via nicotine addiction (Etter, 
2018), only one of the included studies measured and took into account the nicotine 
content of the e-cigarettes used. This study indicated that both use of nicotine 
containing e-cigarettes and (to a lesser extent) non-nicotine containing e-cigarettes are 
strongly associated with later smoking (Treur et al., 2018). This suggests that nicotine 
exposure may be one factor in the association between e-cigarette use and later 
smoking, but not the sole mechanism. Unfortunately, the study reported analyses based 
on nicotine versus non-nicotine vaping in which these two groups were not mutually 
exclusive (i.e., individuals would be in both analysis groups if they tried both nicotine 
containing and nicotine free e-cigarettes). Thus, it is unclear whether there is an 
association between e-cigarette use among non-smokers and later smoking when users 
have not been exposed to nicotine. To determine whether there is a nicotine 
dose-response involved in the association, we would also need to observe the frequency 
of e-cigarette use prior to smoking. The one study that looked at frequency of use (at 4 
levels) indicated that there may be a dose-response to nicotine when comparing use just 
once/twice to use weekly/daily (Wills et al., 2017), but the odds of later smoking did not 
increase linearly with each increased level of frequency of use. As nicotine is 
metabolised differently on an individual basis, direct measures of nicotine rather than 
frequency of use may be necessary to determine whether there is a dose-response. 
Although nicotine may play a causal role in the relationship between e-cigarette use and 
smoking, without further study of any dose-response relationship (including the study of 
nicotine content and frequency of e-cigarette use), I cannot confidently infer causality 
according to Bradford-Hill criteria.  
The heterogeneity statistics of 88% (unadjusted analyses) and 85% (adjusted analyses) 
indicate that my effect estimates should be interpreted with caution. When studies 
included in meta-analyses are substantially statistically heterogenous (i.e., they vary in 
population, study design, risk of bias etc.), estimates of the combined effect may not be 
meaningful and confidence in the generalisability of the findings is reduced (Higgins et 
al., 2008; Higgins, Thompson, Deeks, & Altman, 2003). Although there is no commonly 
agreed upon strict threshold for heterogeneity, as a rough guide the Cochrane handbook 





heterogeneity (Higgins et al., 2008). Age contributed to the observed heterogeneity in 
this meta-analysis – the association was stronger in studies including those under the 
age of 18 years than studies excluding them. In adolescence, risk-taking is common 
(Reyna & Farley, 2006) and decision making for health-risk behaviours is influenced by 
peers, societal influences and parental monitoring, but these factors are less influential 
to adults (Halpern-Felsher, Baker, & Stitzel, 2016). Such factors are likely to be 
confounders of the association between e-cigarette use and later smoking (particularly 
in studies of those under the age of 18 years) and should be included as covariates 
where possible. The results stratified by location also suggested there may be societal 
influences on the association; the association was stronger among studies based in the 
UK than those based in the US. This suggests that country-specific societal factors, such 
as legislation, taxation, social norms, and public opinion, may be confounding this 
association such that study results may not be generalisable to other countries.  
Considering the reservations which I have outlined, it is still unclear whether e-cigarette 
use is causing young people to start smoking. However, a substantial number (10%) of 
young people were identified in these studies who have used e-cigarettes as 
non-smokers. Although many of the studies failed to account for whether the young 
people were using e-cigarettes regularly or frequently (rather than just experimenting), 
this does raise concerns about the potential health impact of long-term nicotine use 
aside from exposure to other constituents of cigarette smoke. Future studies should aim 
to understand why youth and young adults vape, and whether this relates to continued 
smoking and vaping and should employ novel methods to explore the potential health 
effects related to long-term nicotine use. For example, in this thesis I have explored the 
smoking and vaping behaviour associated with different reasons for vaping (Chapter 3) 
and I have used multivariable Mendelian randomisation (MVMR) to explore the effects 
of nicotine on various health outcomes while accounting for cigarette consumption in 
general, and vice versa (Chapter 5).  
2.6 Chapter Summary 
There is a strong consistent association in observational studies between e-cigarette use 
among non-smokers and later smoking. However, findings from published observational 
studies do not provide clear evidence that this is explained by a gateway effect rather 





should explore the factors influencing e-cigarette use and consider including relevant 
potential confounders, such as better measures of impulsivity and other measures of 
propensity to risk-taking, as well as objective measures of smoking status in order to 
better explore the potential role of e-cigarettes as a gateway to smoking. Studies that 
explore the genetic underpinnings of these behaviours and use negative control 
outcomes may also help improve our understanding of the association between 
e-cigarette use and later smoking. Finally, to prevent the use of e-cigarettes among 
young people (and potential consequences of e-cigarette use, such as smoking), it is 
important to identify adolescents and young adults who are more likely to use 
e-cigarettes. It is also necessary to understand why they use e-cigarettes and explore 
whether this impacts their longer-term smoking and vaping behaviour. In the next 
Chapter, I start to explore this by i) looking at the characteristics of e-cigarette users and 
never users to identify which young adults are more likely to use e-cigarettes; and ii) 
exploring the association between different reasons for vaping and later smoking and 







Chapter 3 Who uses and continues to use 
e-cigarettes and why? 
This chapter closely resembles sections from the following pre-print: 
Khouja, J. N., Taylor, A. E., & Munafò, M. R. (2020). Associations between reasons for 
vaping and current vaping and smoking status: Evidence from a UK based cohort. Drug 
and Alcohol Dependence, 217, 108362; doi.org/10.1016/j.drugalcdep.2020.108362.  
Khouja, J. N., Taylor, A. E., & Munafò, M. R. (2020). Associations between reasons for 
vaping and current vaping and smoking status: Evidence from a UK based cohort. 
medRxiv; doi:10.1101/19006007.  
I took the lead in designing, implementing and interpreting this observational study with 
the support of my co-authors. Specifically, MM and AT provided feedback on the design 
of the study and during the preparation of the manuscript. I was responsible for the data 
analysis and was responsible for writing the first draft of the manuscript and editing the 
manuscript in response to comments from co-authors and reviewers.  
 
3.1 Chapter Overview 
As discussed in Chapters 1 and 2, it is important to know who is vaping, why, and how 
this may relate to their later smoking and vaping behaviour. In this Chapter, I compare 
the characteristics of ever vapers versus never vapers in a cohort of 3,994 young adults 
in the Avon Longitudinal Study of Parents and Children (ALSPAC). I further explore the 
characteristics of ever vapers by comparing former and current vapers. For ever vapers, I 
describe the retrospectively self-reported reasons for vaping by 23 years of age and 
explore the association with vaping and smoking status at 24 years. Using logistic 
regression, I assess the association with subsequent vaping behaviour among ever 
vapers who had ever smoked, and with subsequent smoking behaviour among 
individuals who had been regular smokers prior to vaping. I restrict my analysis to ever 






Of an estimated 3.6 million vapers in Great Britain, over half now consider themselves 
ex-smokers (Action on Smoking and Health, 2019a). As discussed in Chapter 1, evidence 
suggests e-cigarettes are less harmful than cigarettes (Public Health England, 2015) and 
can be an effective smoking cessation aid (Hartmann-Boyce et al., 2020). Nevertheless, 
34% of adult smokers have not tried e-cigarettes (Action on Smoking and Health, 2019a), 
and not all who have tried them have successfully quit smoking (Hartmann‐Boyce et al., 
2016; Zhu, Zhuang, Wong, Cummins, & Tedeschi, 2017). Given the popularity of 
e-cigarettes, it is important to know which individuals use e-cigarettes, why, and 
whether different reasons for use are associated with continued use of e-cigarettes and 
smoking cessation.  
As discussed in Chapter 1, one study in the US showed that vapers are more likely to be 
male and have a lower income (Levy et al., 2017). Additionally, smokers and ex-smokers 
who had quit in the last 3 years were more likely to have used e-cigarettes than those 
who had not, but a lower percentage of current and regular vapers were current 
smokers compared to ever vapers (Levy et al., 2017). In the UK, current and non-current 
vapers differ in terms of socio-economic status, number of cigarettes smoked per day 
and quit attempts in the last year (Brown et al., 2014). However, there is limited 
research exploring whether these differences are observable among young adults in the 
UK. 
Among adults (18+ years) in Great Britain, the primary reasons for vaping are related to 
smoking cessation (Action on Smoking and Health, 2019a). Currently, there is limited 
evidence of why young adults in Great Britain vape, but evidence from elsewhere in the 
world suggests that their reasons for vaping may differ from older adults. Evidence from 
the US suggests that adolescents and young adults vape primarily out of curiosity (Kong 
et al., 2015) or because their friends/family vape (Tsai et al., 2018). In a study of South 
Korean adolescents who had ever smoked and ever vaped, the most common reason for 
vaping among infrequent users was out of curiosity, but the most common reasons 
given for frequent vaping were to quit smoking and being able to vape indoors (Lee et 





Vaping to quit smoking was also associated with continued vaping among US middle and 
high school students (Bold et al., 2016). Although some studies have explored 
associations between reasons for vaping and continuation or discontinuation of vaping 
and smoking (Bold et al., 2016; Nicksic et al., 2019; Saddleson et al., 2016; Yong et al., 
2019), there is limited evidence from the UK. Furthermore, young adults in their 
mid-twenties are a relatively understudied subgroup in research on reasons for vaping; 
most research either focusses on school children, students or older adults. 
In this study, I aimed to explore the characteristics of young adults who are vaping or 
have previously vaped, and whether different reasons for vaping are associated with 
continued vaping and smoking. Specifically, I sought to investigate whether different 
retrospectively recalled reasons for vaping by 23 years are associated with vaping 
and/or smoking one year later among a UK cohort of young adults.  
3.3 Methods 
3.3.1 Study Population 
Young adults enrolled in ALSPAC formed the study sample. The profile of the cohort has 
previously been described in two publications (Boyd et al., 2013; Fraser, Macdonald-
Wallis, Tilling, Boyd, Golding, Smith, et al., 2013) and the phases of enrolment are 
described in more detail in the cohort profile update (Northstone et al., 2019). The total 
sample size for the cohort is 15,454 pregnancies, resulting in 15,589 foetuses (Figure 
3.1). Please note that the study website contains details of all the data that is available 
through a fully searchable data dictionary and variable search tool 
(http://www.bristol.ac.uk/alspac/researchers/our-data/). ALSPAC study data from 22 
years onwards were collected and managed using REDCap electronic data capture tools 
hosted at the University of Bristol (Harris et al., 2009). 
The questionnaires on vaping and smoking at 23+ years of age were completed by 4,222 
study children (from here on in described as young adults) and 3,241 of these also 
completed the questionnaires at 24+ years of age. The 23+ questionnaire was 
completed by the young adults between the ages of 23 and 25 and the 24+ 
questionnaire was completed a year later when the young adults were between 24 and 
26 years. For ease, I will refer to these time points as 23 years and 24 years respectively. 








Figure 3.1. Flow chart depicting the process of data inclusion in the analysis of the 
associations between reasons for vaping at 23 years and vaping and smoking at 24 
years. 
*Figures shown for ever vapers and ever smokers, for ever vapers and prior smokers n = 






Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committees. Informed consent for the use of data 
collected via questionnaires and clinics was obtained from participants following the 
recommendations of the ALSPAC Ethics and Law Committee at the time. 
3.3.2 Measures 
3.3.2.1 Participant characteristics. A range of behavioural and lifestyle factors were 
measured in order to compare the characteristics of: (i) ever vapers (who have vaped at 
least once) versus never vapers; and (ii) former vapers (who have vaped at least once 
but reported not currently vaping at 23 years) versus self-reported current vapers. 
Where these characteristics were measured at multiple timepoints in ALSPAC, I selected 
the variable which measured the characteristic nearest to the exposure measure at 23 
years. Maternal smoking in pregnancy was recorded at 18 weeks gestation and was 
based on whether the mother responded yes to smoking in the first 3 months of 
pregnancy. Body mass index (BMI) was measured in clinic at 17 years and was calculated 
from self-reports of height and weight to the nearest one decimal place using the 
calculation: weight(kg)/height(m)2. Measures of risk-taking were taken at 20 years 
(alcohol, tobacco, cannabis and other drugs and gambling). Alcohol use was measured 
using the Alcohol Use Disorders Identification Test (Babor, Higgins-Biddle, Saunders, & 
Monteiro, 2001). Tobacco use was self-reported in response to a question asking 
whether they had ever smoked a whole cigarette (response options: yes/no). Cannabis 
use was measured via a question asking if the young person had tried cannabis 
(response options: yes/no). Other drug use was determined by a response of one or 
more when asked how many other illicit drugs the young person had ever used. 
Education/employment status and parenthood status (i.e., whether the young person 
had become a parent or not) were measured at 21 years. Education and employment 
status were gathered via a question asking the young person if they were currently in 
education, training or employment (response options: yes/no). The young adults were 
asked whether they were a parent at 21 years old. Responses of ‘Yes – biological’ and 
‘Yes – non-biological’ were recoded to ‘yes’ to create a binary variable (yes/no). Mental 
health factors, measured at 21 years, were anxiety and low mood in the past 4 weeks. 
Anxiety was measured using the General Anxiety Disorder (GAD-7) questionnaire 





time in the 4 weeks prior to completing the questionnaire at 21 years that the young 
person had felt downhearted and depressed. Response options included: ‘All of the 
time’, ‘Most of the time’, ‘Some of the time’, ‘A little of the time’, and ‘None of the 
time’. This was recoded into a binary variable of ‘None of the time’ versus all other 
responses. Factors relating to vaping (age first vaped, frequency of use, duration of use, 
device type used) were measured at 23 years (full questions and answer options 
provided are presented in Appendix 4). Vaping and smoking status were measured at 
both 23 and 24 years (questions and answer options are described in 3.3.2.2 and 
3.3.2.3). 
3.3.2.2 Exposure. Exposure was measured at 23 years. To determine whether 
questionnaire respondents had ever vaped, they were asked “Have you ever used/vaped 
an electronic cigarette (e-cigarette) or other vaping device?”. To determine whether 
they had ever smoked, they were asked “Have you ever smoked a whole cigarette 
(including roll-ups)?”. To determine whether respondents were regular smokers just 
prior to vaping, they were asked “Did you smoke tobacco regularly just before you 
started using electronic cigarettes/vaping devices?”. In a multiple-choice question at 23 
years, respondents who had ever vaped before were asked “what are/were your 
reasons for using electronic cigarettes/vaping devices?” and instructed to cross all 
answers that applied. Seven response options were available: “To help me quit 
smoking”, “To help me cut down on the number of cigarettes I smoke”, “To help me 
with cravings in situations where I cannot smoke e.g. travel, indoors”, “Pleasure”, 
“Curiosity”, “Friends use them” and “Other”. The “Other” option was rarely selected and 
thus was not included in this analysis.  
3.3.2.3 Outcome. At 24 years, e-cigarette outcome data was collected via questionnaire 
on current vaping. Current vaping was self-reported by the respondent in response to 
the question “Do you currently use/vape e-cigarettes or other vaping devices?”. To 
determine smoking status at 24 years, the young adults were asked “Have you smoked 
any cigarettes in the past 30 days?”.  
3.3.2.4 Potential confounders. Various demographic factors were measured which have 
previously been shown to impact the likelihood of vaping and smoking and could 
potentially influence the reason given for vaping (Hartwell et al., 2017; Hedman et al., 





Millward, & Sandford, 2012). Sex was recorded at birth. Parental socioeconomic position 
(SEP) was recorded at 18 weeks gestation and was assessed via parental occupational 
status (based on the higher of the mother or partner's occupational social class using the 
1991 British Office of Population and Census Statistics classification). Ethnicity was 
recorded at 32 weeks gestation and was classified as white or non-white. The young 
person’s ethnic background was defined as non-white if their mother responded that 
she or her partner was any other race or ethnic group than white.  
3.3.3 Statistical Analysis 
3.3.3.1 Differences in participant characteristics. Differences between never and ever 
vapers as well as former and current vapers were assessed using a χ2 test (binary 
outcomes) or t-test (continuous outcomes). 
3.3.3.2 Reasons for e-cigarette use and smoking/vaping behaviour. In a series of 
logistic regressions, I explored the association between retrospectively reported reasons 
for vaping by 23 years and vaping and smoking continuation at 24 years. Each of the six 
reasons for vaping were analysed individually as a binary variable (indicated/not 
indicated as a reason for use). Vaping and smoking status were treated as binary 
variables (i.e., current vaper versus not current vaper and smoker versus not current 
smoker). Firstly, I explored the association between reasons for vaping (retrospectively 
reported at 23 years) and current vaping at 24 among ever vapers at 23 years. I planned 
to stratify this analysis by ever smokers and never smokers at 23 years. Secondly, I 
explored the association between reasons for vaping (retrospectively reported at 23 
years) and current smoking at 24 among ever vapers at 23 who were regular smokers 
just prior to first e-cigarette use. These regressions were analysed with and without 
adjustment for demographic factors (sex, ethnicity, parental SEP, and age in months at 
23-year questionnaire).  
3.3.3.3 Additional analysis. As it is not clear whether individuals were dual using 
products in the main analysis (i.e., when separately observing continued vaping and 
continued smoking), I further explored the association between reasons for vaping and 
later vaping and smoking status using multinomial logistic regression. Vaping and 
smoking status were categorised into four groups: current smoker (smoking but not 





(vaping but not smoking at 24 years), or neither user (neither vaping nor smoking at 24 
years). Analyses were adjusted for demographic factors (sex, ethnicity, parental SEP, and 
age in months at 23-year questionnaire). Analyses were restricted to 1) ever vapers who 
had ever smoked at 23 years and 2) ever vapers at 23 years who had smoked regularly 
just prior to vaping. I also planned to restrict the analyses to ever vapers who had never 
smoked at 23 years. 
3.3.3.4 Multiple imputation. A majority of the young adults who completed the 
questionnaire on vaping at 23 years and stated they had ever vaped and ever smoked 
also had complete outcome data (71%) and complete covariate data (62%). I used 
multiple imputation to increase the sample size available for analysis and minimise bias 
due to attrition. There were no clear differences between the young adults who did and 
did not complete the 24-year questionnaire in terms of reasons for use, other than 
those who vaped out of curiosity were less likely to have missing outcome data at 24 
years (p = 0.003). Current vapers (p < 0.001) and current smokers (p < 0.001) at 23 years 
were more likely to have missing outcome data at 24 years which indicates that it is 
plausible that the data are missing not at random (Jakobsen, Gluud, Wetterslev, & 
Winkel, 2017). As multiple imputation is not advised where data are missing not at 
random (Jakobsen et al., 2017), I have been conservative in my multiple imputation and 
only imputed missing covariate data. All those included in the analysis had complete 
exposure and outcome data. Adjusted analyses were repeated using multiply imputed 
data. Multiple imputation is a recommended method to account for missing data 
(Sterne et al., 2009). The multiple imputation by chained equations procedure was 
completed using the ICE package in Stata 15.1 which created 100 datasets with 20 
cycles. I imputed missing covariate data for the 668 young adults who completed the 
questionnaires at 23 and 24 years and responded that they had ever smoked and ever 
used an e-cigarette. Further details of the imputation, including the auxiliary variables 
used, can be found in Appendix 5. 
3.3.3.5 Minimum detectable effect. A power calculation indicated that I had sufficient 
power (90%) to detect a minimum odds ratio of 1.51. The calculation assumed a 
two-tailed hypothesis (α= 0.05) and was based on a logistic regression of vaping to quit 
smoking by 23 years and vaping status (vaping versus non-vaping) at 24 years. In the 





vaping, 45 were vapers and 395 were non-vapers at 24 years. Therefore, the calculation 
was based on an 10% probability of an event in the control group. 
 
3.4 Results 
3.4.1 Characteristics of Vapers at Age 23 
The characteristics of the young adults are described in Table 3.1, grouped into never 
vapers (n = 3,013), and ever vapers (n = 981); ever vapers were also grouped into former 
vapers (n = 814) and current vapers (n = 167). A higher percentage of ever vapers were 
male, of lower parental SEP at birth, and had a mother who smoked in pregnancy. A 
higher percentage of ever vapers engaged in other potentially addictive or harmful 
behaviours; more ever vapers were harmful or hazardous drinkers and had ever used 
drugs or gambled than never vapers. Ever vapers were also more likely to report anxiety 
or low mood, smoking by the age of 20 or 23 years, and be current, weekly or daily 
smokers than never vapers at 23 years. Vaping among never smokers was rare; only 5% 
of ALSPAC participants who had ever vaped had never smoked, and less than 1% of ever 
vapers defined themselves as a current vaper who had never smoked at 23 years. There 
were no clear differences between these groups in terms of ethnicity, BMI, 
unemployment or parenthood. On average, participants were 23 years old across all 
groups at the initial questionnaire. The age at which ever vapers first vaped was similar 
among both current and former vapers (median = 22 years of age). There were few clear 
differences between former and current vapers. Current vapers were more likely to 
have had lower parental SEP at birth, report anxiety and have smoked by the age of 23 






Table 3.1. Characteristics of the study population for never, former and current e-cigarette users at 23 years (N = 3,994). 
  Ever vapers 
 Never vapers 
(n = 3,013) 
Ever vapers 




(n = 814) 
Current 
(n = 167) 
p-value 
Characteristic N (%*) N (%*)  N (%*) N (%*)  
Female 2005 (67%) 599 (61%) .002 502 (62%) 97 (58%) .387 
Parental SEP (manual) 1005 (38%) 372 (43%) .007 297 (42%) 75 (50%) .067 
Ethnicity (non-white) 116 (4%) 33 (4%) .509 26 (4%) 7 (5%) .512 
Mother smoked in pregnancy 380 (13%) 205 (22%) <.001 165 (22%) 40 (25%) .314 
Harmful/hazardous alcohol use 1033 (49%) 401 (67%) <.001 348 (69%) 53 (55%) .008 
Cannabis use (ever) 923 (41%) 505 (80%) <.001 424 (80%) 81 (79%) .673 
Other drug use (ever) 401 (18%) 299 (50%) <.001 255 (51%) 44 (46%) .354 
Gambled (ever) 322 (15%) 143 (24%) <.001 117 (23%) 26 (26%) .563 
Anxiety 730 (36%) 280 (52%) <.001 229 (51%) 51 (62%) .052 
Low mood 1269 (63%) 381 (73%) <.001 321 (72%) 60 (74%) .742 
Overweight/obese BMI 420 (17%) 150 (19%) .087 122 (19%) 28 (23%) .268 
Currently unemployed 151 (7%) 44 (8%) .428 37 (8%) 7 (9%) .920 
Parenthood status (had a child) 91 (4%) 32 (6%) .142 24 (5%) 8 (10%) .108 
Ever smoked by 23 years 1467 (49%) 932 (95%) <.001 767 (94%) >162 (>98%) .005 
Current smoker at 23 years 355 (12%) 617 (63%) <.001 510 (63%) 107 (64%) .716 
Weekly smoker at 23 years**  58 (28%) 111 (39%) .012 89 (37%) 22 (44%) .383 
Daily smoker at 23 years**  150 (42%) 335 (54%) <.001 277 (54%) 58 (55%) .940 
 Mean (SD) Mean (SD)  Mean (SD) Mean (SD)  
Age (initial questionnaire)  23.9 (0.5) 23.9 (0.5) .854 23.9 (0.5) 23.8 (0.5) .386 
*Due to missing data, the percentage of users refers to the number of participant/participants who responded. **Only current smokers were asked this question. 
SEP = Socioeconomic position. The highest socioeconomic position of the mother or father was coded as manual vs non-manual occupation. Harmful/hazardous 
alcohol use was defined as a score of 8 or more on the Alcohol Use Disorders Identification Test (AUDIT). Anxiety was defined as scores of 5 or more on the GAD-7 
which indicated mild to severe anxiety. Low mood was defined as feeling downhearted and depressed in the last 4 weeks and was not an indicator of clinical 
diagnosis. Unemployment status was defined as not currently being employed or engaging in any form of full or part-time education or training. Less than five 











3.4.2 Reasons for Vaping 
Participants’ reasons for vaping by 23 years are shown in Table 3.2. Current vapers were 
more likely than former vapers to vape for all reasons except ‘out of curiosity’, the most 
popular reason given for ever vaping (51%). Most young adults (56%) selected only one 
reason for vaping, 23% selected two reasons, 11% selected three reasons, 4% selected 
four reasons, 1% selected five reasons and less than 1% selected six reasons for vaping. 
4% did not select any reasons for vaping. Due to small numbers of never smokers who 
had tried vaping at 23 years (n = 47), I did not conduct any inferential statistics 
comparing current or former vapers to never smokers who have ever vaped. None of 
the never smokers vaped for smoking-related reasons by 23 years (as expected), 83% 
vaped out of curiosity, 17% vaped because their friends did, and 6% vaped for pleasure. 
 
 





(n = 814) 
Current vapers 




Reasons for vaping by 23 N (%) N (%) p-value N (%) 
Vaped to quit smoking 
 
222 (27%) 113 (68%) <0.001 335 (34%) 
Vaped to cut down number of 
cigarettes smoked 
161 (20%) 68 (41%) <0.001 229 (23%) 
Vaped to help with cravings in 
situations when unable to 
smoke 
64 (8%) 8 (25%) <0.001 72 (7%) 
Vaped for pleasure 
 
119 (15%) 54 (32%) <0.001 173 (18%) 
Vaped out of curiosity 
 
469 (58%) 32 (19%) <0.001 501 (51%) 
Vaped because friends used 
them 







3.4.2.1 Reasons for vaping and smoking/vaping behaviour. Due to small numbers of 
never smokers who had tried vaping at 23 years (n = 47), analyses were restricted to 
ever-smokers who had ever vaped and were not stratified by ever smoking status. 
Almost all of the never smokers who had vaped by 23 years did not use either 
e-cigarettes or cigarettes at 24 years. The study sample consisted of 668 young adults 
who had completed both questionnaires and had ever vaped and smoked by 23 years. 
412 of these young adults were regular smokers just prior to vaping. The median time 
between questionnaire completion at 23 years and 24 years was 12 months. The age at 
which the young adults first vaped ranged from 17 to 24 years (SD = 1; median = 22) and 
on average occurred 2 years before questionnaire completion. Table 3.3 displays vaping 
characteristics for vapers at 23 years. At 24 years, 49% of the young adults (n = 330) 
were current smokers who were not currently vaping. Dual use (n = 62) and current 
vaping (n = 47) were less common. A substantial proportion of the young adults were 
neither users at 24 years (n = 229). Of the 412 regular smokers just prior to vaping, 59% 
were current smokers at 24 (n = 244), and dual use (n = 51), current vaping (n = 35), and 
neither use (n = 82) were less common.  
 
Table 3.3. Prevalence of e-cigarette use characteristics among young adults who had 
ever smoked and ever vaped at 23 years (N = 668). 
E-cigarette use characteristic N (%) 
Current use at 23 105 (16%) 
Current smoker and vaper (dual user)  67 (10%) 
Current vaper (not current smoker) 38 (6%) 
Currently vapes at least monthly  97 (15%) 
Currently vapes and has vaped for a month or longer  91 (14%) 
   
Former use by 23 563 (84%) 
Used to vape at least once a month but not a current user  195 (29%) 
Used an e-cigarette for a month or longer in the past but not a current user  144 (22%) 
  
Device types used by 23  
Ever used a 1st generation device 200 (30%) 
Ever used a 2nd generation device 340 (51%) 







3.4.2.2 Reasons for vaping and associated smoking/vaping behaviour. The unadjusted 
and unimputed adjusted results of the logistic regressions are shown in Appendix 6 and 
Appendix 7. The imputed adjusted results are shown in Table 3.4. The results were 
consistent, with all associations in the same direction with a similar magnitude. 
Vaping to quit smoking by 23 years was associated with higher likelihood of continuing 
to vape at 24 years (odds ratio [OR] = 3.51, 95% confidence interval [95% CI] = 2.29 to 
5.38, p < 0.001) and a lower likelihood of continuing to smoke (OR = 0.50, 95% CI = 0.32 
to 0.78, p = 0.002) at 24 years. Vaping to cut down the number of cigarettes smoked by 
23 years was associated with a higher likelihood of continuing to vape at 24 years (OR = 
2.90, 95% CI = 1.87 to 4.50, p < 0.001) and a higher likelihood of continuing to smoke at 
24 years (OR = 1.62, 95% CI = 1.02 to 2.58, p = 0.041). Vaping to curb cravings for 
cigarettes by 23 years (OR = 4.35, 95% CI = 2.57 to 7.37, p < 0.001) and for pleasure by 
23 years (OR = 3.22, 95% CI = 2.01 to 5.15, p < 0.001) were also associated with higher 
likelihood of continuing to vape at 24 years. Vaping out of curiosity by 23 years was 
associated with lower likelihood of continuing to vape at 24 years (OR = 0.41, 95% CI = 
0.26 to 0.63) and a higher likelihood of continuing to smoke at 24 years (OR = 1.66, 95% 
CI = 1.04 to 2.65, p = 0.035). Vaping because friends vaped by 23 years was associated 
with higher likelihood of continuing to smoke at 24 years (OR = 1.78, 95% CI = 0.95 to 





Table 3.4. Associations between reasons for vaping by 23 years and current vaping at 24 years among ever vapers and ever smokers and current smoking at 
24 years among ever vapers and prior smokers. 
 Vaping at 24 years among ever vapers and ever smokers 
by 23 years (n=668) 
 
Smoking at 24 years among ever vapers by 23 years and 
regular smokers just prior to vaping* (n=412) 




OR 95% CI p-value  
N (%) 
OR 95% CI p-value 
To quit smoking 228 (34%) 3.51 2.29, 5.38 <.001  217 (53%) 0.50 0.32, 0.78 .002 
To cut down  166 (25%) 2.90 1.87, 4.50 <.001  158 (38%) 1.62 1.02, 2.58 .041 
To curb cravings  75 (11%) 4.35 2.57, 7.37 <.001  70 (17%) 0.84 0.47, 1.49 .553 
Pleasure 118 (18%) 3.22 2.01, 5.15 <.001  57 (14%) 0.88 0.47, 1.65 .685 
Curiosity 351 (53%) 0.41 0.26, 0.63 <.001  158 (38%) 1.66 1.04, 2.65 .035 
Friends used them 153 (23%) 0.63 0.37, 1.09 .10  71 (17%) 1.78 0.95, 3.36 .073 
The analyses were run on multiply imputed data for individuals who ever smoked and ever vaped. Both analyses adjusted for demographic factors (sex, 
ethnicity, socioeconomic position, and age in months at 23-year questionnaire). *This analysis was restricted to those who had reported that they smoked 





3.4.2.3 Additional analysis. The results of the additional analysis which explored the 
association between reasons for vaping and smoking and vaping status (current vaper, 
current smoker, dual user or neither user) are displayed in Table 3.5. It is difficult to 
interpret the results for smoking-related reasons for vaping among the full sample given 
that non-smokers could not provide a reason relating to quitting or cutting down 
cigarettes. Thus, associations between smoking-related reasons and smoking and vaping 
status are only meaningful in the restricted sample of smokers just prior to vaping. The 
analyses supported the main analyses and also showed that vaping for smoking-related 
reasons and pleasure were associated with higher likelihood of dual use compared to 
current smoking at 24 years. Additionally, vaping to quit smoking (among those who 
were smoking just prior to vaping) and vaping for pleasure (among the full sample) were 
associated with increased likelihood of neither use compared with current smoking at 24 
years. Among those who were smokers just prior to first e-cigarette use, vaping because 
friends vaped was associated with lower likelihood of being a neither user compared to 
a current smoker at 24 years. Vaping out of curiosity was associated with lower 
likelihood of being a dual user and higher likelihood of being a neither user compared to 
being a current smoker at 24 years among the full sample. However, for those who were 
smokers just prior to first e-cigarette use, vaping out of curiosity was only associated 






Table 3.5. Associations between reasons for vaping by 23 years and vaping and smoking status at 24 years among ever vapers and ever smokers as well as 
ever vapers and smokers just prior to starting to vape. 
Reason for e-cigarette use  Full sample (n=668)  Smokers just prior to vaping (n=412) 
Smoking/vaping behaviour (Yes/No) aRRR 95% CI p-value  (Yes/No) aRRR 95% CI p-value 
To quit 228/440     217/195    
Current smoker  114/216 1 (ref) (ref)  108/136 1 (ref) (ref) 
Current dual user  36/26 2.74 1.57, 4.78 <.001  33/18 2.36 1.25, 4.44 .008 
Current vaper 28/19 2.82 1.50, 5.31 .001  27/8 4.35 1.88, 10.03 .001 
Neither user 50/179 0.53 0.36, 0.78 .001  49/33 1.83 1.09, 3.06 .021 
To cut down 166/502     158/254    
Current smoker 95/235 1 (ref) (ref)  91/153 1 (ref) (ref) 
Current dual user 35/27 3.35 1.90, 5.92 <.001  32/19 2.98 1.57, 5.66 .001 
Current vaper 12/35 0.87 0.43, 1.76 .69  11/24 0.81 0.38, 1.76 .60 
Neither user 24/205 0.29 0.18, 0.47 <.001  24/58 0.71 0.41, 1.24 .23 
To curb cravings  75/593     70/342    
Current smoker 30/300 1 (ref) (ref)  28/216 1 (ref) (ref) 
Current dual user 44/18 5.66 2.94, 10.90  <.001  21/216 5.58 2.77, 11.25 <.001 
Current vaper  8/39 2.00 0.84, 4.73 .12  7/28 2.07 0.81, 5.28 .13 
Neither user 14/215 0.70 0.37, 1.35 .29  14/68 1.73 0.85, 3.51 .13 
Pleasure 118/550     57/355    
Current smoker 40/290 1 (ref) (ref)  23/221 1 (ref) (ref) 
Current dual user 23/39 4.27 2.29, 7.98 <.001  17/34 4.83 2.28, 10.22 <.001 
Current vaper 15/32 3.35 1.64, 6.85 .001  6/29 2.09 0.76, 5.74 .15 
Neither user 40/189 1.51 0.93, 2.44 .094  11/71 1.55 0.71, 3.41 .27 
Curiosity 351/317     158/254    
Current smoker 163/167 1 (ref) (ref)  101/143 1 (ref) (ref) 





The models were run on multiply imputed data for individuals who ever smoked and ever vaped (Model 3) and individuals who had been regularly smoking 
prior to vaping (Model 6). Both models adjusted for demographic factors (sex, ethnicity, socioeconomic position, and age in months at 23-year 
questionnaire). Note: aRRR = adjusted relative risk ratio. Ref = reference category.
Current vaper 10/37 0.28 0.13, 0.59 <.001  5/30 0.24 0.09, 0.64 .005 
Neither user 150/79 1.94 1.36, 2.77 <.001  30/52 0.81 0.48, 1.38 .44 
Friends used them 153/515     71/341    
Current smoker  78/252 1 (ref) (ref)  50/194 1 (ref) (ref) 
Current dual user 10/52 0.61 0.30, 1.27 .19  7/44 0.60 0.25, 1.42 .24 
Current vaper 8/39 0.70 0.31, 1.57 .39  5/30 0.64 0.24, 1.75 .39 




3.4.2.3 Exploratory analysis. To further investigate the association between vaping out 
of curiosity and later neither use (among the full sample only), I ran some exploratory 
analyses. Specifically, I was interested in whether the association may reflect a group of 
‘experimenters’ who try smoking and vaping but do not continue to smoke or vape. I 
explored the association between vaping out of curiosity by 23 years and current vaping 
(versus non-current vaping) and current smoking (versus not current smoking) at 24 
years among those who were not regular smokers just prior to vaping (n = 251). Vaping 
out of curiosity was associated with a lower likelihood of currently vaping at 24 years 
among young adults who had not regularly smoked just prior to vaping (aOR = 0.24, 95% 
CI 0.10 to 0.61, p = 0.002) but was not clearly associated with current smoking at 24 
years (aOR = 0.63, 95% CI 0.34 to 1.16, p = 0.144). 
3.5 Discussion 
The results indicate that there are substantial differences in characteristics between 
young adults who have never and ever vaped at 23. Vaping out of curiosity and to quit 
smoking were common reasons for vaping among young adults in this UK-based sample. 
Five out of the six reasons for vaping by 23 years included in this study were strongly 
associated with continued vaping at 24 years; vaping for reasons related to smoking (to 
quit, cut down, and curb cravings) and vaping for pleasure were associated with a higher 
likelihood of continued vaping whereas vaping out of curiosity was associated with a 
lower likelihood of continued vaping. Four out of six reasons for vaping by 23 years were 
associated with continued smoking at 24 years; vaping to quit smoking was associated 
with a lower likelihood of continued smoking whereas vaping to cut down, out of 
curiosity and because friends vaped were associated with higher likelihood of continued 
smoking. 
Similar to previous findings (Brown et al., 2014), I found that vapers were more likely to 
have a lower parental SEP at birth than never vapers. Vapers were also more likely to 
report risk-taking behaviours such as drug use and gambling and were more likely to 
report mental health issues. Smoking has previously been associated with similar 
characteristics (Hiscock et al., 2012; Jamal et al., 2016; Lai, Lai, Page, & McCoy, 2000; 
Minichino et al., 2013). This similarity could indicate a common liability for both 




which could explain why not all young adults who vape go on to quit smoking. 
Alternatively, smoking could mediate the relationship between risk-taking and vaping; 
most vapers in this cohort smoked prior to vaping and some started vaping to help them 
quit smoking. In line with previous findings (Levy et al., 2017), vapers were more likely to 
be ever, weekly or daily smokers at 23 years, and vaping among never smokers was rare. 
Even though 52% of the sample did not provide a smoking-related reason for vaping and 
I cannot determine order of product use for all participants, it is unlikely that vaping led 
to smoking in this cohort; only 1% of the young adults were not smokers just prior to 
first using an e-cigarette but stated they had started smoking regularly since using an 
e-cigarette. However, this figure may include ex-smokers who took up vaping to avoid 
relapsing to smoking (and therefore were not regularly smoking just before starting to 
use an e-cigarette). 
My results imply that vaping to quit smoking may facilitate young adult’s quit attempts; 
young adults who smoked just prior to vaping who vaped for this reason were less likely 
to continue to smoke at 24 years and were more likely to be neither users than current 
smokers compared with those who did not vape for this reason. This is in line with the 
growing amount of evidence that vaping can facilitate smoking cessation (Hartmann-
Boyce et al., 2020). My findings also support previous findings among middle and high 
school students (Bold et al., 2016) and college students in the US (Saddleson et al., 2016) 
which found that vaping to quit smoking was associated with higher likelihood of 
continued vaping compared with not vaping for this reason. For some individuals, vaping 
to quit smoking could encourage the continued use of e-cigarettes rather than quitting 
nicotine products entirely. If these people aim to be completely nicotine free, they may 
need additional help to quit vaping or reduce the levels of nicotine in their e-liquid once 
they have successfully quit smoking.  
Although vaping to cut down smoking is similar in terms of motive, the associated 
behaviour was quite different from vaping to quit smoking. Those who were regular 
smokers just prior to starting to vape and vaped to cut down were more likely to still be 
smokers at 24 years than those who did not vape to cut down. Similar to previous 
findings (Bold et al., 2016) they were also more likely to continue vaping (i.e., be dual 
users) which suggests that these individuals were not encouraged to quit smoking by 




these users may not actually intend to quit smoking, and intention may be necessary for 
e-cigarettes to act as an effective smoking cessation tool. Second, the comparison group 
includes those who vaped with the sole intention to quit smoking which could 
potentially mask a decreased likelihood of continuing smoking among those who vaped 
to cut down. However, adjusting for use to quit smoking did not substantially change the 
results (OR = 1.62, 95% CI = 1.01 to 1.60). Third, recall bias may be an issue; those who 
were unable to quit smoking may report that they only intended to cut down. Fourth, as 
the study was over a relatively short time period, these users may still be in the process 
of quitting and may eventually quit entirely.  
Vaping to curb cravings for cigarettes and vaping for pleasure were less common. There 
is little evidence to suggest that vaping to curb cravings or for pleasure hampers 
smoking cessation. Equally, there is little evidence to suggest that vaping for these 
reasons encourages smoking cessation.  
Consistent with previous research conducted in the US, I found that curiosity is the most 
common reason for vaping among young adults (Kong et al., 2015). In line with previous 
evidence (Bold et al., 2016), young adults were less likely to continue to vape at 24 years 
and were more likely to be neither users than current smokers if they had vaped out of 
curiosity rather than if they had not. As the full sample are ever smokers who have ever 
vaped, this may highlight a group of ‘experimenters’ who try both vaping and smoking 
but do not continue either behaviour. This is supported by my exploratory analysis; 
there was no clear evidence of an association with vaping out of curiosity and later 
smoking among those who were not regular smokers just prior to initially vaping. 
Similarly, for those who had smoked less than 100 cigarettes in their lifetime, curiosity 
was a common reason for use in a study of young adults in the US (Biener, Song, Sutfin, 
Spangler, & Wolfson, 2015). This is also consistent with what I hypothesised in the 
discussion of Chapter 2; although there is a strong association between ever vaping 
among never smokers and subsequent smoking, this could be due to a shared liability 
(e.g., propensity to risk-taking) which leads young adults to experiment with both 
products but not lead to continued smoking. I further test this hypothesis in Chapter 4. 
Interestingly, those who had been regular smokers just prior to starting to vape and who 
did so out of curiosity were more likely to still be smoking at 24 years and were less 




out of curiosity. This implies that smokers who vape out of curiosity do not want to quit 
or are less able to quit smoking compared to those who vape for other reasons (e.g., to 
quit smoking). Ultimately, the evidence suggests that vaping out of curiosity is not 
associated with transitions in smoking/vaping status; vaping out of curiosity was 
negatively associated with continued vaping, and there was only an association with 
later smoking among those who were already regularly smoking just prior to vaping.  
These results provide strong evidence for associations between reasons for e-cigarette 
use and later vaping and smoking status using a large UK-based young adult cohort while 
adjusting for a range of potential confounders. However, further research is needed to 
fully explore the potential implications of these findings using methods which can 
support stronger causal inference. For example, to explore whether intention to quit 
smoking is necessary for young adults to quit smoking using e-cigarettes, a randomised 
controlled trial could be designed whereby young adults receive instructions to either 
try to cut down the number of cigarettes smoked or quit all together. Comparing 
smoking cessation rates between the two conditions would allow us to infer with 
greater confidence whether intention to quit is necessary for effective smoking 
cessation among young adults using e-cigarettes. However, instructing an individual to 
quit may not be sufficient for them to actually intend to quit, so it may be a poor proxy 
for intention. Therefore, the results may not accurately reflect intention to quit but 
reflect instruction to quit (i.e., an intention to treat model). Nevertheless, if the findings 
of such a study were to corroborate the current findings, it would provide stronger 
support for interventions aiming to encourage smokers to quit smoking with the 
assistance of e-cigarettes.  
Despite utilising a rich data source (ALSPAC), the study was limited by the measures 
included. This was particularly an issue for the exposure; the reasons for vaping were 
self-reported retrospectively. This measure could suffer from recall bias as individuals 
may have started vaping years prior to completing the questionnaire. For example, 
young adults may be less likely to state that they vaped to quit smoking if they were 
unsuccessful in their quit attempt. Also, the reasons for vaping chosen were not 
exclusive for each young person due to the multiple-choice format of this question. As 
with many previous studies, a multiple-choice item was used to determine reasons for 




potential reasons for vaping which are omitted from this analysis. The young adults 
were also provided with an ‘other’ option in the questionnaire where they could provide 
open answer responses, however, this was rarely selected (4% of the sample) or 
selected without another reason being specified (2%) so was not included in the 
analysis. Vaping for flavour-related reasons is common in the US (Landry et al., 2019) but 
‘flavours’ was not an option in the 23-year questionnaire. ‘Flavours’ was included in the 
24-year questionnaire (selected by 17% of respondents). In cross-sectional analysis, 
there was evidence that vaping for flavours by 24 years was associated with increased 
likelihood of current vaping (aOR = 1.70, 95% CI 1.15 to 2.53), but was not clearly 
associated with current smoking (aOR = 1.06, 95% CI 0.59 to 1.95). Additionally, the 
answer options that were provided may have primed a response in the young adults 
which was biased towards smoking cessation as three of the six were related to 
smoking. 
Although I employed multiple imputation methods to minimise bias (Sterne et al., 2009) 
and the ALSPAC response rate has remained consistent in the last eight yearly 
questionnaires (~4000 respondents), another limitation of this study is that missing data 
could have introduced selection bias. Evidence suggests that smokers may be less likely 
to participate in ALSPAC (Taylor et al., 2018); therefore, there may be fewer individuals 
vaping or vaping for smoking-related reasons than in the full sample.  
The timing of this cohort study may impact the generalisability of the findings. 
E-cigarettes are still a relatively new product compared to cigarettes; consequently, 
cigarettes were available to this cohort of young adults for a considerable period of their 
adolescence before e-cigarettes became widely available in 2007. In 2007, the study 
sample were roughly 17 years old and cigarette initiation has been shown to peak at 
around 15-16 years of age (Marcon et al., 2018), so it is likely that many of these young 
adults experimented with cigarettes prior to being exposed to e-cigarettes. Adolescents 
today are being exposed to both e-cigarettes and cigarettes during adolescence, a key 
period for experimentation and risk-taking behaviour, and this may have an impact on 
their reasons for vaping as well as their current vaping and smoking status. Although it 
would be interesting to observe the association between reasons for vaping and later 
vaping and smoking status among those who were never smokers when they first vaped, 




would also be interesting to observe the associations among never smokers at 23 years 
but there are too few individuals who had vaped but never smoked at 23 years (who 
also responded to the questionnaire at 24 years) to conduct any meaningful analysis. Of 
note, none of these excluded individuals used an e-cigarette for smoking-related 
reasons by 23 years (as expected), the majority vaped out of curiosity, and almost all of 
them were neither users at 24 years. 
3.6 Chapter Summary 
In conclusion, vapers were more likely than never vapers to be male, of lower parental 
SEP at birth, have poor mental health and engage in other risky behaviours as well as be 
current weekly or daily smokers. These factors are also associated with smoking which, 
as suggested in Chapter 2, could indicate a shared liability to both behaviours, or could 
be due to smoking leading to e-cigarette use. I also found that vaping to quit smoking is 
associated with increased likelihood of later vaping but decreased likelihood of later 
smoking among those who were smokers just prior to starting to use e-cigarettes. In 
contrast, vaping to cut down was associated with continued smoking. This implies that 
intention to quit smoking may be necessary for young adults to effectively stop smoking 
using e-cigarettes. Vaping out of curiosity does not appear to lead to continued vaping 
or smoking among those who were not regularly smoking just prior to vaping. In Chapter 
2, I found that e-cigarette use is associated with later smoking and my findings in this 
Chapter could be consistent with either of my suggested explanations for this 
association. Curious vapers my not vape enough to become dependent on nicotine, and 
therefore do not seek other nicotine sources, or smoking and vaping may share a 
common liability (i.e., a propensity to experiment and engage in risky behaviour). I have 
further explored these potential shared factors (SEP and risk-taking) while investigating 





Chapter 4 Does genetic liability to smoking 
initiation influence e-cigarette use? 
This chapter closely resembles sections from the following pre-print: 
Khouja, J. N., Wootton, R. E., Taylor, A. E., Davey Smith, G., & Munafò, M. R. (in press). 
Association of genetic liability to smoking initiation with e-cigarette use in young adults. 
PLOS Medicine.  
Khouja, J. N., Wootton, R. E., Taylor, A. E., Davey Smith, G., & Munafò, M. R. (2020). 
Association of genetic liability to smoking initiation with e-cigarette use in young adults. 
MedRxiv; doi: https://doi.org/10.1101/2020.06.10.20127464. 
I took the lead in designing, implementing and interpreting this study with the support 
of my co-authors. Specifically, MM, RW, AT and GDS provided feedback on the design of 
the study and during the preparation of the manuscript. I was responsible for the data 
analysis and was responsible for writing the first draft of the manuscript and editing the 
manuscript in response to comments from co-authors and reviewers.  
4.1 Chapter Overview 
In Chapter 1, I described the strong association between e-cigarette use and smoking 
which could be due to a causal effect of e-cigarette use on smoking, a causal effect of 
smoking on e-cigarette use, or a common cause (or confounding) between the two 
behaviours. As seen in Chapter 2, never smokers who use e-cigarettes are more likely to 
subsequently smoke than those who do not; this could imply that e-cigarette use causes 
adolescents and young adults to smoke. In contrast, as shown in Chapter 3, a common 
reason given for using e-cigarettes is to quit smoking; therefore, smoking leads young 
adults to use e-cigarettes to alleviate symptoms of withdrawal when quitting. Another 
explanation for the association between e-cigarette use and smoking is that the 
behaviours share a ‘common liability’ such as a genetic predisposition to both smoke 
and vape. In Chapter 3, I found that a higher percentage of ever vapers engaged in other 
potentially addictive or harmful behaviour than never vapers, suggesting the shared 




genome-wide association studies (GWAS) of e-cigarette use to directly compare the 
genetic variants associated with e-cigarette use and smoking, but there is a 
well-powered GWAS of smoking initiation. Using summary results from the smoking 
initiation GWAS, I create smoking initiation polygenic risk scores (PRS) at varying p-value 
thresholds for young adults (23-26 years) of European ancestry in the Avon Longitudinal 
Study of Parents and Children (ALSPAC). In this Chapter, I explore the association 
between smoking initiation PRS and ever e-cigarette use at 24 years in ALSPAC to 
explore shared genetic influences on e-cigarette use. 
4.2 Introduction  
As discussed in Chapter 3, the use of e-cigarettes for smoking cessation is common 
among young adults in the UK (Khouja, Taylor, & Munafò, 2020); therefore, it would be 
logical to assume that smoking causally influences e-cigarette use in this population. 
However, some studies have shown an association between e-cigarette use and 
subsequent smoking among non-smokers (Khouja, Suddell, Peters, Taylor, & Munafo, 
2020; Soneji, Barrington-Trimis, Wills, Leventhal, et al., 2017), which suggests the 
possibility that e-cigarette use may also act as a gateway to smoking (sometimes 
referred to as the gateway hypothesis), particularly among adolescents. In Chapter 2, in 
which I described the meta-analysed results of these studies, I found a strong and 
consistent positive association between e-cigarette use (among never smokers) and 
later smoking for youth aged 30 years or younger, but I concluded that there is currently 
insufficient evidence that this association is causal (Khouja, Suddell, et al., 2020). I 
discussed the distinct possibility that the association may be due to vaping and smoking 
sharing a common liability. In Chapter 3, I found that a higher percentage of ever vapers 
engaged in other potentially addictive or harmful behaviour than never vapers, 
suggesting the shared liability may relate to risk-taking. Understanding more about the 
nature of the association between smoking and e-cigarette use is vital to inform tobacco 
control policies that aim to prevent youth smoking initiation (e.g., by restricting access 
to e-cigarettes). Specifically, it is important to understand whether the association found 
among adolescents and young adults is causal, or due to other factors that influence 




As I previously mentioned in Chapter 1, there is some evidence for a shared genetic 
liability to both smoking and e-cigarette use (Allegrini et al., 2019). This could indicate a 
causal relationship in that smoking causes vaping (i.e., vertical pleiotropy), or it could be 
due to genetic variants that separately influence both behaviours (i.e., horizontal 
pleiotropy) (Davey Smith & Hemani, 2014). One biologically plausible explanation for a 
genetic link between smoking and e-cigarette use is that they are both influenced by the 
same genetic variants that influence an individual’s response to nicotine or their 
nicotine metabolism. However, evidence suggests that some of the genetic influence on 
smoking initiation is mediated by personality traits, such as risk-taking and impulsivity, 
that influence (among other things) smoking uptake (Heath, Madden, Slutske, & Martin, 
1995). These traits can be observed in childhood (prior to smoking or vaping initiation), 
particularly among those with externalising disorders (Samek & Hicks, 2014). Using data 
from an early GWAS of smoking (Tobacco and Genetics Consortium, 2010), Allegrini and 
colleagues (2019) suggested that the genetic link found in their research between 
smoking and e-cigarette use may reflect these personality traits. 
Using genetic variants, I can explore whether genetic predisposition to smoking is 
associated with e-cigarette use, and which factors or mechanisms may influence the 
association. As I discussed in Chapter 1, I would ideally explore the genetic overlap 
between smoking and e-cigarette use by comparing the genetic variants identified in a 
GWAS of each behaviour, but at present there are no large, well-powered GWAS of 
e-cigarette use. However, a GWAS of various smoking behaviours which identified 378 
single nucleotide polymorphisms (SNPs) associated with smoking initiation is available 
(Liu et al., 2019). Using these SNPs, smoking initiation PRS can be created and 
associations between these PRS and a range of outcomes can be examined. 
Causality cannot be inferred from such analyses, but as I explained in Chapter 1, 
negative control outcomes can be used to inform the overall evaluation of whether an 
association is causal via a hypothesised route (Lipsitch, Tchetgen Tchetgen, & Cohen, 
2010). Triangulating evidence from outcomes where a simple biological pathway from 
smoking to the outcome is implausible (e.g., gambling), or impossible (e.g., externalising 
behaviour or socioeconomic position [SEP] in childhood, before smoking has occurred) 
can aid our understanding of potential pathways by which smoking and vaping may 




include a biological pathway from smoking to e-cigarette use (i.e., vertical pleiotropy), a 
shared genetic predisposition which influences smoking and vaping independently (i.e., 
horizontal pleiotropy), or a genetic liability to a broader, risk-taking phenotype which 
causes both smoking and vaping (i.e., a shared risk factor). Alternatively, triangulation 
could aid our understanding of whether an association is due to a shared genetic 
predisposition between parents and offspring. Where parents share their offspring’s 
smoking initiation predisposition and consequently expose their offspring to cigarette 
smoke in utero or in childhood, an apparent effect of a child’s own genetic variants may 
be a result of their environment due to their parents’ genetic variants. If associations are 
only found between smoking initiation PRS and e-cigarette use, but not negative control 
outcomes, this would support the vertical pleiotropy interpretation; however, if an 
association is also found with negative control outcomes, this would suggest that 
horizontal pleiotropy is occurring or that shared parent-offspring genetic predisposition 
may be confounding the association.  
 
 
Figure 4.1. Potential models of shared liability for the relationship between genetic 






Additionally, using varying p-value thresholds to create PRS could help to identify the 
presence of horizontal pleiotropy. Calculating PRS at less strict p-value thresholds than 
the genome-wide significant threshold increases the percentage variance in the 
phenotype explained by the score, and thus increases power to detect an association. 
However, using less stringent thresholds will also tend to increase the likelihood of 
including genetic variants which are related to factors other than the exposure of 
interest, making the PRS less specific (and may eventually result in PRS which explain 
less variance in the exposure). The more SNPs included in a PRS, the less likely it is that 
the effect of each variant on the trait of interest is proportional to the effect of each 
variant on the exposure, and the more likely it is proportional to the effects on other 
(horizontally pleiotropic) traits (Hemani, Bowden, & Davey Smith, 2018), increasing the 
likelihood that any associations found between the PRS and an outcome could be due to 
horizontal pleiotropy. Triangulating evidence from a variety of thresholds and a variety 
of outcomes may provide a clearer picture of the true association; associations observed 
when more stringent PRS thresholds are used could be due to a causal effect of 
smoking, while associations observed only at less stringent thresholds among negative 
control outcomes may indicate horizontal pleiotropy.   
In this study, I investigated whether smoking initiation PRS are associated with ever use 
of e-cigarettes in young adulthood. I also aimed to explore any associations with 
outcomes that are not plausibly biologically related (e.g., gambling) or that precede 
smoking (e.g., hyperactivity in childhood), to determine whether the association 
between smoking and e-cigarette use could reflect a broader risk-taking phenotype 
captured by the smoking initiation PRS. 
4.3 Methods 
4.3.1 Data Sources 
4.3.1.1 GSCAN. The GWAS & Sequencing Consortium of Alcohol and Nicotine use 
(GSCAN) report summary level statistics from a GWAS of smoking initiation (Liu et al., 




summary statistics, with ALSPAC (N = 11,345) removed, through correspondence with 
GSCAN to eliminate data overlap with the target sample. Due to data sharing 
restrictions, 23andMe were also excluded from this data (N = 599,289) leaving a total 
sample size of 621,457. Smoking initiation was defined as ever being a regular smoker. 
The exact definition varied across the cohorts included in the GWAS, with 3 different 
definitions: 1) Have you smoked over 100 cigarettes over the course of your life? 2) Have 
you ever smoked every day for at least a month? 3) Have you ever smoked regularly? 
4.3.1.2 ALSPAC. The target sample consisted of participants from ALSPAC (Boyd et al., 
2013; Fraser, Macdonald-Wallis, Tilling, Boyd, Golding, Davey Smith, et al., 2013). This 
study recruited pregnant women residing in Avon, UK with expected dates of delivery 
from 1st April 1991 to 31st December 1992. The phases of enrolment are described in 
detail in the cohort profile paper and its update (Northstone et al., 2019). A total of 
15,454 mothers were recruited, resulting in 15,589 foetuses. Of these, 14,901 were alive 
at 1 year of age. Genetic data was available for 9,085 young adults and, after samples 
which did not pass quality control were removed, PRS were created for 7,859 unrelated 
individuals of European ancestry. Of these individuals, 2,905 also had data for our main 
outcome at 24 years regarding their vaping behaviour. Sample sizes varied by outcome 
due to restrictions (e.g., restricting to never smokers) and differing timepoints of 
measurement (i.e., missing data). 
4.3.2 Polygenic Risk Scores 
I used summary data from GSCAN (excluding ALSPAC and 23andMe, N = 621,457) to 
select SNPs associated with smoking initiation. GSCAN report beta coefficients of the 
change in standard deviation in smoking initiation per one unit of change in genetic risk 
(i.e., per risk allele). I converted the beta coefficients to log odds ratios and gave each 
participant a score which indicated the average number of risk alleles (0, 1 or 2 effect 
alleles) they possessed for the selected SNPs. As some SNPs are more strongly 
associated with the phenotype (smoking initiation), I multiplied the number of risk 
alleles by the log odds ratios from the summary statistics (with ALSPAC and 23andMe 
removed) to create a weighted score. Then, I standardised the scores by transforming 
them to z-scores. Z-scores indicate how many standard deviations a value lies away from 




selected five groups of SNPs to be included in five different PRS for each participant. I 
used PLINK to create PRS at the p < 5x10-8 threshold using the SNPs which met the 
genome-wide significance threshold in the GSCAN GWAS of smoking initiation (Liu et al., 
2019). Using PRSice software, I calculated the PRS at all other thresholds (Euesden et al., 
2015). The data I acquired from GSCAN had already been pruned for SNPs with a Minor 
Allele Frequency (MAF) > 0.001 where at least 10% of the maximum sample size had 
SNP data available in at least three of the consortium studies. In addition, I pruned the 
SNPs using PLINK software to ensure low linkage disequilibrium (r2 < 0.1).  
4.3.3 Outcomes 
4.3.3.1 E-cigarette use. At 24 years (between 2016 and 2017), outcome data was 
collected via questionnaire on whether participants had ever vaped. Ever use was 
defined as ever having used/vaped an e-cigarette or other vaping device and was 
determined by response to the question “Have you ever used/vaped an electronic 
cigarette (e-cigarette) or other vaping device?”. Response options were: yes; no.  
4.3.3.2 Smoking. I included self-reported ever smoking and smoking initiation as 
positive control outcomes (i.e., outcomes for which an association with the exposure is 
expected). Ever smoking by 24 years was defined as having ever smoked a whole 
cigarette (including roll-ups) and was determined by response to the question “Have you 
ever smoked a whole cigarette (including roll-ups)?”. Response options were: yes; no. 
Smoking initiation by 24 years was defined as having smoked 100 or more cigarettes in 
their lifetime which was determined by response to the question “How many cigarettes 
have you smoked altogether in your lifetime?”. Response options were: less than 5; 
5-19; 20-49; 50-99; 100 plus. I recoded these responses into 2 categories: initiated 
smoking (100 plus cigarettes) and did not initiate smoking (all other response options). 
4.3.3.3 Negative controls. I included four negative control outcomes at age 23 and 24 in 
the analysis: high number of sexual partners, having been in trouble with the law, ever 
gambling, and enjoying taking risks. These variables were selected on the basis of being 
related to broad risk-taking behaviour, but where a causal pathway from smoking was 
not considered biologically plausible. To determine the number of sexual partners the 
young adults had had, they were asked “All together, in your life so far, how many 




determined the threshold considered to be a high number of sexual partners at 23 years 
by using the upper quartile for number of lifetime sexual partners in the ALSPAC sample 
(11 or more self-reported sexual partners at 23 years). Having been in trouble with the 
law recently (since 23rd birthday) was self-reported at 24 years and was determined by 
response to the question “Have any of these happened since you were 23 years old and 
did they affect you? You were in trouble with the law.” Response options were: yes, 
affected me a lot; yes, moderately affected; yes, mildly affected; yes, but didn’t affect 
me at all; no, did not happen. I recoded these responses into two categories: yes 
(responses beginning with “yes”) and no (response “no, did not happen”). I determined 
whether a young adult had ever gambled by 24 years using responses to the question 
“Have you ever participated in any of the form of gambling listed?”. The list included: 
Tickets for the National Lottery; Scratchcards; Tickets for any other lottery; The football 
pools; Bingo cards or tickets; Fruit slot machines; Virtual gaming machines in a 
bookmaker’s to bet on a virtual roulette, keno, bingo etc.; Table games (roulette, dice or 
cards) in a casino; Online gambling like playing poker, bingo, slot machine style games, 
or casino games for money; Online betting with a bookmaker on any event or sport; 
Betting exchange; Betting on horse races in a bookmakers, by phone, or at the track; 
Betting on dog races in a bookmakers, by phone, or at the track; Betting on any other 
event or sport at the bookmakers, by phone or at the venue; Spread-betting; Private 
betting, playing cards or games for money with friends, family or colleagues; Any other 
form of gambling. If the participant had ever engaged in any of these activities, I 
considered them to have ever gambled. Enjoying taking risks at 24 years was 
determined in response to a question asking to “indicate how much you agree or 
disagree with [this] statement” with the statement being “I quite enjoy taking risks”. 
Response options were: agree strongly; agree somewhat; disagree somewhat; disagree 
strongly. I recoded these responses into 2 categories: yes (responses beginning with 
“agree”) and no (responses beginning with “disagree”). 
I included three negative control outcomes at age 7: hyperactivity, conduct disorder 
(CD) and oppositional defiant disorder (ODD). These externalising disorders are 
indicators of impulsivity in childhood and later life (Samek & Hicks, 2014) and were 
selected on the basis that few (if any) children at this age have smoked, ruling out a 
causal pathway from their own smoking to these outcomes. Hyperactivity and conduct 




years and ODD was measured using the Development and Well-Being Assessment 
(DAWBA) at 7 years. Scores of 0-5 for hyperactivity are considered ‘normal’, and above 5 
is considered borderline/abnormal (i.e., hyperactive/attention deficit hyperactivity 
disorder [ADHD]) out of a possible score of 10. Scores of 0-2 out of a possible 10 for 
conduct disorder (determined by teacher/parent) are considered ‘normal’, and above 
are considered borderline/abnormal (i.e., CD). I considered any awkward symptoms (out 
of a possible 18) before the age of 7 to be abnormal (i.e., ODD). 
I also included parental SEP at birth in the analysis, which was assessed using the 1991 
Office of Population Censuses and Surveys (OPCS) occupation classification (manual vs 
non-manual; measured during pregnancy at 32 weeks gestation). This outcome was 
based on highest occupation of both parents at birth (preceding smoking) and was 
selected on the basis that it could not possibly be caused by a young person’s own 
smoking.  
4.3.4 Statistical Analyses 
I carried out all of my analysis in Stata 15.1 (StataCorp, 2017) using logistic regression 
which I adjusted for age, sex and the first 10 principal genetic components of population 
stratification. Principal components adjustment is often used in genetic research to 
address issues of population stratification (Zhao, Mitra, Kanetsky, Nathanson, & 
Rebbeck, 2018) whereby common differences in allele frequencies exist among 
sub-populations. I assessed the association between smoking initiation PRS and (i) ever 
e-cigarette use by age 24, (ii) regular e-cigarette use at age 24, (iii) smoking initiation, 
and (iv) negative control outcomes (risk-taking behaviours, externalising disorders, and 
SEP).  
I repeated the main analysis using a restricted sample of never smokers (who have 
smoked less than 100 cigarettes in their lifetime) to explore whether any associations 
remained when the association could not be caused by the young adult’s own smoking. I 
also restricted the analysis to those who had never smoked a whole cigarette in their 





A total of 378 SNPs were identified as genome-wide significant in the GSCAN GWAS of 
smoking initiation (Liu et al., 2019), 356 of which were available in ALSPAC. I removed 
nine SNPs at the pruning stage (removing SNPs with r2 > 0.1 within 50 kb), leaving 347 
SNPs for inclusion in the most stringent PRS (p-value threshold p < 5x10-8). The number 
of SNPs included in each PRS at the less stringent thresholds are shown in Table 4.1. Of 
note, for the PRS calculated at these less stringent thresholds, I used the significance 
level reported in the restricted sample (excluding ALSPAC and 23andMe) summary data. 
Table 4.1. p-value thresholds and number of SNPs included in polygenic risk scores. 







4.4.1 Characteristics of the sample 
Table 4.2 shows the characteristics of the sample; 878 (30%) young adults were 
self-reported ever e-cigarette users by 24 years and 1,695 (64%) were self-reported ever 
smokers. Of those who had ever vaped, 95% (n = 830) had ever smoked at least one 
whole cigarette and 71% (n = 616) had smoked 100 or more cigarettes. Less than 1% of 
the sample had used an e-cigarette prior to smoking. Self-reported smoking and 
e-cigarette use were associated with lower parental SEP and having externalising 
disorders in childhood (Table 4.3). Self-reported smoking and e-cigarette use were also 
associated with increased odds of engaging in risk-taking behaviours (Table 4.3). 
Table 4.2. Characteristics of young adults in ALSPAC. 
Characteristic N (%) 
Ever used an e-cigarette by 24 (used once or more) 878 (30%) 
Regularly used an e-cigarette at 24 (used at least once a month) 150 (5%) 
Ever smoked by 24 (1 cigarette or more) 1,695 (64%) 
Initiated smoking by 24 (100 cigarettes or more) 972 (33%) 
Ever used an e-cigarette but not initiated smoking by 24 262 (13%) 




Been in trouble with the law since 23rd birthday  69 (2%) 
Enjoys taking risks at 24 1,618 (55%) 
Ever gambled at 24 2,156 (74%) 
Hyperactivity at 7 2,219 (42%) 
Conduct disorder at 7 1,199 (22%) 
Oppositional defiant disorder at 7 1,868 (35%) 
Parental SEP (manual) 1,068 (27%) 
 Mean (SD) 
Age in months at 24-year questionnaire 298 (6) 
Note: Sample sizes varied by characteristic due to differing timepoints of measurement 
(i.e., missing data).* 11 or more sexual partners, determined using the upper quartile for 
number of lifetime sexual partners in the ALSPAC sample (11 sexual partners).  
Table 4.3. Association between self-reported e-cigarette use and smoking and 




n OR 95% CI p 
Ever used e-cigarettes by 24     
Number of sexual partners at 23* 2013 2.40 1.93, 2.97 <0.001 
Been in trouble with the law since 23rd 
birthday  
2891 2.43 1.49, 3.95 <0.001 
Enjoys taking risks at 24 2896 1.62 1.37, 1.90 <0.001 
Ever gambled at 24 2860 2.05 1.68, 2.51 <0.001 
Hyperactivity at 7 2340 1.34 1.12, 1.61 0.002 
Conduct disorder at 7 2375 1.24 1.00, 1.53 0.054 
Oppositional defiant disorder at 7 2380 1.25 1.04, 1.51 0.017 
Parental SEP  2630 1.46 1.13, 1.90 0.004 
     
Ever initiated smoking by 24 (>100 
cigarettes) 
    
Number of sexual partners at 23* 2034 3.21 2.60, 3.96 <0.001 
Been in trouble with the law since 23rd 
birthday  
2922 2.12 1.30, 3.44 0.002 
Enjoys taking risks at 24 2927 1.78 1.52, 2.09 <0.001 
Ever gambled at 24 2890 1.67 1.39, 2.02 <0.001 
Hyperactivity at 7 2363 1.22 1.02, 1.45 0.032 
Conduct disorder at 7 2396 1.17 0.95, 1.45 0.143 
Oppositional defiant disorder at 7 2407 1.23 1.02, 1.47 0.026 
Parental SEP  2655 1.59 1.24, 2.05 <0.001 
*Low (<11) vs. high (11 or more) number of sexual partners, determined using the upper 
quartile for number of lifetime sexual partners in the ALSPAC sample (11 sexual 





4.4.2 PRS for Smoking Initiation and Self-Reported Smoking 
I observed positive associations between smoking initiation PRS and ever smoking 
(having smoked at least 1 cigarette in a lifetime) by the age of 24 years (p < 5x10-8 
threshold OR [OR10-8]  = 1.25, 95% CI 1.16 to 1.35) and smoking initiation (having smoked 
at least 100 cigarettes in a lifetime) by the age of 24 years (OR10-8 = 1.29, 95% CI 1.19 to 
1.39). I found strong associations between PRS and self-reported smoking measures at 
all p-value thresholds (Table 4.4). 
Table 4.4. Associations between polygenic risk scores for smoking initiation with ever 
e-cigarette use, ever smoking and smoking initiation. 
Outcome 
p-value threshold 
N OR 95% CI p 
Ever e-cigarette use by 24 2,894    
5×10-8  1.24 1.14, 1.34 <0.001 
0.0005  1.27 1.17, 1.38 <0.001 
0.005  1.36 1.26, 1.48 <0.001 
0.05  1.39 1.28, 1.51 <0.001 
0.5  1.39 1.28, 1.51 <0.001 
Regular e-cigarette use at 24 (at 
least once a month) 2,894    
5×10-8  1.18 1.00, 1.40 0.049 
0.0005  1.22 1.03, 1.44 0.019 
0.005  1.22 1.04, 1.44 0.017 
0.05  1.18 1.00, 1.39 0.051 
0.5  1.22 1.04, 1.44 0.018 
Ever smoking by 24 (1 cigarette or 
more) 
2,931    
5×10-8  1.25 1.16, 1.35 <0.001 
0.0005  1.27 1.17, 1.38 <0.001 
0.005  1.32 1.22, 1.43 <0.001 
0.05  1.33 1.23, 1.44 <0.001 
0.5  1.34 1.24, 1.44 <0.001 
Smoking initiation (100 cigarettes 
or more) by 24 
2,925    
5×10-8  1.29 1.19, 1.39 <0.001 
0.0005  1.38 1.27, 1.49 <0.001 
0.005  1.46 1.34, 1.58 <0.001 
0.05  1.49 1.37, 1.61 <0.001 
0.5  1.49 1.37, 1.39 <0.001 
Ever e-cigarette use by 24 among 
never smokers (<100 cigarettes*) 
1,937    
5×10-8  1.10 0.97, 1.26 0.150 
0.0005  1.05 0.92, 1.20 0.464 




0.05  1.15 1.00, 1.31 0.046 
0.5  1.18 1.04, 1.35 0.012 
Ever e-cigarette use by 24 among 
never smokers (<1 cigarette**) 
1037    
5×10-8  1.28 0.94, 1.74 0.111 
0.0005  1.10 0.81, 1.48 0.550 
0.005  1.27 0.94, 1.71 0.124 
0.05  1.39 1.02, 1.90 0.039 
0.5  1.57 1.16, 2.12 0.004 
Note: Ever smoking and smoking initiation models were included as positive controls. 
Analyses were adjusted for age, sex and principal components 1-10. *Never smokers in 
this analysis were defined as having smoked less than 100 cigarettes in their lifetime. 
**Never smokers in this analysis were defined as never having smoked a whole cigarette 
in their lifetime. 
 
4.4.3 PRS for Smoking Initiation and Self-Reported E-cigarette Use 
I observed positive associations between smoking initiation PRS and self-reported ever 
use of e-cigarettes by the age of 24 years (OR10-8 = 1.24, 95% CI 1.14 to 1.34) and 
self-reported regular (at least once a month) e-cigarette use at 24 years (OR10-8 = 1.18, 
95% CI 1.00 to 1.40). I observed these associations at all p-value thresholds (Table 4.4). 
Among those who had never initiated smoking (i.e., smoked < 100 cigarettes in their 
lifetime), I found no clear evidence for an association between PRS for smoking initiation 
and ever e-cigarette use at the most stringent p-value thresholds. However, I found 
evidence of a positive association with PRS calculated with less stringent thresholds (p < 
0.5 threshold OR = 1.18, 95% CI 1.04 to 1.35; Table 4.4). I found similar patterns of 
association among those who had never smoked any cigarettes (Table 4.4). 
4.4.4 PRS for Smoking Initiation and Negative Controls  
I observed a positive association between smoking initiation PRS and high number of 
sexual partners by 23 years (OR10-8 = 1.15, 95% CI 1.05 to 1.26) and having ever gambled 
by 24 years (OR10-8 = 1.12, 95% CI 1.03 to 1.22) at all p-value thresholds (Table 4.5). I 
found some evidence of a positive association between smoking initiation PRS and 
enjoying taking risks at 24 years (OR0.005 = 1.11, 95% CI 1.03 to 1.19), but this was less 




association between smoking initiation PRS and having been in trouble with the law 





Table 4.5. Associations between polygenic risk scores for smoking initiation with 
negative controls of risky behaviour. 
Outcome 
p-value threshold 
n OR 95% CI p 
Number of sexual partners by 23 
years* 
2,505    
5×10-8  1.15 1.05, 1.26 0.003 
0.0005  1.12 1.02, 1.23 0.019 
0.005  1.18 1.08, 1.29 <0.001 
0.05  1.25 1.14, 1.37 <0.001 
0.5  1.30 1.19, 1.43 <0.001 
Been in trouble with the law since 
23rd birthday  
2,928    
5×10-8  1.00 0.79, 1.28 0.988 
0.0005  1.12 0.88, 1.43 0.352 
0.005  1.11 0.87, 1.41 0.407 
0.05  1.04 0.82, 1.33 0.745 
0.5  0.90 0.71, 1.15 0.394 
Enjoys taking risks at 24 years 2,932    
5×10-8  1.06 0.98, 1.14 0.154 
0.0005  1.05 0.98, 1.14 0.163 
0.005  1.11 1.03, 1.19 0.005 
0.05  1.09 1.01, 1.17 0.029 
0.5  1.08 1.01, 1.16 0.033 
Ever gambled by 24 years 2,899    
5×10-8  1.12 1.03, 1.22 0.008 
0.0005  1.16 1.07, 1.26 0.001 
0.005  1.16 1.06, 1.26 0.001 
0.05  1.20 1.10, 1.30 <0.001 
0.5  1.15 1.06, 1.25 0.001 
Note: Number of sexual partners, trouble with the law, enjoying risk-taking and 
gambling models were included as negative controls. Analyses were adjusted for age, 
sex and principal components 1-10. *Low (<11) vs. high (11 or more) number of sexual 
partners.  
 
I found evidence of a positive association between smoking initiation PRS and 
hyperactivity at 7 years (OR0.0005 = 1.10, 95% CI 1.04 to 1.16) but not at the most 
stringent threshold (Table 4.6). I also observed a positive association with CD at 7 years 
(OR10-8 = 1.10, 95% CI 1.03 to 1.17) at all thresholds (Table 4.6). I found some evidence of 




= 1.08, 95% CI 1.02 to 1.14). I also found a positive association with lower parental SEP 
(OR10-8 = 1.08, 95% CI 1.01 to 1.16) at all thresholds (Table 4.7).  
Table 4.6. Associations between polygenic risk scores for smoking initiation with 
negative controls of externalising disorders in childhood. 
Outcome 
p-value threshold 
n OR 95% CI p 
Hyperactivity at 7 years 5,227    
5×10-8  1.02 0.96, 1.08 0.511 
0.0005  1.10 1.04, 1.16 0.001 
0.005  1.14 1.08, 1.20 <0.001 
0.05  1.14 1.08, 1.21 <0.001 
0.5  1.15 1.08, 1.21 <0.001 
Conduct disorder at 7 years 5,334    
5×10-8  1.10 1.03, 1.17 0.004 
0.0005  1.11 1.04, 1.19 0.001 
0.005  1.11 1.04, 1.18 0.002 
0.05  1.08 1.01, 1.15 0.021 
0.5  1.08 1.01, 1.15 0.017 
Oppositional defiant disorder at 7 
years 
5,325    
5×10-8  1.02 0.96, 1.08 0.496 
0.0005  1.08 1.02, 1.14 0.013 
0.005  1.04 0.98, 1.10 0.200 
0.05  1.04 0.98, 1.10 0.173 
0.5  1.02 0.96, 1.08 0.529 
Note: Hyperactivity and conduct disorder were assessed using the strengths and 
difficulties questionnaire (SDQ) and oppositional defiant disorder was assessed using the 
development and wellbeing assessment (DAWBA). All variables were recoded into 
binary outcomes (no disorder/symptoms versus borderline/disorder/symptoms). 
 
Table 4.7. Associations between polygenic risk scores for smoking initiation with 
negative controls of socioeconomic indicators. 
Outcome 
p-value threshold 
n OR 95% CI p 
Parental SEP at birth (manual) 6,702    
5×10-8  1.08 1.01, 1.16 0.017 
0.0005  1.13 1.06, 1.21 <0.001 
0.005  1.16 1.09, 1.24 <0.001 
0.05  1.11 1.03, 1.18 0.003 




Note: SEP = Socioeconomic position. Parental SEP was based on the higher of the 
mother or partner's occupational social class using the Office of Population Censuses 
and Surveys (OPCS) occupation codes. 
 
4.5 Discussion 
In contrast to the results of Allegrini and colleagues (2019), when using the most recent 
GWAS for smoking initiation, PRS were strongly associated with ever e-cigarette use by 
24 years. As expected, I observed an association of smoking initiation PRS and both ever 
smoking and smoking initiation. It was notable that the associations of the smoking 
initiation PRS and both smoking and e-cigarette use were of similar magnitude, although 
this could be due to the high correlation between the two behaviours. 
The association between smoking initiation PRS and e-cigarette use could be explained 
by smoking causally influencing e-cigarette use. This hypothesis is supported by 
observational evidence; as discussed in Chapter 3, use of e-cigarettes for smoking 
cessation is common among both young adults in the UK (Khouja, Taylor, et al., 2020) 
and adults in Great Britain (Action on Smoking and Health, 2017). However, the 
associations observed among the restricted analysis and between the negative control 
outcomes suggest there may be other factors at play – there may be shared genetic risk 
factors that influence both behaviours. Among never smokers, I found weak evidence of 
an association between PRS for smoking initiation and e-cigarette use, which suggests 
that e-cigarette use is not simply caused by smoking but that there is a shared genetic 
aetiology influencing both behaviours. Hence, what appears to be a gateway between 
e-cigarette use and smoking in previous studies (described in Chapter 2), could actually 
be a shared genetic liability, and the order of use is coincidental or due to other factors 
such as perceived risk or misreporting of smoking status (Khouja, Munafò, et al., 2020).  
Alternatively, the smoking initiation PRS may be capturing much more than just smoking 
or nicotine use. Using less stringent p-value thresholds to create the PRS increases the 
percentage variance that it explains of the phenotype, and therefore the power to 
detect an association (up to a point); using less stringent thresholds also increases the 
likelihood of capturing SNPs which are related to other factors than the exposure of 




variance in the exposure and more variance in other (horizontally pleiotropic) correlated 
variables. Increasing magnitudes of association with PRS and negative controls at less 
stringent p-value thresholds suggests that the smoking initiation PRS is capturing, at 
least in part, a broad phenotype which is not entirely specific to smoking/nicotine.  
Although I observed weaker associations between risk-taking factors and smoking 
initiation PRS compared to e-cigarette use and smoking, the associations are still 
relatively strong and consistent. Recent observational evidence also indicated a strong 
association between e-cigarette use and smoking prior to adjusting for risk-taking 
behaviours and other shared risk factors, but showed no clear evidence of an association 
after adjusting for risk-taking behaviours and other shared risk factors (Kim & Selya, 
2019). This suggests that the association between smoking initiation PRS and both 
smoking initiation and e-cigarette use could be due to the PRS predicting general 
risk-taking behaviour, including both smoking and e-cigarette use.  
I also found an association between the smoking initiation PRS and externalising 
disorders in childhood (7 years) which precedes the age at which cigarettes are first 
smoked in the vast majority of cases in this cohort (>99%), and therefore cannot be a 
causal effect of own smoking. However, this association could potentially be due to 
causal in utero effects of maternal smoking in pregnancy or maternal smoking in 
childhood, since maternal and offspring genotype will be correlated. ADHD has been 
shown to be associated with in utero smoke exposure, and the effects are stronger 
among genetically-related mother-offspring pairs compared to unrelated 
mother-offspring pairs, suggesting an inherited effect (Thapar et al., 2009). 
Nevertheless, combined with evidence that liability to ADHD increases the likelihood of 
smoking initiation and vice versa (Treur et al., 2019), our results suggest the possibility 
that the smoking initiation PRS is capturing a broad impulsivity phenotype.  
The association observed between smoking initiation PRS and parental SEP also suggests 
the PRS is capturing a broader phenotype than one relating specifically to nicotine or 
smoking. It is impossible for parental SEP at birth to be caused by the young adults’ own 
smoking, so I can be confident that this association is not a result of own smoking 
causing SEP. This suggests that the smoking initiation PRS could actually be capturing an 




behaviour. Although introducing noise is to be expected when using the less stringent 
p-value thresholds for SNP inclusion, it is concerning that the PRS created using the 
genome-wide significant threshold appear to be capturing a broader phenotype than 
the one intended as these PRS may be used in Mendelian randomisation (MR) analysis. 
The associations observed here have important implications for the use of smoking 
initiation PRS in MR. This method is often implemented to provide unconfounded causal 
estimates, as long as the assumptions of MR hold (Davey Smith & Ebrahim, 2003). One 
assumption is that the genetic instrument (e.g., smoking initiation PRS) is not associated 
with any confounders (e.g., risk-taking, childhood externalising disorders, SEP). The 
association we observed between smoking initiation PRS and negative control 
outcomes, even when restricted to only genome-wide significant SNPs, indicates that 
smoking initiation PRS may not be a valid instrument to use in MR to investigate the 
causal effects of smoking initiation. This emphasises the importance of using pleiotropy 
robust methods (e.g., MR-Egger). Another assumption is the InSIDE (Instrument Strength 
Independent of Direct Effect) assumption that SNP-exposure effects (e.g., the effect of 
smoking initiation SNPs on smoking initiation) should not be correlated with horizontal 
pleiotropic effects (e.g., the effect of smoking initiation SNPs on broad risk-taking 
behaviour). The association observed between the smoking initiation PRS and multiple 
risk-taking behaviours and externalising disorders in childhood suggests that the 
smoking initiation SNPs may be capturing a broader phenotype, such as risk-taking, 
which is not specific to smoking or nicotine, and thus this assumption may be violated. 
One approach which could be used to address this is Steiger filtering which can be used 
to exclude SNPs which explain more variance in the outcome over and above the 
variance in the exposure (Hemani et al., 2018; Hemani et al., 2017). The same approach 
can be applied in MR studies using smoking initiation PRS to remove SNPs which explain 
more variance in the negative control outcomes used in this study (or other 
phenotypes/proxies for risk-taking behaviour) than variance in smoking initiation. 
However, if the InSIDE assumption is perfectly violated (i.e., if the SNP effect on broad 
risk-taking causes smoking initiation), the smoking initiation PRS will be an invalid 
instrument using any MR method. At the very least, triangulating evidence across 
multiple MR methods (e.g., median weighted and mode based) would be advised in MR 
studies using smoking initiation PRS but, ideally, other causal inference methods should 




which are not as highly associated with impulsivity, such as smoking heaviness, could be 
useful if including such measures would be appropriate for the research question. 
There are a number of limitations of this study. First, the relatively low sample size – 
particularly when investigating associations with regular e-cigarette use and restricting 
to never smokers. The results of my restricted analysis may suffer from low power as a 
result. Similarly, lack of power may explain why I found no clear association between the 
smoking initiation PRS and being in trouble with the law; only 7% of the study sample 
had been in trouble with the law in the past year. Second, restricting my analysis to 
never smokers could have introduced collider bias (Cole et al., 2010). Collider bias occurs 
when you condition (restrict, stratify or adjust regression analyses) on, or control for a 
collider (a variable which is influenced by both the exposure and the outcome) in your 
analysis. In this analysis I found that smoking initiation PRS were strongly associated 
with smoking initiation; if e-cigarette use also causes young adults to smoke (as 
discussed in Chapter 2), then smoking status is a collider and conditioning on this 
variable (i.e., restricting analysis to never smokers) may inflate any association between 
smoking initiation PRS and e-cigarette use. In this sample, there are very few individuals 
for whom e-cigarette use preceded smoking, so it is unlikely that collider bias has been 
introduced in this way. However, if both smoking initiation PRS and unmeasured 
confounders influence smoking initiation (as shown in Figure 4.2), then smoking 
initiation is a collider and conditioning on smoking initiation (i.e., restricting the analysis 
to never smokers) could induce bias (Paternoster, Tilling, & Davey Smith, 2017).  
 
 
Figure 4.2. A directed acyclic graph demonstrating potential collider bias introduced by 





Third, although my restricted analysis (excluding smokers) could be used to explore the 
gateway hypothesis, this cohort is not appropriate to directly study the gateway 
hypothesis. The young adults in ALSPAC were approximately 17 years old when 
e-cigarettes became widely available, and therefore were exposed to cigarettes earlier 
in their adolescence than e-cigarettes and had more opportunity to smoke than use 
e-cigarettes than later birth cohorts. Furthermore, I found in Chapter 3 that using 
e-cigarettes for smoking cessation/reduction is common, so given the age and nature of 
the sample as well as the reasons provided for e-cigarette use, it is not unexpected that 
we would observe an association between a PRS that predicts smoking initiation and 
e-cigarette use. However, it is unexpected that we would observe an association with 
risk-taking, which suggests a potential broader risk-taking behaviour underlying this 
phenotype. Future research should explore this association in a larger sample of 
individuals with exposure to both cigarettes and e-cigarettes during adolescence. 
Fourth, the attrition rate in ALSPAC is considerable – only 2,905 of the 7,859 non-related 
participants of European ancestry with genetic data responded to the questions about 
vaping in the 24-year questionnaire – and missingness in this cohort has previously been 
associated with smoking initiation PRS (Taylor et al., 2018). I found that those with 
higher smoking initiation PRS were less likely to have been included in this analysis due 
to attrition (OR10-8 per standard deviation of smoking initiation PRS = 0.87, 95% CI 0.83 
to 0.91) so my estimates may be biased by selection and the association could be 
stronger than observed here. However, interpretation of any study including smoking 
initiation PRS will be difficult as the association between smoking initiation PRS and 
attrition could induce bias such as collider bias (Munafò, Tilling, Taylor, Evans, & Davey 
Smith, 2018).  
4.6 Chapter Summary 
In conclusion, I found some evidence to suggest there is a shared genetic aetiology 
between smoking and e-cigarette use. This supports my hypothesis in Chapter 2; what 
appears to be a gateway between e-cigarette use and smoking in observational studies 
could actually be a result of shared liability, specifically a shared genetic aetiology. 
However, this does not rule out a potential gateway effect, and there is likely a causal 
relationship between smoking and later e-cigarette use given the reasons provided in 




externalising disorders in childhood and parental SEP at birth. This suggests the smoking 
initiation PRS is not specific to smoking or nicotine use but is capturing something much 
broader, potentially a risk-taking phenotype. Therefore, adolescents and young adults 
may use e-cigarettes because they are genetically predisposed to risk-taking and they 
consider e-cigarette use to be risky. This could explain why researchers have observed 
associations between e-cigarette use and subsequent smoking in observational studies 
(as discussed in Chapter 2) as smoking is also considered to be a risky behaviour. Future 
research is needed to explore this further in a population which has been exposed to 
both e-cigarettes and cigarettes in adolescence. Researchers should also be cautious 
about inferring causality from MR analyses using smoking initiation PRS. In Chapter 5, I 





Chapter 5 What is the health impact of 
nicotine exposure versus other constituents 
of smoking? 
This chapter closely resembles sections from the following pre-print: 
Khouja, J. N., Sanderson, E., Wootton, R. E., Taylor, A. E., & Munafò, M. R. (2021). A 
multivariable Mendelian randomisation study exploring the direct effects of nicotine on 
health compared with the other constituents of tobacco smoke: Implications for e-
cigarette use. MedRxiv; doi: https://doi.org/10.1101/2021.01.12.21249493.  
I took the lead in designing, implementing and interpreting this study with the support 
of my co-authors. Specifically, MM, RW, AT and ES provided feedback on the design of 
the study and during the preparation of the manuscript. I was responsible for the data 
analysis and was responsible for writing the first draft of the manuscript and editing the 
manuscript in response to comments from co-authors and reviewers.  
5.1 Chapter Overview 
In Chapter 3 I found that vaping for reasons related to smoking cessation is common 
among young adults in the UK, but the long-term health effects of vaping (such as the 
long-term effects of nicotine use without tobacco smoke exposure) are currently 
unknown. As e-cigarettes have not been available for long enough to observe the 
long-term health consequences of use, the methods used to determine the effects of 
smoking (i.e., longitudinal observational methods) cannot be adopted to explore the 
effects of vaping. Furthermore, it is difficult to disentangle the effects of e-cigarette use 
from the effects of smoking given they are highly correlated. In this Chapter, I use a 
novel method (multivariable Mendelian randomisation [MVMR]) to explore the effects 
of using nicotine – the addictive common constituent of cigarettes and e-cigarettes – 





Of an estimated 3.6 million e-cigarette users in Great Britain, 22% use e-cigarettes to aid 
quitting (Action on Smoking and Health, 2019a) and in Chapter 3, I found that vaping to 
quit smoking was the second most common reason given for using e-cigarettes. 
Although evidence suggests that e-cigarettes may reduce harm by aiding smoking 
cessation (Hartmann-Boyce et al., 2020; McNeill et al., 2015), the long-term health 
effects of nicotine exposure via e-cigarette use remain unknown. 
In contrast, the long-term health outcomes of smoking are well-known due to the 
abundance of observational evidence demonstrating associations between smoking and 
health issues such as chronic obstructive pulmonary disease (COPD), coronary heart 
disease (CHD) and poor lung function (Das, 2003; Jayes et al., 2016; Khan, Shabbir, 
Ansari, & Zia, 2010; West, 2017). Consistent evidence across many observational studies 
provides strong support for a causal effect (Hill, 1965), which is further supported by 
genome-wide association studies that identify smoking-related genetic variants when 
examining these outcomes (Gage, Davey Smith, Ware, Flint, & Munafo, 2016; Hobbs et 
al., 2017; Polfus et al., 2013; Zhang et al., 2014). However, it remains unclear which 
constituents of tobacco smoke (e.g., nicotine, carbon monoxide etc.) negatively impact 
health, or have the largest effects.  
Until e-cigarettes became widely available in 2007, nicotine replacement therapy (NRT) 
was the primary source of nicotine without tobacco. Long-term NRT use is rare among 
ex-smokers (Shahab, Dobbie, et al., 2017) and non-smokers (Jackson et al., 2019); 
consequently, there is little evidence of the long-term effects of nicotine use when not 
consumed in tobacco products. Ideally, to explore the effect of long-term nicotine use 
on health outcomes, I would conduct a randomised controlled trial (RCT) with never-
smokers randomised to use nicotine or placebo and observe the differences between 
groups for a range of health outcomes over time. However, it would be unethical to 
expose never-smokers to an addictive and potentially harmful drug, and the individuals 
would need to be followed up for decades to observe the long-term effects.  
As I described in Chapter 1, Mendelian randomisation (MR) is a method which is often 




(Davey Smith & Ebrahim, 2003). The method assumes that the laws of Mendelian 
genetics (segregation and independent assortment) are held at a population level i.e., a 
random assortment of genes are transferred from parents to their offspring (Nitsch et 
al., 2006). For example, if an individual inherits the rs16969968 genetic variant which 
predisposes them to be more tolerant of nicotine, then they are likely to be a heavier 
smoker (i.e., smoke one more cigarette per day per risk allele) on average than an 
individual with no risk alleles (Ware, van den Bree, & Munafò, 2011). In theory, the 
inheritance of these genetic variants is independent of confounding factors which often 
distort observational evidence, and therefore mimics the randomisation process in an 
RCT, reducing issues of both confounding and reverse causality (Nitsch et al., 2006; 
Swanson et al., 2017). The MR method estimates the total causal effect of one exposure 
on one outcome. For example, to explore the potential harm of using 
nicotine-containing products (e.g., e-cigarettes), I could use MR methods to estimate the 
total effect of e-cigarette use on COPD. However, to conduct MR analysis we require 
large genome-wide association studies (GWAS) of the exposure, to identify genetic 
variants that can be used as proxies for this exposure. At present, there are no published 
GWAS of e-cigarette use, nor are there currently any cohorts or consortia with sufficient 
numbers of e-cigarette users to conduct this analysis. Furthermore, e-cigarette use and 
smoking are highly correlated (Action on Smoking and Health, 2019a) and may share a 
genetic aetiology (as found in Chapter 4); to ensure any associations found are not due 
to confounding effects of smoking, the GWAS should be restricted to never-smokers, but 
as I discussed in Chapter 2, few never-smokers regularly vape (Action on Smoking and 
Health, 2019a; Bauld et al., 2017; Hammond et al., 2019).  
As I described in Chapter 1, multivariable MR (MVMR) is an extension of the inverse 
variance weighted (IVW) MR method; rather than calculating the total effect, MVMR is 
used to explore the direct causal effect of two or more exposures on an outcome 
(Lawlor et al., 2019; Sanderson et al., 2019). When two exposures are related, MVMR 
can estimate the effect of one exposure on an outcome while accounting for the effect 
of the other exposure on the outcome (i.e., the direct effect) even when there is overlap 
in the genetic effects on the two exposures. As cigarettes contain nicotine, smoke 
exposure and nicotine intake are highly related; therefore, MVMR is a suitable method 
to explore the direct effects of nicotine versus the direct effect of all of the other 




GWAS have previously identified genetic variants associated with smoking heaviness 
(i.e., average number of cigarettes smoked per day [CPD]) as well as cotinine – a highly 
specific biomarker which captures recent nicotine exposure (Figure 5.1). Given that 
cotinine has a longer half-life (16 hours) than nicotine (2 hours), and that 70-80% of 
nicotine is rapidly metabolised into cotinine, cotinine levels are a good proxy for nicotine 
exposure (Benowitz et al., 2009).  
 
 
Figure 5.1. A diagram to show the by-products of nicotine metabolism. Adapted from 
Benowitz et al. (2009). 
 
By using these genetic variants as proxies for nicotine (GN) and smoking (GS) – including 
those variants which predict both nicotine and smoking heaviness (GSN) – in an MVMR 
analysis (Figure 5.2a), I can explore the direct effect of cotinine while taking into account 
the effect of smoke exposure (Figure 2b) and vice versa (Figure 5.2c). The total effects of 
smoking heaviness on health outcomes includes the effect of cotinine on health 
outcomes, but by exploring the direct effect of smoking heaviness while controlling for 
the direct effect of cotinine (and confounding factors), I can observe the effect of the 
remaining constituents of tobacco smoke aside from cotinine (Figure 5.2c). In other 
words, among smokers, I can explore the health effects caused by nicotine versus the 











Figure 5.2. Directed acyclic graphs to show the relationship between genetic 
instruments (GS, GSN, and GN), exposures (smoking heaviness and cotinine), confounding 





The aim of this study was therefore to explore the direct effects of nicotine (as 
measured by cotinine, independent of cigarettes per day) compared with the direct 
effect of all other constituents of tobacco smoke aside from nicotine (as measured by 
CPD, independent of cotinine) on health outcomes known to be caused by smoking. 
5.3 Methods 
5.3.1 Data Sources 
The data sources for the exposures and outcomes (including sample sizes) are shown in 
Figure 5.3. I describe each of the data sets obtained from these sources as either 
individual-level or summary-level data. As described in Chapter 1, individual-level data 
consist of genetic, exposure and outcome data for all individual participants with which 
genetic associations can be calculated. Where individual-level data are provided, 
summary-level data can be generated for further analysis (Figure 5.3). Summary-level 
data contain only the overall genetic associations with the exposure and outcome for 
the whole sample, and can be used to identify suitable genetic instruments and the 






Figure 5.3. A flow chart describing the SNP inclusion process for the Multivariable Mendelian Randomisation analyses. 
Note: SNPs = single nucleotide polymorphisms; BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV-1 = forced expiratory volume in 
1 second; FVC = forced vital capacity; CHD = chronic heart disease. *SNPs were selected for inclusion in the main analysis using a p-value threshold (p < 
510-6); ** SNPs were selected for inclusion in the supplementary analysis was completed using the genome wide significant threshold (p < 510-8). Boxes 
with dashed borders indicate where individual-level data was used to generate summary-level data. Boxes with solid borders indicate summary-level data. 




5.3.1.1 The Cotinine Consortium. Ware et al. (2016) report summary level statistics 
from a GWAS meta-analysis of cotinine levels (per standard deviation change) among 
daily smokers of European ancestry. The meta-analysis is comprised of data from 11 
studies in the Cotinine Consortium (N = 4,548). Cotinine levels were provided by daily 
smokers at or after 17 years of age and were determined from serum, urine, or plasma 
samples (dependent on the sample available) and quantified using immunoassay, 
radioimmunoassay or mass spectrometry. Specific cotinine thresholds (dependent on 
the assessment method) were used to reduce the inclusion of non-smokers and 
non-daily smokers in the analysis. Further information, including the age of participants, 
location, setting and assessment method for each cohort are detailed in the 
supplementary material of Ware et al. (2016). Cotinine levels were standardised (i.e., 
transformed into z-scores) at the individual study-level prior to conducting the GWAS, 
therefore the GWAS were conducted using the standardised cotinine levels. SNPs were 
reported as independent if they reached genome-wide significance using an iterative 
process of conditional analyses. This process involved re-running the meta-analysis for 
each region identified by the initial meta-analysis while conditioning on the SNP with the 
lowest p-value. The next strongest signal was identified from this conditional 
meta-analysis. This SNP was then conditioned on in the second conditional 
meta-analysis. This process was repeated until no residual signal remained below a 
threshold of p < 5×10−8.  
5.3.1.2 GSCAN. The GWAS & Sequencing Consortium of Alcohol and Nicotine use 
(GSCAN) report summary level statistics from a GWAS of smoking heaviness (Liu et al., 
2019). This GWAS was based on 337,334 participants of European ancestry from 29 
cohorts. Summary statistics, with the UK Biobank (N = 120,744) removed, were obtained 
through correspondence with GSCAN to eliminate data overlap with the target sample. 
Due to data sharing restrictions, 23andMe were also excluded from this data (N = 
73,380) leaving a total sample size of 143,210. Smoking heaviness was defined as the 
number of CPD smoked either as a current or former smoker (including hand-rolled and 
manufactured cigarettes). Where the number of cigarettes per day was reported as an 
integer, responses were binned into 5 groups (1-5; 6-15; 16-25; 26-35; 36+ cigarettes per 
day); where studies had created pre-defined bins, these were used. For the majority of 
studies, a single question was used to determine the number of CPD (e.g., how many 




deviation (calculated from the weighted average prevalence across all studies). SNPs 
were reported as independent if they explained additional variance in conditional 
analyses using a partial correlation-based score statistic (Jiang et al., 2018).  
5.3.1.3 UK Biobank. I obtained individual-level data from UK Biobank, a 
population-based health research resource consisting of approximately 500,000 people, 
aged between 38 years and 73 years, who were recruited between the years 2006 and 
2010 from across the UK (Allen, Sudlow, Peakman, Collins, & Biobank, 2014). With a 
particular focus on identifying determinants of human diseases in middle-aged and older 
individuals, participants provided a wide range of health information (data available at 
www.ukbiobank.ac.uk). A full description of the study design, participants and quality 
control (QC) methods have been described in detail previously (Allen et al., 2014; 
Mitchell et al., 2019). UK Biobank received ethics approval from the Research Ethics 
Committee (REC reference for UK Biobank is 11/NW/0382; project number 9142).  
5.3.2 Health Outcomes 
I have provided UK Biobank field IDs for each health outcome. IDs can be entered into 
the online variable search platform where information can be found on measurement 
(available at http://biobank.ndph.ox.ac.uk/showcase/search.cgi).  
5.3.2.1 Body Mass Index. Standing height and weight were measured during a UK 
Biobank Assessment Centre visit (field IDs 50 and 21002). BMI was calculated as: weight 
(kg)/height (m)2. 
5.3.2.2 Chronic Obstructive Pulmonary Disease. COPD cases were identified as 
participants who responded that they had been diagnosed with COPD in response to the 
question "Has a doctor ever told you that you have had any of the conditions below?" 
(field ID 22130). 
5.3.2.3 Forced Expiratory Volume and Forced Vital Capacity. Forced expiratory volume 
in 1 second (FEV-1) and forced vital capacity (FVC) were measured multiple times using a 
Vitalograph spirometer (field IDs 20150 and 20151). I used the ‘best measure’ of both 
FEV-1 and FVC which were identified as the highest value recorded with no 




5.3.2.4 Coronary Heart Disease. CHD diagnosis was determined using linked hospital 
admission data (field IDs 41270 and 41271) with ICD codes relating to ischemic heart 
disease (ICD-9 410-414; ICD-9 4100-4149; ICD-10 I20-I25). The measure included angina 
pectoris, acute myocardial infarction, subsequent myocardial infarction, certain current 
complications following acute myocardial infarction, other acute ischaemic heart 
diseases, and chronic ischaemic heart disease.  
5.3.2.5 Heart Rate. Heart rate (beats per minute [bpm]) was assessed on multiple 
occasions per session (field ID 102). Heart rate can be affected by numerous factors such 
as exercise (Evans, 1985) and stress (Kim, Cheon, Bai, Lee, & Koo, 2018). To allow time 
for the participant’s heart rate to normalise during the session, I used the second 
measure taken within the session. 
5.3.2.6 Smoking Status. In UK Biobank, smoking status was categorised as never, 
previous and current smoking (field 20116). From this variable, I derived an ‘ever 
smoking’ variable which was defined as currently or having previously smoked 
occasionally, most days or daily (i.e., having smoked more than just once or twice). 
Current smoking was defined as currently smoking occasionally, most days or daily. 
Former smoking (referred to as ‘previous smoking’ in UK Biobank) was defined as not 
currently smoking but having previously smoked occasionally, most days or daily (i.e., 
more than just once or twice). Those who have tried smoking once or twice or who have 
never smoked were categorised as never smokers.  
5.3.3 Statistical Analysis 
After restricting the sample to individuals of White British ancestry (Bycroft et al., 2018) 
and excluding those with mismatched sex, with missing array data, who were related or 
withdrew their consent to participate, the sample size was 337,010 (Mitchell et al., 
2019). Using individual-level data from UK Biobank, I generated summary-level data by 
regressing each SNP on each of the health outcomes, adjusting for 10 principal 
components of population stratification. As shown in Figure 5.3, four datasets were 
generated according to smoking status: ever smokers (i.e., both current and former 
smokers; n = 151,809), current smokers (n = 33,354), former smokers (n = 118,455), and 
never smokers (n = 184,016). Binary outcomes were estimated using logistic regressions, 




All analyses were carried out in Stata 15.1 (StataCorp, 2017). 
5.3.4.1 Selection of genetic variants. Genetic variants related to the phenotype of 
interest (cotinine levels or smoking heaviness) were selected for inclusion in the analysis 
based on the reported results of the relevant GWAS (Figure 5.3). Independent SNPs at 
the genome-wide significant level (p < 5×10-8) were selected for inclusion – 55 SNPs 
were identified as associated with smoking heaviness independently of any other SNP 
associations (Liu et al., 2019) and 3 SNPs were identified as associated with cotinine 
levels independently of any other SNP associations (Ware et al., 2016). 
For MVMR analyses, all included SNPs (i.e., those relating to smoking heaviness as well 
as those relating to cotinine levels) must also be independent of each other, so an 
additional clumping stage was added to ensure overall SNP independence (LD R2 < 0.1, > 
500 kb). As I used a different method of determining independence in this study 
(clumping) compared to the GWAS of cotinine levels (conditional independence), 1 SNP 
which was considered conditionally independently associated with cotinine levels in the 
original GWAS (rs57064725) was not considered independent from the other cotinine 
SNPs in the MVMR analysis. As fewer SNPs were associated with cotinine than with 
smoking heaviness, where a SNP associated with cotinine levels was in LD with a SNP 
associated with smoking heaviness, the SNP associated with smoking heaviness was 
removed.  
Due to the limited number of independent SNPs associated with cotinine levels at the 
genome-wide significant threshold (n = 2), I lowered the significance threshold used for 
inclusion of cotinine SNPs in the main analyses to p < 5x10-6. Where a SNP was identified 
for inclusion but was not available in either of the other summary data sets (e.g., 
available in the Cotinine Consortium summary data but not available in the GSCAN 
summary data or Biobank data), I selected proxy SNPs with a minimum linkage 
disequilibrium (LD) R2 of 0.8. Proxy SNPs were available for 5 SNPs which were 
associated with smoking heaviness but were not available in the cotinine GWAS 
summary data, and for 1 SNP which was associated with cotinine but not available in the 
smoking heaviness GWAS summary data or UK Biobank data. I excluded 2 SNPs which 
were associated with smoking heaviness which were not available in the cotinine GWAS 




with LD R2 > 0.8). Details of the SNPs included in each analysis, and proxies used, are 
provided in Appendix 8.  
Instrument strength was tested using the conditional F-statistic for MVMR and Cochran 
Q statistic (Sanderson, Spiller, & Bowden, 2020). Instrument strength is quantified using 
the mean F-statistic in the IVW method (Bowden & Holmes, 2019). As a general rule, the 
F-statistic should be greater than 10. The Cochran Q statistic tests for instrument 
strength in the two sample summary data setting by detecting heterogeneity among 
causal estimates (Bowden & Holmes, 2019). Q estimates should be less than the number 
of SNPs included in the model.  
5.3.4.2 Univariable Mendelian randomisation. For comparison with the main analysis, I 
considered the total effect of both cotinine levels and smoking heaviness on each health 
outcome (BMI, COPD, FEV-1, FVC, CHD and heart rate) using MR with summary data 
from the Cotinine Consortium and GSCAN, and summary data (generated using 
individual-level data) from UK Biobank. I used four complimentary methods (inverse 
variance weighted [IVW], MR-Egger, weighted median based estimation and weighted 
modal based estimation) (Bowden et al., 2015; Bowden, Davey Smith, et al., 2016; 
Burgess, Butterworth, & Thompson, 2013; Hartwig, Davey Smith, & Bowden, 2017). 
Using a variety of MR methods with different assumptions with respect to horizontal 
pleiotropy – which occurs when single genetic variants influence multiple phenotypes 
(Davey Smith & Hemani, 2014) – facilitates understanding of whether the effect of the 
exposure on the outcome is causal. Consistent results across these methods provide 
stronger evidence to support a true causal effect which is not the result of a false 
positive (Lawlor, Tilling, & Davey Smith, 2016). I also estimated the weighted regression 
dilution (I2GX) for each MR-Egger analysis (Bowden, Del Greco, et al., 2016). I applied 
simulation extrapolation SIMEX (Lederer & Küchenhoff, 2006) corrections to MR-Egger 
analysis where I2GX estimates were below 0.9 (which would indicate the effect estimate is 
biased by 10% due to measurement error) (Bowden, Del Greco, et al., 2016). This 
analysis was first restricted to ever smokers to capture the long-term effects of 
smoking/nicotine use (i.e., including ex-smokers who may have quit smoking due to 
developing a health issue), and then further restricted to current smokers only to 
explore the potential effects of smoking cessation (i.e., recoverable effects). If a poor 




indicate that that health outcome is short term and may improve following smoking 
cessation. 
5.3.4.3 Multivariable Mendelian randomisation. I explored the direct effects of 
cotinine levels and smoking heaviness individually (i.e., accounting for the other 
phenotype) using MVMR with two complimentary methods – IVW and MVMR-Egger 
(Sanderson et al., 2019). All of the SNPs included in this analysis were associated with 
either cotinine levels or smoking heaviness (or both). To explore the recoverable and 
long-term outcomes of smoking, this analysis was first restricted to ever smokers, and 
then restricted to current smokers.  
I also stratified the analysis by former smoking status to further explore recoverable 
effects, and I additionally stratified the analysis by ever smoking status to explore 
potential horizontal pleiotropy. Horizontal pleiotropy is problematic for the 
interpretation of MR results because horizontally pleiotropic genetic variants are not 
valid instruments – effects observed among never smokers could indicate horizontally 
pleiotropic effects (i.e., the included SNPs influence the outcome directly, or via another 
phenotype, but not through smoking), or it could indicate misreporting of smoking 
status or population stratification.  
 
5.4 Results 
5.4.1 Descriptive Statistics 
Of the 337,010 individuals with available data in UK Biobank, 54% were male, the mean 
age was 56, and the average BMI was 27.39. A total of 1,245 (1%) had a diagnosis of 
COPD and 28,652 (9%) had a diagnosis of CHD. Average FEV-1 was 2.87 litres, average 
FVC was 3.80 litres, and average heart rate was 68.98 bpm. A total of 184,016 (55%) 
were never smokers and 151,809 (45%) were ever smokers, of whom 33,354 (10%) were 
current smokers and 118,455 (35%) were former smokers. A total of 1,185 UK Biobank 




5.4.2 Univariable Mendelian Randomisation  
The results of the univariable MR analysis of cotinine levels (n = 10 SNPs) and 
smoking-related health outcomes among ever smokers and current smokers are 
displayed in Table 5.1. The results of the MR analysis of smoking heaviness (cigarettes 
per day; n = 54 SNPs) and smoking-related health outcomes among ever smokers and 
current smokers are shown in Table 5.2. Results are reported per standard deviation 
(SD) increase in the exposure phenotype (i.e., cotinine/cigarettes per day) and relate to 
the results of the IVW estimation except where otherwise specified. Tests of the 
weighted regression dilution (I2GX), instrument validity and heterogeneity can be found 




Table 5.1. Univariable Mendelian randomisation analysis of cotinine and smoking-
related health outcomes among ever and current smokers (n = 10 SNPs). 
Health  
outcome 
MR method Ever smokers  Current smokers 
 Effect 95% CI p-value  Effect 95% CI p-value 
BMI IVW 0.03 -0.11, 0.16 0.671  -0.35 -0.75, 0.05 0.086 
 MR-Egger (SIMEX) 0.03 -0.91, 0.98 0.944  -1.73 -4.07, 0.61 0.147 
 W. median  0.01 -0.12, 0.14 0.934  -0.39 -0.77, -0.02 0.041 
 W. mode -0.01 -0.21, 0.19 0.925  0.22 -0.60, 1.05 0.593 
COPD IVW 0.24 -0.12, 0.60 0.189  0.53 -0.10, 1.15 0.099 
 MR-Egger (SIMEX) 0.92 -1.75, 3.58 0.502  1.07 -3.32, 5.47 0.633 
 W. median  0.03 -0.30, 0.36 0.842  0.54 -0.11, 1.19 0.102 
 W. mode -0.01 -0.46, 0.44 0.968  0.44 -0.65, 1.53 0.430 
FEV-1 IVW -0.03 -0.06, 0.00 0.041  -0.06 -0.11, -0.02 0.005 
 MR-Egger (SIMEX) -0.17 -0.31, -0.02 0.023  -0.23 -0.51, 0.06 0.118 
 W. median  -0.03 -0.06, 0.00 0.021  -0.05 -0.10, 0.01 0.100 
 W. mode -0.03 -0.08, 0.01 0.150  -0.01 -0.10, 0.07 0.736 
FVC IVW -0.02 -0.04, 0.00 0.049  -0.05 -0.10, -0.01 0.024 
 MR-Egger (SIMEX) -0.10 -0.20, 0.00 0.053  -0.12 -0.27, 0.02 0.103 
 W. median  -0.02 -0.05, 0.00 0.100  -0.04 -0.10, 0.02 0.205 
 W. mode -0.04 -0.08, 0.00 0.060  -0.03 -0.11, 0.05 0.487 
CHD IVW -0.01 -0.10, 0.09 0.860  0.00 -0.15, 0.15 0.982 
 MR-Egger (SIMEX) 0.03 -0.33, 0.39 0.874  -0.04 -0.82, 0.74 0.919 
 W. median  0.05 -0.03, 0.14 0.244  0.09 -0.08, 0.26 0.292 
 W. mode 0.07 -0.03, 0.18 0.172  0.07 -0.15, 0.30 0.529 
Heart IVW 0.27 -0.02, 0.56 0.070  0.75 0.10, 1.39 0.023 
Rate MR-Egger (SIMEX) 0.98 -0.74, 2.70 0.262  3.24 -0.29, 6.77 0.072 
 W. median  0.23 -0.10, 0.57 0.172  0.46 -0.26, 1.18 0.207 
 W. mode 0.18 -0.45, 0.82 0.575  0.12 -1.14, 1.38 0.850 
Note: A p-threshold of 5×10-6 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with cotinine. BMI = body mass index; COPD = chronic 
obstructive pulmonary disease; FEV-1 = forced expiratory volume in 1 second; FVC = 
forced vital capacity; CHD = chronic heart disease; IVW = inverse variance weighted; w. 
median = weighted median; w. mode = weighted mode. Effects are betas for continuous 
variables (BMI, FEV-1, FVC and HR) and log odds ratios for binary outcomes (COPD and 







5.4.2.1 Total effects of cotinine levels on health outcomes. The total effects of cotinine 
levels on health outcomes among ever smokers are displayed in Table 5.1. Among ever 
smokers, there was some evidence to suggest that higher cotinine levels cause 
decreased FEV-1 (β = -0.03 litres, 95% CI -0.06 to 0.00 per SD increase in cotinine levels) 
and FVC (β = -0.02 litres, 95% CI -0.04 to 0.00 per SD increase in cotinine levels) and 
weak evidence to suggest that higher cotinine levels increased heart rate (β = 0.27 bpm, 
95% CI -0.02 to 0.56 per SD increase in cotinine levels). These results were consistently 
in the same direction for all methods. There was no clear evidence to suggest a causal 
effect of cotinine levels on BMI or the risk of COPD or CHD. 
The total effects of cotinine levels on health outcomes among current smokers are 
displayed in Table 5.1. Among current smokers, there was evidence to suggest that 
higher cotinine levels cause decreased BMI (weighted median β = -0.39 kg/m2, 95% 
CI -0.77 to -0.02 per SD increase in cotinine levels), FEV-1 (β = -0.06 litres, 95% CI -0.11 
to -0.02 per SD increase in cotinine levels), and FVC (β = -0.05 litres, 95% CI -0.10 to -0.01 
per SD increase in cotinine levels). There was also evidence that higher cotinine levels 
cause increased heart rate (β = 0.75 bpm, 95% CI 0.10 to 1.39 per SD increase in cotinine 
levels). These results were consistently in the same direction (with the exception of the 
modal estimation for BMI). There was no clear evidence to suggest a causal effect of 
cotinine on risk of CHD or COPD.  
The results did not substantially differ from the results when the more stringent 






Table 5.2. Univariable Mendelian randomisation analysis of cigarettes per day (CPD) and 





Ever smokers  Current smokers 
 Effect 95% CI p  Effect 95% CI P 
BMI IVW -0.09 -0.42, 0.23 0.578  -1.52 -2.15, -0.90 <0.001 
 MR-Egger -0.66 -1.13, -0.19 0.006  -2.14 -3.09, -1.19 <0.001 
 W. median -0.32 -0.57, -0.07 0.013  -2.49 -3.00, -1.98 <0.001 
 W. mode -0.26 -0.46, -0.06 0.010  -2.63 -3.11, -2.15 <0.001 
COPD IVW 1.58 0.96, 2.21 <0.001  2.57 1.64, 3.50 <0.001 
 MR-Egger 0.98 0.03, 1.93 0.044  1.78 0.36, 3.21 0.014 
 W. median 2.25 1.58, 2.91 <0.001  3.83 2.66, 5.00 <0.001 
 W. mode 2.39 1.79, 2.99 <0.001  3.82 2.68, 4.96 <0.001 
FEV-1 IVW -0.16 -0.22, -0.10 <0.001  -0.29 -0.40, -0.17 <0.001 
 MR-Egger -0.09 -0.17, 0.00 0.060  -0.21 -0.39, -0.03 0.020 
 W. median -0.23 -0.28, -0.19 <0.001  -0.44 -0.54, -0.34 <0.001 
 W. mode -0.22 -0.26, -0.18 <0.001  -0.45 -0.54, -0.35 <0.001 
FVC IVW -0.13 -0.19, -0.06 <0.001  -0.19 -0.31, -0.08 <0.001 
 MR-Egger -0.01 -0.10, 0.08 0.753  -0.06 -0.23, 0.11 0.512 
 W. median -0.15 -0.21, -0.10 <0.001  -0.28 -0.40, -0.16 <0.001 
 W. mode -0.14 -0.19, -0.09 <0.001  -0.27 -0.39, -0.14 <0.001 
CHD IVW 0.11 -0.04, 0.27 0.152  0.11 -0.14, 0.35 0.396 
 MR-Egger -0.16 -0.39, 0.06 0.151  -0.22 -0.58, 0.15 0.250 
 W. median 0.16 0.00, 0.32 0.049  0.14 -0.18, 0.45 0.392 
 W. mode 0.10 -0.04, 0.24 0.149  0.11 -0.18, 0.39 0.454 
Heart  IVW 1.35 0.71, 1.98 <0.001  3.03 1.78, 4.29 <0.001 
Rate MR-Egger 0.56 -0.39, 1.52 0.248  1.91 -0.01, 3.83 0.051 
 W. median 1.57 0.99, 2.15 <0.001  4.88 3.56, 6.20 <0.001 
 W. mode 1.68 1.11, 2.25 <0.001  4.82 3.57, 6.08 <0.001 
Note: A p-threshold of 5×10-8 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with smoking heaviness (cigarettes per day [CPD]). 
BMI = body mass index; COPD = chronic obstructive pulmonary disease; FEV-1 = forced 
expiratory volume in 1 second; FVC = forced vital capacity; CHD = chronic heart disease; 
IVW = inverse variance weighted; w. median = weighted median; w. mode = weighted 
mode. Effects are betas for continuous variables (BMI, FEV-1, FVC and HR) and log odds 
ratios for binary outcomes (COPD and CHD) per standard deviation increase in number 





5.4.2.2 Total effects of smoking heaviness on health outcomes. The total effects of 
smoking heaviness on health outcomes among ever smokers are displayed in Table 5.2. 
Among ever smokers, there was no clear evidence of an effect of smoking heaviness on 
BMI in the IVW analysis, but there was consistent evidence of increased smoking 
heaviness causing decreased BMI (MR-Egger β = -0.66 kg/m2, 95% CI -1.13 to -0.19 per 
SD increase in cigarettes smoked per day) across the other methods. There was also 
evidence of increased smoking heaviness causing decreased FEV-1 (β = -0.16 litres, 95% 
CI -0.22 to -0.10 per SD increase in cigarettes smoked per day) and FVC (β = -0.13 litres, 
95% CI -0.19 to -0.06 per SD increase in cigarettes smoked per day). There was 
consistent evidence to suggest that increased smoking heaviness causes increased risk 
of COPD (lnOR = 1.58, 95% CI 0.96 to 2.21 per SD increase in cigarettes smoked per day). 
The effect of smoking heaviness on risk of CHD was less clear, with inconsistent evidence 
across methods (weighted median lnOR = 0.16, 95% CI 0.00 to 0.32 per SD increase in 
cigarettes smoked per day, but there was no clear evidence of an effect across the other 
methods). There was consistent evidence to suggest that increased smoking heaviness 
causes increased heart rate across all methods (β = 1.35 bpm, 95% CI 0.71 to 1.98 per SD 
increase in cigarettes smoked per day) except for MR-Egger. 
The total effects of smoking heaviness on health outcomes among current smokers are 
displayed in Table 5.2. Among current smokers, there was strong evidence to suggest 
that increased smoking heaviness causes lower BMI (β = -1.52 kg/m2, 95% CI -2.15 
to -0.90 per SD increase in cigarettes smoked per day), FEV-1 (β = -0.29 litres, 95% 
CI -0.40 to -0.17 per SD increase in cigarettes smoked per day) and FVC (β = -0.19 litres, 
95% CI -0.31 to -0.08 per SD increase in cigarettes smoked per day) and increased heart 
rate (β = 3.03 bpm, 95% CI 1.78 to 4.29 per SD increase in cigarettes smoked per day) 
and risk of COPD (lnOR = 2.57, 95% CI 1.64 to 3.50 per SD increase in cigarettes smoked 
per day). There was no clear evidence of an effect of smoking heaviness on CHD.  
5.4.2.3 Tests of directional pleiotropy. MR-Egger intercepts can be used to indicate 
directional pleiotropy (i.e., evidence that the effect estimate has been biased in a 
particular direction). Where the intercept value differs from 0, there is evidence of 
directional pleiotropy (Bowden et al., 2015). There was some evidence of directional 




(Table 5.3). There was some evidence of directional pleiotropy in the MR-Egger intercept 
analysis of smoking heaviness and all outcomes except COPD (Table 5.3). 
There was no clear evidence of directional pleiotropy in the MR-Egger intercept analysis 
of cotinine and all health outcomes among current smokers (Table 5.3). There was some 
evidence of directional pleiotropy in the MR-Egger intercept analysis of smoking 
heaviness and both FVC and CHD among current smokers (Table 5.3). 
The results of the MR-Egger analyses were mostly consistently in the same direction 
with the other methods. All of the methods provided estimates in the opposite direction 
to the MR-Egger estimation for the effect of smoking heaviness on CHD among ever and 
current smokers, however, the confidence intervals crossed the null in all but one 
estimate. 
 
Table 5.3. MR-Egger test of directional pleiotropy among ever and current smokers. 
  Ever smokers  Current smokers 
Exposure Outcome Intercept 95% CI p-value  Intercept 95% CI p-value 
Cotinine BMI 0.000 -0.13, 0.13 0.999  0.211 -0.11, 0.53 0.198 
 COPD -0.104 -0.45, 0.25 0.560  -0.081 -0.65, 0.49 0.778 
 FEV-1 0.021 0.00, 0.04 0.036  0.025 -0.01, 0.06 0.194 
 FVC 0.012 0.00, 0.03 0.118  0.010 -0.01, 0.03 0.337 
 CHD -0.006 -0.06, 0.05 0.835  0.005 -0.12, 0.13 0.928 
 Heart Rate -0.110 -0.35, 0.13 0.370  -0.382 -0.86, 0.09 0.115 
CPD BMI 0.027 0.01, 0.04 0.002  0.029 -0.01, 0.06 0.096 
 COPD 0.029 -0.01, 0.06 0.101  0.038 -0.01, 0.09 0.155 
 FEV-1 -0.004 -0.01, 0.00 0.029  -0.004 -0.01, 0.00 0.259 
 FVC -0.005 -0.01, 0.00 0.001  -0.006 -0.01, 0.00 0.043 
 CHD 0.013 0.01, 0.02 0.001  0.015 0.00, 0.03 0.024 
 Heart Rate 0.037 0.00, 0.07 0.035  0.054 -0.02, 0.12 0.133 
Note: Cotinine single nucleotide polymorphisms (SNPs) were selected for inclusion 
based on a threshold of p < 5×10-6. A p-threshold of 5×10-8 was used to determine the 
SNPs associated with smoking heaviness (cigarettes per day [CPD]). BMI = body mass 
index; COPD = chronic obstructive pulmonary disease; FEV-1 = forced expiratory volume 
in 1 second; FVC = forced vital capacity; CHD = chronic heart disease; 95% CI = 95% 





5.4.3 Multivariable Mendelian Randomisation  
The results of the MVMR analysis using summary data exploring the direct effects of 
cotinine and cigarettes per day (n = 54 SNPs) on health outcomes are displayed in Table 
5.4 for ever smokers, current smokers, former smokers, and never smokers using the 
IVW method. Results are presented per SD increase in the exposure phenotype (i.e., 
cotinine/cigarettes per day). 
The Cochran’s Q statistics were greater than the number of SNPs included (N = 54) in the 
majority of the models, indicating heterogeneity. This could be due to horizontal 
pleiotropy, therefore I repeated the main analysis using the MVMR-Egger method (Table 
5.5), a pleiotropy robust method which corrects for measured and unmeasured 
pleiotropy (Rees, Wood, & Burgess, 2017). However, the statistical power of 






Table 5.4. Multivariable Mendelian randomisation IVW analysis of cotinine and 
cigarettes per day (CPD) and smoking related health outcomes among ever, current, 
former and never smokers (n = 54 SNPs). 
 Smoking  Cotinine  CPD  
Outcome Status Effect 95% CI p-value  Effect 95% CI p-value Q 
BMI Ever 0.04 -0.17, 0.24 0.725  0.10 -0.47, 0.68 0.721 263.00 
 Current 0.05 -0.24, 0.34 0.723  -1.81 -2.64, -0.98 <0.001 118.22 
 Former 0.04 -0.16, 0.25 0.658  0.68 0.10, 1.26 0.022 206.09 
 Never -0.04 -0.21, 0.13 0.639  0.96 0.46, 1.45 <0.001 228.42 
COPD Ever 0.03 -0.21, 0.28 0.783  1.99 1.28, 2.70 <0.001 56.28 
 Current 0.11 -0.28, 0.51 0.564  3.38 2.27, 4.49 <0.001 42.21 
 Former -0.02 -0.33, 0.30 0.915  1.31 0.40, 2.22 0.006 64.52 
 Never 0.25 -0.18, 0.67 0.253  -1.54 -2.75, -0.33 0.013 43.21 
FEV-1 Ever -0.01 -0.03, 0.02 0.659  -0.22 -0.29, -0.15 <0.001 109.57 
 Current -0.02 -0.07, 0.03 0.447  -0.34 -0.48, -0.20 <0.001 84.01 
 Former 0.00 -0.03, 0.03 0.951  -0.19 -0.26, -0.11 <0.001 98.14 
 Never 0.01 -0.02, 0.03 0.575  -0.03 -0.09, 0.03 0.331 97.75 
FVC Ever 0.00 -0.04, 0.03 0.779  -0.19 -0.28, -0.09 <0.001 130.57 
 Current -0.02 -0.08, 0.04 0.492  -0.24 -0.41, -0.06 0.008 84.25 
 Former 0.00 -0.04, 0.03 0.939  -0.17 -0.28, -0.07 0.001 118.94 
 Never 0.01 -0.02, 0.04 0.691  -0.05 -0.13, 0.04 0.281 118.86 
CHD Ever -0.03 -0.13, 0.06 0.459  0.31 0.05, 0.58 0.021 125.08 
 Current -0.02 -0.17, 0.12 0.742  0.30 -0.11, 0.70 0.145 64.77 
 Former -0.04 -0.14, 0.07 0.468  0.31 0.02, 0.61 0.036 119.44 
 Never -0.06 -0.14, 0.02 0.156  0.01 -0.21, 0.24 0.909 64.61 
Heart  Ever 0.03 -0.30, 0.36 0.857  1.83 0.88, 2.79 <0.001 115.13 
rate Current 0.50 -0.06, 1.05 0.079  3.00 1.41, 4.59 <0.001 66.34 
 Former -0.15 -0.51, 0.21 0.412  1.42 0.40, 2.44 0.007 107.19 
 Never -0.16 -0.52, 0.20 0.377  -0.06 -1.10, 0.97 0.902 174.15 
Note: A p-threshold of 5×10-8 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with CPD. A lower threshold of 5×10-6 was used to 
determine the SNPs associated with cotinine due to the low number of SNPs associated 
at the 5×10-8 threshold. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease. Effects are betas for continuous variables (BMI, FEV-1, FVC and 
HR) and log odds ratios for binary outcomes (COPD and CHD) per standard deviation 
increase in cotinine levels/number of cigarettes per day. The Cochran Q statistic tests for 







Table 5.5. Multivariable Mendelian randomisation Egger analysis of cotinine and 
cigarettes per day (CPD) and smoking related health outcomes among ever, current, 
former and never smokers (n = 54 SNPs). 
 Smoking  Cotinine  CPD 
Outcome Status Effect 95% CI p-value  Effect 95% CI p-value 
BMI Ever -0.01 -0.25, 0.23 0.926  -1.02 -2.01, -0.03 0.044 
 Current 0.01 -0.34, 0.36 0.952  -3.38 -4.82, -1.93 <0.001 
 Former -0.01 -0.25, 0.23 0.939  -0.46 -1.46, 0.54 0.368 
 Never -0.11 -0.31, 0.09 0.277  -0.03 -0.89, 0.82 0.941 
COPD Ever 0.01 -0.28, 0.31 0.935  1.35 0.05, 2.65 0.042 
 Current 0.00 -0.51, 0.51 0.996  3.80 1.56, 6.03 <0.001 
 Former 0.00 -0.38, 0.37 0.996  0.36 -1.29, 2.02 0.668 
 Never 0.24 -0.31, 0.78 0.390  -2.88 -5.28, -0.49 0.018 
FEV-1 Ever 0.00 -0.03, 0.03 0.888  -0.11 -0.24, 0.01 0.081 
 Current -0.01 -0.07, 0.05 0.684  -0.19 -0.45, 0.07 0.149 
 Former 0.01 -0.02, 0.04 0.668  -0.10 -0.23, 0.03 0.145 
 Never 0.01 -0.02, 0.03 0.569  -0.01 -0.12, 0.10 0.861 
FVC Ever 0.00 -0.04, 0.04 0.856  -0.02 -0.19, 0.15 0.813 
 Current -0.02 -0.09, 0.05 0.544  0.06 -0.24, 0.37 0.696 
 Former 0.01 -0.03, 0.05 0.642  -0.04 -0.22, 0.15 0.704 
 Never 0.01 -0.03, 0.04 0.739  -0.03 -0.19, 0.13 0.710 
CHD Ever -0.07 -0.17, 0.04 0.236  0.02 -0.46, 0.50 0.940 
 Current -0.15 -0.30, 0.01 0.066  -0.30 -1.01, 0.42 0.417 
 Former -0.04 -0.16, 0.08 0.494  0.10 -0.44, 0.64 0.711 
 Never -0.06 -0.16, 0.03 0.175  -0.21 -0.62, 0.20 0.319 
Heart  Ever -0.13 -0.52, 0.26 0.506  0.61 -1.11, 2.33 0.486 
rate Current 0.46 -0.19, 1.12 0.167  0.36 -2.44, 3.15 0.803 
 Former -0.32 -0.74, 0.09 0.130  1.10 -0.79, 2.99 0.253 
 Never -0.46 -0.87, -0.06 0.024  -1.64 -3.47, 0.20 0.081 
Note: A p-threshold of 5×10-8 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with CPD. A lower threshold of 5×10-6 was used to 
determine the SNPs associated with cotinine due to the low number of SNPs associated 
at the 5×10-8 threshold. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease. Effects are betas for continuous variables (BMI, FEV-1, FVC and 
HR) and log odds ratios for binary outcomes (COPD and CHD) per standard deviation 
increase in cotinine levels/number of cigarettes per day. The Cochran Q statistic tests for 







5.4.3.1 Instrument strength. Instrument strength was calculated using the adapted 
F-statistic for use with MVMR (Sanderson et al., 2020). The two-sample conditional 
F-statistic indicates instrument strength of each exposure when accounting for the 
prediction of other exposures in the model (i.e., whether the SNPs jointly predict 
smoking heaviness after predicting cotinine levels). As a general rule-of-thumb, 
F-statistics above 10 indicate strong instruments. This indicated that the SNPs included 
in the analysis are strong instruments for assessing the direct effects of smoking 
heaviness while accounting for the effect of cotinine levels (F = 21.66). However, this 
also indicated that the SNPs may not be strongly associated with cotinine levels while 
accounting for the effect of smoking heaviness (F = 6.83). Therefore, I cannot be as 
confident in the estimate of the direct effect of nicotine on smoking-related health 
outcomes. Nevertheless, I can compare the total and direct effects of smoking heaviness 
to evaluate whether the total effects are still present when taking nicotine into account; 
if they differ in magnitude or direction, this gives an indication that nicotine is having a 
substantial direct effect on the health outcome. These conditional F-statistics were 
calculated with the use of a less stringent threshold (p < 5x10-6) for the inclusion of SNPs 
associated with cotinine levels; use of the less stringent threshold improved the 
instrument strength compared with the genome-wide significant threshold by adding 
more independent SNPs that are only associated with cotinine and not with smoking 
heaviness (p < 5x10-8, F for smoking heaviness = 17.53; F for cotinine = 3.36).   
5.4.3.2 Direct effects of cotinine levels on health outcomes. When taking into account 
the effect of other constituents of cigarette smoke, there was some weak evidence to 
suggest that increased cotinine levels cause increased heart rate among current smokers 
(β = 0.50 bpm, 95% CI -0.06 to 1.05 per SD increase in cotinine levels) in the IVW 
analysis. However, there was no clear evidence of this among ever or former smokers 
(Table 5.4) indicating some evidence of an acute effect only. There was no clear 
evidence of any other effect of cotinine levels on smoking-related health outcomes in 
the IVW analysis (Table 5.4). In the MVMR-Egger analysis, the results were similar but 
there was weak evidence to suggest that cotinine lowers the risk of CHD among current 
smokers (Table 5.5) and there was no clear evidence of an effect of cotinine on heart 




5.4.3.3 Direct effects of smoking heaviness on health outcomes. When taking into 
account the effect of cotinine levels in the IVW analysis, there was no clear evidence to 
suggest an effect of increased smoking heaviness on BMI among ever smokers (Table 
5.4), but there was evidence to suggest that increased smoking heaviness decreases BMI 
among current smokers (β = -1.81 kg/m2, 95% CI -2.64 to -0.98 per SD increase in 
cigarettes smoked per day) and increases BMI among former smokers (β = 0.68 kg/m2, 
0.10 to 1.26 per SD increase in cigarettes smoked per day). Interestingly, I also found 
that genetic propensity for increased smoking heaviness increases BMI among never 
smokers which may indicate horizontal pleiotropy. The results of the MVMR-Egger 
analysis were similar for current smokers, but there was evidence to suggest that that 
increased smoking heaviness decreases BMI among ever smokers (β = -1.02 kg/m2, 95% 
CI -2.01 to -0.03 per SD increase in cigarettes smoked per day), and there was no clear 
evidence among former and never smokers. 
When taking into account the effect of cotinine levels in the IVW analysis, there was 
evidence to suggest that increased smoking heaviness causes increased risk of COPD 
among ever smokers (lnOR = 1.99, 95% CI 1.28 to 2.70 per SD increase in cigarettes 
smoked per day), current smokers (lnOR = 3.38, 95% CI 2.27 to 4.49 per SD increase in 
cigarettes smoked per day) and former smokers (lnOR = 1.31, 0.40 to 2.22 per SD 
increase in cigarettes smoked per day). Interestingly, the opposite effect was found 
among never smokers (lnOR = -1.54, 95% CI -2.75 to -0.33 per SD increase in cigarettes 
smoked per day) which is indicative of horizontal pleiotropy or collider bias. The results 
of the MVMR-Egger were similar for ever, current and never smokers, but there was 
little evidence of an effect among former smokers (Table 5.5). 
There was evidence in the IVW analysis to suggest that increased smoking heaviness 
causes decreased FEV-1 and FVC among ever smokers (β = -0.22 litres, 95% CI -0.29 
to -0.15; β = -0.19 litres, 95% CI -0.28 to -0.09 per SD increase in cigarettes smoked per 
day respectively), current smokers (β = -0.34 litres, 95% CI -0.48, -0.20; β = -0.24 litres, 
95% CI -0.41 to -0.06 per SD increase in cigarettes smoked per day respectively) and 
former smokers (β = -0.19 litres, 95% CI -0.26 to -0.11; β = -0.17 litres, 95% CI -0.28 
to -0.07 per SD increase in cigarettes smoked per day respectively). There was no clear 
evidence to suggest an effect of smoking heaviness on FEV-1 and FVC among never 




or FVC in the MVMR-Egger analysis except for FEV-1 among ever smokers (β = -0.11 
litres, 95% CI -0.24 to 0.01 per SD increase in cigarettes smoked per day; Table 5.5).  
There was evidence to suggest that increased smoking heaviness causes increased risk 
of CHD among ever smokers (lnOR = 0.31, 95% CI 0.05 to 0.58 per SD increase in 
cigarettes smoked per day) and former smokers (lnOR = 0.31, 95% CI 0.02 to 0.61 per SD 
increase in cigarettes smoked per day), but not among current or never smokers (Table 
5.4). There was no clear evidence of an effect of smoking heaviness on CHD among ever, 
current, former, or never smokers in the MVMR-Egger analysis (Table 5.5). 
There was also evidence to suggest that increased smoking heaviness increases heart 
rate among ever smokers (β = 1.83 bpm, 95% CI 0.88 to 2.79 per SD increase in 
cigarettes smoked per day), current smokers (β = 3.00 bpm, 95% CI 1.41 to 4.59 per SD 
increase in cigarettes smoked per day) and former smokers (β = 1.42 bpm, 95% CI 0.40 
to 2.44 per SD increase in cigarettes smoked per day), but not never smokers (Table 5.4). 
In the MVMR-Egger analysis however, there was only weak evidence an increased 
genetic propensity to heavier smoking decreases heart rate (β = -1.62 bpm, 95% CI -3.47 
to 0.20 per SD increase in cigarettes smoked per day). 
5.4.4 Comparing the Total and Direct Effects 
The total and direct IVW effects of cotinine and smoking heaviness are shown 
side-by-side for comparison in Figure 5.4 for ever smokers, and Figure 5.5 for current 
smokers. The results of the MR-Egger and MVMR-Egger results are also shown for 
comparison in the Appendix 13 for ever smokers and Appendix 14 for current smokers. 
By comparing the total and direct effects, I am able to evaluate whether the total effects 
are still present when taking smoking heaviness or nicotine into account; if they differ in 
magnitude or direction, this gives an indication that the other exposure is having a 
substantial direct effect on the health outcome.  
5.4.4.1 Comparing the total and direct effects on ever smokers. Among ever smokers, 
the differences between the total and direct effects of smoking heaviness were 
negligible for the IVW (Figures 5.3) and Egger (Appendix 13) analyses. The effect 







Figure 5.4. Univariable and multivariable Mendelian randomisation analysis of cotinine 
and smoking heaviness (cigarettes per day) and smoking-related health outcomes 
among ever smokers (n = 54 SNPs).  
Note: A p-threshold of 5×10-8 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with CPD. A lower threshold of 5×10-6 was used to 
determine the SNPs associated with cotinine due to the low number of SNPs associated 
at the 5×10-8 threshold. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease. Effects are betas for continuous variables (BMI, FEV-1, FVC and 
HR) and log odds ratios for binary outcomes (COPD and CHD) per standard deviation 
increase in cotinine levels/number of cigarettes per day. Univariable analyses presented 
are the total effects using the inverse variance weighted (IVW) method. The 




5.4.4.2 Comparing the total and direct effects on current smokers. Among current 
smokers, the differences between the total and direct effects of smoking heaviness were 
negligible in the IVW (Figure 5.4) and Egger (Appendix 14) analyses. The effect estimates 
were similar in magnitude and direction, and the confidence intervals overlapped. 
Bigger differences in magnitude were seen in the MR-Egger and MVMR-Egger analysis 






Figure 5.5. Univariable and multivariable Mendelian randomisation analysis of cotinine 
and smoking heaviness (cigarettes per day) and smoking-related health outcomes 
among current smokers (n = 54 SNPs). 
Note: A p-threshold of 5×10-8 was used to determine the Single Nucleotide 
Polymorphisms (SNPs) associated with CPD. A lower threshold of 5×10-6 was used to 
determine the SNPs associated with cotinine due to the low number of SNPs associated 
at the 5×10-8 threshold. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease. Effects are betas for continuous variables (BMI, FEV-1, FVC and 
heart rate) and log odds ratios for binary outcomes (COPD and CHD) per standard 
deviation increase in cotinine levels/number of cigarettes per day. Univariable analyses 
presented are the total effects using the inverse variance weighted (IVW) method. The 




5.4.5 Sensitivity Analysis 
The results did not substantially differ from the results reported when the more 
stringent threshold of p < 5×10-8 was used (Appendix 15). All the effects described in the 
IVW MVMR analysis were also evidenced in the sensitivity analyses and, in addition, I 
found weak evidence of a negative effect of increased genetic propensity for higher 
cotinine levels on CHD among never smokers (lnOR = -0.13, 95% CI -0.24 to -0.02 per SD 
increase in cotinine levels). 
 
5.5 Discussion 
My findings generally support the known effects of smoking on health. Critically, the 
direct effects of smoking heaviness are generally similar to the total effect of smoking 
heaviness, suggesting that these health outcomes are not caused by nicotine (here 
proxied by cotinine) per se, but by the other non-nicotine constituents of cigarette 
smoke. In contrast, there is little clear evidence of a direct effect of nicotine on 
smoking-related health outcomes, although this could be due to a lack of statistical 
power. Combined, this evidence indicates that nicotine may have little impact on the 
health outcomes resulting from smoking, whereas the other constituents of cigarette 
smoke appear to cause numerous health effects related to smoking. This suggests that 
nicotine use without exposure to cigarette smoke (e.g., via e-cigarettes) could result in 
fewer negative health consequences related to smoking. 
When interpreting these results, it is important to consider the strength of the 
instruments used. The adjusted F-statistics indicated that the instrument used as a proxy 
for smoking heaviness was strong, but the instrument used as a proxy for cotinine was 
weak (Sanderson et al., 2020). In univariable MR, the F-statistic simply indicates the 
instrument strength of the single exposure; however, the conditional F-statistic in the 
MVMR context indicates instrument strength of each exposure when accounting for the 
prediction of other exposures in the model (i.e., whether the SNPs jointly predict 
smoking heaviness after predicting cotinine levels). Therefore, the conditional F-statistic 
indicates that I can be confident in the estimate of the direct effect of smoking 




constituents of tobacco smoke aside from nicotine). However, I cannot be as confident 
in the estimate of the direct effect of nicotine on smoking-related health outcomes. The 
main genetic variant identified in the cotinine GWAS (rs10851907) is in LD with 
rs16969968 (a known functional variant associated with smoking heaviness) which could 
explain why the instrument is conditionally weak (Ware et al., 2011). For the most part, 
the differences between the total and direct effects of smoking heaviness were 
negligible, implying that nicotine has little direct impact on smoking-related health 
outcomes and that nicotine use without smoke exposure (e.g., via e-cigarettes) is 
unlikely to result in smoking-related poor health outcomes.  
Interestingly, I found evidence of a positive effect of genetic propensity to heavier 
smoking on BMI among former smokers and those who have never smoked before in 
the IVW MVMR analysis. Among never smokers, the IVW MVMR results suggest that 
increased genetic propensity to heavier smoking appears to cause increased BMI, as well 
as decreased risk of COPD. In the MVMR-Egger results only, there is evidence that 
increased genetic propensity to heavier smoking appears to decrease heart rate. The 
effect estimates of these analyses cannot be meaningfully interpreted as never smokers 
do not smoke any cigarettes per day (despite being predisposed to heavier smoking), 
but the results (including the high Cochran’s Q statistics and weaker evidence of effects 
in the MVMR-Egger analyses compared with the IVW analyses) are indicative of 
horizontal pleiotropy (i.e., the genetic variants influencing smoking heaviness also 
separately influence BMI/COPD through a pathway other than smoking). Furthermore, 
Taylor and colleagues (2014) also found a positive effect of genetic propensity to heavier 
smoking on BMI among never smokers. However, stratifying on the exposure (i.e., 
smoking status) as I have in this analysis could introduce collider bias (Taylor & Munafò, 
2014). Predisposition to heavier smoking may influence the likelihood of becoming an 
established smoker after trying smoking, or the likelihood of an established smoker 
quitting and becoming a former smoker. Additionally, poor health outcomes may lead 
smokers to quit smoking; thus, smoking status is a collider, and stratifying by this collider 
could lead to biased effect estimates indicating a causal effect when there is no true 
effect. Additionally, selection into UK Biobank could have introduced collider bias; the 
proportion of smokers in UK Biobank is lower than the UK population, and the mortality 
rate (indicative of poor health) is also comparatively low. If smoking and poor health 




negatively biased associations whereby we would expect to see a more negative 
association (i.e., stronger evidence that increased smoking heaviness causes poor 
health) than would be observed in the intended study population (Munafò et al., 2018). 
Alternatively, misreporting of smoking status (i.e., reporting to be a never smoker 
despite being a smoker or former smoker) or second-hand smoke exposure via family 
members with a shared genetic predisposition to heavier smoking could result in 
seemingly causal effects among never smokers. 
This study is the first to attempt to explore the effects of nicotine use while considering 
the direct effects of exposure to other constituents of cigarette smoke (and vice versa). I 
have employed a novel method (MVMR) to explore the causal effect of nicotine on 
potential health outcomes in order to give an indication of possible future health 
consequences of long-term nicotine-containing e-cigarette use. However, this study is 
not without limitations. First, there are issues interpreting findings where the number of 
cigarettes per day are used as a proxy for smoke exposure. As described by Taylor, 
Davies, et al. (2014), the number of cigarettes smoked per day is often used to 
determine lifetime smoke exposure, but there are individual differences in smoking 
topography (i.e., number of puffs taken per cigarette, average volume per puff etc.) 
which are not captured by measures of cigarettes smoked per day, meaning measures of 
cigarettes per day may not adequately capture smoke exposure. Thus, the exclusion 
restriction assumption is violated as the variants are affecting the outcome via other 
pathways (although these pathways are still potentially related to smoking) not just the 
number of cigarettes smoked per day. This may be reflected in the MR-Egger test of 
directional pleiotropy which indicates that directional pleiotropic effects are observed in 
the relationship between smoking heaviness and health outcomes, particularly among 
ever smokers. As there is a smaller sample of current smokers but the size of the 
intercept is similar to the intercept for ever smokers, there may be some pleiotropic 
effects for current smokers too but there is insufficient power to detect this as a 
significant effect. While I have attempted account for horizontal pleiotropy by using 
pleiotropy robust methods, the statistical power of MVMR-Egger analysis is limited and 
given that the instrument used as a proxy for cotinine is weak, low statistical power may 
be an issue in this analysis. Second, cotinine levels are not a perfect measure of nicotine 
exposure; nicotine metabolism (and therefore cotinine levels) can be affected by a 




independent physiological effects (Hatsukami et al., 1998; Moran, 2012). Third, BMI 
(one of the health outcomes of interest) can impact metabolism in general (Wurtz et al., 
2014), so could influence nicotine metabolism. Consequently, cotinine levels could differ 
due to individual differences in metabolism rather than differential exposure to nicotine, 
so there is likely to be some measurement error in the estimates used to determine 
which SNPs are independently associated with nicotine consumption. Fourth, the 
conditional F-statistic indicated that the estimates of the direct effects of nicotine 
exposure on the health outcomes are likely to suffer from weak instrument bias and 
should therefore be interpreted with caution. The GWAS of cotinine (Ware et al., 2016) 
was based on a relatively small sample size (N = 4,548) compared to the GWAS of 
smoking heaviness (N = 120,744) (Liu et al., 2019) and may have lacked power to detect 
some influential SNPs.  
As more and more GWAS summary data become available, a larger scale GWAS of 
cotinine may reveal more independent SNPs which can be used as an instrument for 
nicotine exposure. Future research could extend on these findings using a stronger 
instrument for cotinine which would allow for clearer interpretation of the causal effect 
of long-term nicotine use.  
5.6 Chapter Summary 
Although I found clear evidence of a direct causal effect of exposure to the other 
constituents of cigarette smoke aside from cotinine on a range of health outcomes, I 
only observed some evidence of a direct effect of cotinine on increased heart rate and 
decreased risk of CHD. Despite potential weak instrument bias in the estimates of the 
direct effect of cotinine, nicotine use via cigarettes appears to have little impact on the 
selected smoking-related health outcomes because there is little difference between the 
total effects of smoking heaviness (when cotinine exposure is not taken into account) 
and the direct effects of smoking heaviness (when the direct effect of cotinine is taken 
into account). Although nicotine may still have a small influence on health when 
exposure is independent of smoking, nicotine does not appear to be the primary cause 
of the negative effects of cigarettes on health. This suggests that long-term use of 
nicotine without the other constituents of cigarette smoke (e.g., vaping or NRT use) 




However, future studies should further explore the role of nicotine with a stronger 
instrument (if relevant data become available). In Chapter 6, I further explore the 
relationship between nicotine and health using experimental methods by investigating 




Chapter 6 How does acute nicotine exposure 
affect appetite?  
This chapter closely resembles sections from the following pre-registered study protocol: 
Ferrar, J., Khouja, J. N., Birch, L., Hamilton-Shield, J., Ness, A., Munafò, M. R., & Attwood, 
A. S. (2019). Effects of nicotine challenge on eating topography in non-dependent 
smokers. Retrieved from osf.io/nathz. 
I assisted in designing and implementing this experimental study with the support of my 
co-authors. I took the lead in managing the study and in the analysis and interpretation 
of the results. Specifically, JF, LB, JHS AN, MM and AA provided feedback on the design 
of the study.  
 
6.1 Chapter Overview 
Although it is widely accepted that there is a causal effect of nicotine on appetite which 
consequently lowers BMI through reduced food intake, the experimental evidence to 
support this hypothesis appears to be weak. Evidence suggests that, following nicotine 
administration, non-smokers display reduced appetite and food intake; however, this 
effect has not clearly been found among smokers (Perkins et al., 1992; Perkins et al., 
1991). In these studies, participants were selected based on their smoking status 
(non-smokers and dependent smokers). Where samples consist of non-smokers, the 
effects of nicotine on nicotine-naïve participants can be aversive as nicotine-naïve 
participants are likely to experience nausea for example (Srivastava, Russell, 
Feyerabend, Masterson, & Rhodes, 1991), which could result in a reluctance to eat. 
Where samples consist of dependent smokers, refraining from smoking before an 
experimental session (in order to control for nicotine exposure) could lead to symptoms 
of withdrawal which could affect participants’ appetite; Jorenby and colleagues (1996) 
observed increased appetite among participants experiencing nicotine withdrawal 




withdrawal when asked to refrain from smoking before a session and equally should not 
experience adverse effects of nicotine exposure due to nicotine naivety. In this chapter, I 
explore the effects of nicotine administration on appetite and subsequent food 
consumption among non-dependent smokers. This study was disrupted by the outbreak 
of the COVID-19 pandemic; therefore, the sample size is lower than planned from my 
power calculation. With this in mind, I refer to this study as a pilot study and present no 
inferential statistics but outline the planned statistical analyses and present descriptive 
statistics for the data collected to date. Data collection will resume in the future within 
the Tobacco and Alcohol Research Group, in order to achieve the pre-planned sample 
size.  
6.2 Introduction 
Alongside smoking, obesity is one of the leading risk factors for death across the globe 
(Ritchie & Roser, 2019), but observational evidence suggests that smoking is associated 
with having a lower BMI (Audrain-McGovern & Benowitz, 2011). It is widely accepted 
that nicotine causes weight reduction by reducing appetite (NHS, 2019b). This suggests 
that using nicotine-containing smoking cessation aids (e.g., e-cigarettes) could prevent 
post-cessation weight gain (Russo et al., 2016; Russo et al., 2018) which often results in 
relapse (Mizes et al., 1998). Alternatively, weight gain may be postponed until the 
individual cuts down their nicotine use via e-cigarettes, but users may be more likely to 
relapse to vaping rather than relapse to smoking if vaping also reduces their weight. 
However, as discussed in Chapter 1, the relationship between BMI and smoking appears 
to be complex; previous evidence from a Mendelian randomisation study suggests that 
although increased smoking heaviness decreases BMI, increased BMI also appears to 
causally influence smoking initiation and increases smoking heaviness (Taylor et al., 
2019). Combining this with evidence that suggests Mendelian randomisation studies 
exploring the relationship between BMI and smoking may be affected by horizontal 
pleiotropy (Taylor, Morris, et al., 2014), demonstrates that further investigation of the 
relationship is necessary before any clear conclusions can be made about causality. 
One hypothesised mechanism by which smoking may influence BMI is through a 
nicotine-induced reduction in appetite and food consumption. After administering 




of appetite declined by 17.5%, whereas appetite ratings increased following placebo 
administration. Similarly, Perkins and colleagues (1991) found participants consumed 
less food following nicotine administration compared with placebo administration. 
However, further investigation revealed a clear effect among non-smokers, but not 
among daily smokers. Another study of male and female daily smokers (using similar 
methods) found that caloric intake increased following nicotine administration 
compared with placebo administration (Perkins et al., 1992). Although the effect of 
nicotine on appetite is often presented as fact by trusted sources, such as the NHS 
(2019b), there is a lack of clear evidence from human experimental studies to support 
the theory that nicotine reduces appetite and food consumption in smokers. 
The mixed findings from experimental studies could be due to lack of statistical power 
(resulting from small sample sizes) or due to confounding factors influencing the 
selected samples. For example, nicotine-naïve non-smokers are likely to feel the adverse 
effects of nicotine (e.g., nausea) as they have not developed a tolerance to nicotine like 
smokers (Srivastava et al., 1991). This could result in an effect on appetite which is not 
seen among those who are experienced with nicotine. In contrast, daily smokers 
develop a tolerance and become dependent on nicotine, thus daily smokers may 
experience withdrawal symptoms (e.g., increased appetite) when asked to refrain from 
smoking before a study (in order to standardise nicotine exposure) which could affect 
their appetite (Jorenby et al., 1996). Non-dependent smokers are experienced with 
nicotine and therefore should not experience adverse effects when exposed to nicotine 
and should also not experience any withdrawal symptoms when asked to refrain from 
smoking. Exploring the effects of nicotine on eating topography among non-dependent 
smokers could avoid the confounding effects of withdrawal seen among dependent 
smokers and aversion seen among non-smokers, yet there is currently no published 
evidence focussed on this subgroup.  
The aim of this study was to explore the effect of nicotine on eating topography. I 
hypothesised that, compared with administration of placebo, administration of nicotine 
would result in reduced self-selected portion size, amount consumed, and food 






Participants were non-dependent smokers recruited using posters, web adverts and 
newsletters. Non-dependent smoking was determined by validated questionnaire 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) and was additionally defined as 
smoking at least five cigarettes per month but not every day. Participants aged between 
18 and 50 years of age and who were fluent in English (i.e., English as first language or 
equivalent level of fluency) were considered eligible for the study. Participants were 
required to be in good physical and psychiatric health (assessed via self-report). 
Those expressing interest in the study were excluded from participation if they were 
using any other form of nicotine (e.g., e-cigarettes or nicotine replacement therapy) 
every day or if they had any contraindications for nicotine or placebo use (Appendix 16). 
Those with self-reported past or present diagnosis of an eating disorder, who were high 
in dietary restraint according to the Dutch Eating Behaviour Questionnaire (DEBQ) or 
with a BMI less than 19 kg/m2 or more than 30 kg/m2 were excluded from participation. 
Interested individuals were excluded from participation if they disliked or had 
allergies/intolerance to the study foods/beverages (pasta, tomato sauce, parmesan 
cheese, apple juice). Those with self-reported, uncorrected visual or auditory 
impairment were excluded from participation. Females who were pregnant or 
breastfeeding were excluded from participation. Pregnancy was assessed by self-report 
initially and – where participants were uncertain – verified by urine screen on the day of 
the test session. 
On the day of testing, participants experiencing nausea (a rating of 50 or more on a 
visual analogue scale [VAS] from 0 [not at all] to 100 [extremely]) were asked to 
reschedule their session. As were participants who failed to adhere to the study 
requirements: failure to abstain from smoking/nicotine for at least 12 hours (exhaling ≥ 
10 parts per million [ppm] carbon monoxide [CO]), failure to abstain from alcohol 
consumption for at least 24 hours (exhaled breath alcohol concentration > 0 µg/100 ml), 




unsweetened, coffees and teas without milk) for at least 3 hours prior to the study (self-
reported). 
After the first 5 participants had completed the study, I made some adjustments to the 
exclusion criteria and procedure. These adjustments were made in order to maximise 
recruitment by: (i) offering a wider range of session times, and (ii) not excluding 
individuals who had abstained from smoking but whose CO readings were between 7 
ppm and 10 ppm. The first 5 participants were asked to attend sessions at 12 pm or 1 
pm and to abstain from eating anything between breakfast and the test session (approx. 
4-5 hours) but due to the change in procedure (additionally offering sessions at 2 pm, 3 
pm and 4 pm), the abstinence period was adjusted to 3 hours before the session. 
Originally, the threshold for CO readings was set to 7 ppm but after a high proportion of 
participants claimed to have abstained but gave a reading of between 7 ppm and 10 
ppm, I decided that the threshold was too sensitive and should be raised to 10 ppm, a 
commonly used threshold for detecting abstinence from smoking (Ramprasad, 
Santhosh, & Lim, 2018). The original protocol and amended protocol can both be found 
on the Open Science Framework (DOI: 10.17605/OSF.IO/XQU8Z). Participants were 
reimbursed £20 (or equivalent course credit) for completing the study. 
6.3.2 Measures and Materials 
6.3.2.1 Physical measures. Expired breath alcohol was measured using an AlcoDigital 
Alcotest 3820 standard device. Expired carbon monoxide was measured using a Bedfont 
Pico+ Smokerlyser device. Height was measured using a Marsden “Leicester” height 
measure and weight was measured using an EKS human weighing scale. BMI was 
calculated as weight (kg)/height (m)2. 
6.3.2.2 Questionnaire measures. Dietary restraint was measured using the DEBQ; 
scores in excess of 2.7 for females or 2 for males indicated high dietary restraint 
(Domoff, 2015). Nicotine dependence was measured using the Fagerström Test of 
Nicotine Dependence (FTND) with scores of 3 or more indicating dependence 
(Heatherton et al., 1991). A 21-item VAS (ranging from 0 [not at all] to 100 [extremely]) 
was used to determine the extent to which participants were experiencing a range of 
subjective effects. The subjective ratings related to food and drink consumption (hunger, 




common nicotine-induced side effects (nausea, dizziness, light-headedness, 
nervousness, sweatiness, headache, heart racing, confusion, weakness), and feelings of 
discomfort (lip discomfort, mouth discomfort, throat discomfort, chest discomfort, and 
stomach discomfort). The Minnesota Nicotine Withdrawal Scale (MNWS) was used to 
determine the extent to which the participant was experiencing nicotine withdrawal 
(Hughes & Hatsukami, 1986). MNWS scores range from 0 to 32 and are the sum of eight 
withdrawal items scored from 0 (none) to 4 (severe). 
6.3.2.3 Buccal sprays. We (the research team and I) delivered nicotine via a peppermint 
flavoured Boots NicAssist 1 mg mouth spray. A dose of 2 mg of nicotine was delivered by 
administering two sprays of the NicAssist solution. We developed a placebo spray which 
mimicked the taste, intensity and sensation of the nicotine spray. The spray contained 
water (88%), Colgate Plax peppermint flavoured mouthwash (3%) and ground black 
pepper (9%). This nicotine dose and placebo solution were piloted prior to this study on 
non-smokers (n = 20) and non-dependant smokers (n = 10) to ensure there was some 
similarity in sensation. The nicotine dose was well tolerated with no adverse events 
reported. Following the nicotine/placebo spray, we administered a spray of mint breath 
spray (Smile, Boots UK) in order to mask the unpleasant taste of the nicotine/placebo 
sprays. 
6.3.2.4 Study food and beverages. During the study, participants received a small glass 
of apple juice (100 ml Copella Cloudy Apple) and a study meal which consisted of 700 g 
of Sainsbury’s basics pasta and 700 g of Sainsbury’s tomato and herb Bolognese pasta 
sauce mixed with 30 g Sainsbury’s grated Italian Parmigiano Reggiano D.O.P. cheese. 
This serving size was selected in order to minimise potential ceiling effects (based on the 
results of prior food consumption studies conducted at the University of Bristol). The 
meal was served with 250 ml water and all foods and beverages were stored and 
prepared in line with the manufacturer’s instructions.  
6.3.2.5 Eating topography measures. Food portions were weighed on a set of kitchen 
scales (MyScales, SF-440) and consumption rate was measured using a Mandometer 
scale (https://mando.se/en/). Consumption rate was additionally calculated manually 




in-session recorded meal start and finish time. Satiety (fullness) was measured via the 
Mandometer mobile phone application. 
6.3.3 Design 
I employed a repeated measures design with one within-participants factor of nicotine 
challenge (nicotine vs. placebo). The research assistants and I implemented a single 
blind procedure of nicotine administration; participants were blinded to the spray they 
were receiving but the researchers were not blinded due to the unique shaping of the 
nicotine spray bottle (although branding was obscured from the participants view) and 
moderate risk of unblinding given the side effects of nicotine administration (e.g., 
hiccups). The order of administration (i.e., nicotine in the first session and placebo in the 
second session vs. placebo in the first session and nicotine in the second session) was 
counter-balanced across participants. 
6.3.4 Procedure 
Invited participants attended two test sessions at the University of Bristol scheduled at 
least one week apart. Upon arrival at the laboratory, participants were encouraged to 
re-read the information sheet (which they had also been sent prior to the day of the test 
session) before providing their written consent to participate. To ensure participants 
could make an informed judgement of their eligibility (i.e., to confirm they were not 
allergic to the study ingredients), a complete list of ingredients and possible side effects 
for both the nicotine and placebo sprays were provided to the participants. A member 
of the research team then screened participants to confirm their eligibility for the study. 
Screening consisted of computerised FTND and DEBQ questionnaire completion, 
computerised nausea rating, pregnancy test (for females unsure of their current 
pregnancy status), alcohol breath test, height and weight measures (in order to calculate 
BMI), CO breath test, and verbal screening of inclusion and exclusion criteria (including 
adverse events and concomitant medication use). Participants who failed to meet the 
eligibility requirements were excluded from participating in the study at this point and 
did not receive any reimbursement. Participants who failed to abstain from smoking, 
alcohol use or food and drink consumption, or who felt unwell/nauseous on the day of 




Eligible participants were randomised to receive either nicotine (2 mg) or placebo in the 
first session and provided basic demographic information (gender, age). They then 
completed the MNWS and baseline questionnaires (VAS) on the computer. Following 
questionnaire completion, the participants received either the nicotine or placebo spray 
(dependent on their condition allocation). The participants were instructed to hold open 
their mouth while the researcher delivered three sprays to their buccal cavity (between 
the participant’s cheek and lower gum). The first two sprays were either the nicotine or 
placebo spray which was immediately followed by one spray of the mint mouth spray. 
Participants were instructed to close their eyes during the process and were asked to 
keep their mouth open and to not swallow for a few seconds after the spray. 
Immediately following the spray administration, participants were given a small glass of 
apple juice to mask any unpleasant flavours of the sprays. Participants in both 
conditions were then asked to sit quietly for a 12.5-minute period which allowed the 
nicotine to be absorbed (in the nicotine condition). We then asked participants to 
complete the post-spray questionnaires (VAS) on the computer. They then received a 
large serving bowl of pasta with serving tongs, a bowl, a serviette, a fork and a glass of 
water. The researcher placed the bowl on the Mandometer in front of the participant 
and provided the participant with a mobile phone with the Mandometer application 
open. The researcher gave verbal instructions to the participants informing them to add 
their desired portion to the bowl and press start on the phone application when they 
were ready to eat. The participant was told that they could add more food to the bowl 
at any time during the meal by tapping the ‘add more food’ option on the Mandometer 
application, serving themselves their desired portion, and tapping ‘start’ before 
continuing to eat. The researcher instructed the participant to tap ‘done’ in the 
application when they were finished eating. Participants were prompted to rate their 
fullness (using a sliding scale from 0% to 100%) every 2 minutes for the duration of their 
meal via the Mandometer application. The serving bowl containing the study meal was 
weighed once before the food was served to the participant, and twice after the 
participant had finished eating to measure: (i) the amount self-served (i.e., including the 
food the participant had served themselves and the food not consumed), and (ii) 
measure the amount actually consumed (i.e., excluding any food the participant served 
themself but did not consume). When participants stated they were finished eating, 




asked which spray (nicotine or placebo) they believed they had received during their 
session and how confident they were that they received this spray on a scale of 0 (not 
confident at all) to 10 (extremely confident) as a manipulation check. The researcher 
gave the participant a study card with details of the experiment and relevant contact 
details) to take away with them and reminded them of the date and time of their next 
session. 
On the second study day, the procedure was similar, but the screening procedures were 
reduced; participants were screened for nausea, pregnancy, failure to abstain from 
alcohol, smoking, food or drink, adverse events and concomitant medication use. The 
experimental procedure only differed in that the alternative spray (placebo/nicotine) 
was delivered, and the participant was debriefed and reimbursed £20 (or equivalent 
course credit). 
6.3.5 Statistical Analysis 
6.3.5.1 Sample size calculation. I used the findings of a randomised controlled trial (in 
which the Mandometer was used to retrain eating behaviour and treat childhood 
obesity and change in portion size was measured within-groups) to calculate the 
minimum sample size required for this study (Ford et al., 2009). This study was selected 
due to the similarity in the outcome measure. Ford and colleagues (2009) found a 45 g 
(SD = 128 g) mean decrease in self-selected portion size in the treatment group. To 
achieve 95% power to detect a similar effect size of dz = 0.35, I calculated that I would 
need to recruit a minimum of 108 participants. 
6.3.5.2 Planned analyses. I planned to perform normality checks prior to analysing the 
data and transform data which were non-normally distributed. I also planned to remove 
extreme outliers (values which lie more than three times the interquartile range below 
the lower quartile or above the upper quartile). After completing any necessary 
transformations and cleaning the data, I intended to explore whether there was a 
difference between the nicotine and placebo conditions for each of the dependent 
variables relating to eating topography (self-served portion size, amount consumed, 
consumption rate) using repeated measures ANOVAs with a within-subjects factor of 
nicotine challenge (nicotine vs. placebo). I planned to use the same model to analyse the 




unadjusted analyses, I intended to re-run the analyses while adjusting for sex, age and 
BMI. Planned statistical analyses have not yet been performed because the study has 
been paused due to the COVID-19 pandemic, but descriptive results for the data 
collected to date are presented. I also intended to explore whether there may be any 
order effects by re-running the analysis stratified by order of nicotine/placebo 
administration. 
6.3.5.3 Manipulation check. As a manipulation check, I first planned to use chi-square 
test to explore whether accuracy substantially differed between the placebo and 
nicotine condition when participants were asked to judge which spray they had received 
and also compare mean confidence ratings. I then intended to explore whether there 
were differences over time between the nicotine and placebo group in the VAS data 
using repeated measures ANOVAs with two within-subjects factors: time (baseline, 
post-spray, post-food) and nicotine challenge (nicotine, placebo). I expected differences 
in VAS measures relating to food and drink consumption to be in line with the findings of 
the main outcomes. I expected VAS ratings relating to common nicotine-induced side 
effects to be greater following nicotine administration compared with placebo 
administration. I expected VAS measures relating to discomfort, which may have an 
impact on eating behaviour, to be similar following placebo and nicotine administration. 
6.3.5.4 Planned sensitivity analyses. I planned to conduct sensitivity analyses whereby I 
repeated the main analysis after excluding individuals who displayed evidence of 
nicotine withdrawal (i.e., participants scoring 9 or more on MNWS) at baseline. I also 
intended to run a second sensitivity analysis while excluding individuals who reported an 




6.4.1 Disruption due to COVID-19 
Data collection commenced on the 13th November 2019 and was due to continue until 




pandemic. The study site (University of Bristol) closed on 24th March 2020 and remained 
closed for human experimental research at the time of my thesis submission. As a result, 
complete data was collected for only 24 participants. As the sample size was much lower 
than was required to achieve 90% power (N = 108), I decided that it would be 
inappropriate to conduct the planned inferential statistics outlined in the methods. 
Instead, I have analysed the data in line with recommendations for pilot and feasibility 
studies and only presented descriptive statistics (means [M], standard deviations [SD], 
and mean differences with 95% confidence intervals where appropriate). Additionally, I 
was unable to access raw Mandometer data. The Mandometer provides simple graphed 
data, but raw data is accessed via communication with the Mando data team who were 
unavailable due to COVID-19. 
6.4.2 Participant Characteristics 
In total, 28 participants completed session one and 24 participants also completed 
session two – two participants withdrew after session 1 (indicating a 92% retention rate) 
and two were unable to complete the second study session due to COVID-19. Of the two 
participants who withdrew after the first session, both had received nicotine in their first 
session. The characteristics described reflect the 24 participants who completed session 
one and two. Six were male (25%) and the average age was 20.25 years of age (ranging 
from 18 to 31). Nicotine dependence in the sample was low (mean FTND score = 0.17, 
SD = 0.48), as was nicotine withdrawal at baseline before placebo (mean MNWS score = 
5.25, SD = 3.97) and nicotine administration (mean MNWS score = 5.75, SD = 5.27). 
Scores for restrictive eating were low (M = 1.65, SD = 0.41) and average BMI was 21.88 
(SD = 2.49).  
6.4.3 Safety  
No participants reported adverse events or serious adverse events following drug 
(nicotine or placebo) administration. 
6.4.4 Manipulation 
In both the placebo and nicotine condition, 75% of participants accurately guessed 




adequately blinded. However, the mean rating of confidence in their guess (on a scale of 
0 [not at all confident] to 10 [extremely confident]) was only 5.5, which suggests 
participants were unsure of their condition and therefore were adequately blinded. 
6.4.5 Self-Selected Portion Size 
Self-selected portion sizes (i.e., the amount of food participants transferred from the 
serving bowl onto their plate irrespective of the amount of food they actually 
consumed) in the placebo condition and the nicotine condition are displayed for each 
participant in Figure 6.1. Following placebo administration, participants served 
themselves 403 g (SD = 162 g) of pasta on average. Following nicotine administration, 
participants served themselves 427 g (SD = 141 g) of pasta on average. This corresponds 






Figure 6.1. Average self-selected food portion (grams) after spray administration. 
Note: The summary of the data is shown as a violin plot which reflects individual 
participant data (solid coloured dots) the data distribution (outer line), and the median 







6.4.6 Food Consumed 
The portion of food consumed in grams by each participant in the placebo condition and 
the nicotine condition are displayed in Figure 6.2. Following placebo administration, 
participants consumed 399 g (SD = 166 g) of pasta on average. Following nicotine 
administration, participants consumed 416 g (SD = 141 g) of pasta on average. This 







Figure 6.2. Average food portion (grams) consumed after spray administration. 
Note: The summary of the data is shown as a violin plot which reflects individual 
participant data (solid coloured dots) the data distribution (outer line), and the median 






6.4.7 Food Consumption Rate 
Consumption rate was measured manually; Mandometer data was unavailable. The 
food consumption rate for each participant in the placebo condition and the nicotine 
condition are displayed in Figure 6.3. Following placebo administration, participants 
consumed 53 g (SD = 17 g) of pasta per minute on average. Following nicotine 
administration, participants consumed 51 g (SD = 16 g) of pasta per minute on average. 







Figure 6.3. Average food consumption rate (grams/minute) after spray administration. 
Note: The summary of the data is shown as a violin plot which reflects individual 
participant data (solid coloured dots) the data distribution (outer line), and the median 







There was considerable missing satiety data where participants had missed or ignored 
prompts to enter their satiety rating. At the start of the meal in the placebo condition, 
19 participants rated their satiety, and 21 participants rated their satiety within 2 
minutes of finishing their meal. At the start of the meal in the nicotine condition, 20 
participants rated their satiety, and 22 participants rated their satiety within 2 minutes 
of finishing their meal. Only 13 participants had sufficient data to calculate change in 
satiety following both placebo and nicotine administration. Change in satiety ratings 
(from meal start time to within 2 minutes of meal completion) in the placebo condition 
and the nicotine condition are displayed for individuals with complete satiety data (n = 
13) in Figure 6.4. Satiety ratings increased by 48% (SD = 16%) on average following food 
consumption in the placebo condition. Satiety ratings increased by 42% (SD = 6%) on 
average following food consumption in the nicotine condition. This corresponds to a 
mean difference of 7% (95% CI -11% to 25%). Satiety ratings increased (i.e., participants 
became fuller after eating) for all participants following meal consumption, bar one 
participant whose satiety ratings decreased during meal consumption following nicotine 







Figure 6.4. Average change in satiety rate (from meal start to within 2 minutes of meal 
completion) following spray administration. 
Note: The summary of the data is shown as a violin plot which reflects individual 
participant data (solid coloured dots) the data distribution (outer line), and the median 








6.4.9 Subjective Measures 
Due to a computing error, baseline subjective data for session two (nicotine condition) 
was unavailable for one participant. The data reported for baseline subjective measures 
in the nicotine administration condition relate to the 23 participants with available data. 
The mean ratings (ranging from 0 [not at all] to 100 [extremely]) at baseline, post-spray 
(after placebo or nicotine administration) and post-food (after food consumption) in the 
placebo condition and the nicotine condition are displayed for each subjective measure 




Table 6.1. Mean VAS ratings of subjective effects over time (baseline, post-spray, post-food). 
 Placebo  Nicotine 
Subjective measure Baseline Post-spray Post-food  Baseline Post-spray Post-food 
Hunger 66.33 (3.35) 67.38 (4.00) 15.63 (3.93)  65.91 (3.72) 55.63 (4.41) 11.04 (3.99) 
Thirst 61.79 (3.27) 56.92 (4.03) 25.17 (3.68)  60.78 (3.29) 49.17 (4.97) 25.63 (3.45) 
Fullness 22.00 (3.92) 20.33 (3.80) 80.04 (2.54)  20.87 (4.25) 25.08 (4.16) 77.25 (3.72) 
Desire to eat 71.33 (2.88) 68.63 (3.81) 13.38 (2.68)  67.30 (4.23) 61.42 (4.03) 11.88 (3.97) 
Desire to drink 69.33 (2.84) 61.50 (3.64) 29.50 (3.54)  72.57 (3.09) 56.08 (4.53) 35.46 (4.85) 
Nausea 16.29 (4.24) 13.33 (3.82) 9.96 (3.64)  15.00 (4.13) 22.71 (4.74) 18.42 (4.75) 
Dizziness 9.92 (3.12) 7.67 (2.44) 5.29 (2.10)  8.00 (2.43) 22.75 (4.54) 12.25 (3.98) 
Light-headedness 15.75 (4.22) 15.46 (4.13) 7.08 (2.69)  13.48 (3.87) 27.46 (4.87) 15.96 (4.36) 
Nervousness 16.67 (3.86) 11.29 (3.88) 5.46 (2.68)  12.30 (3.16) 8.50 (2.62) 8.88 (3.14) 
Sweatiness 19.29 (4.22) 12.13 (3.05) 7.29 (2.46)  21.30 (4.62) 13.71 (3.80) 10.54 (3.65) 
Headache 14.50 (4.72) 13.42 (4.75) 5.50 (1.70)  13.35 (4.52) 20.08 (5.17) 14.54 (4.72) 
Salivation 22.75 (4.36) 22.83 (4.51) 16.71 (5.28)  19.91 (4.93) 21.54 (4.75) 15.33 (5.16) 
Heart racing 4.54 (1.65) 5.33 (1.91) 4.46 (1.97)  7.26 (2.21) 11.63 (3.66) 9.96 (3.45) 
Confusion 5.54 (1.79) 4.71 (1.78) 3.50 (1.98)  7.22 (2.96) 6.75 (2.63) 6.38 (2.03) 
Weakness 14.92 (3.65) 11.71 (3.75) 7.21 (2.48)  15.65 (4.42) 20.54 (4.81) 14.46 (4.57) 
Taste 8.17 (2.76) 21.71 (4.48) 18.25 (5.19)  10.35 (3.28) 26.29 (5.17) 23.58 (6.11) 
Lip discomfort 11.79 (3.57) 10.63 (2.96) 6.33 (1.83)  8.57 (3.57) 14.71 (4.88) 6.88 (2.52) 
Mouth discomfort 7.67 (2.54) 15.17 (3.86) 7.63 (2.13)  7.87 (2.73) 23.67 (4.67) 11.50 (3.91) 
Throat discomfort 10.83 (3.29) 12.83 (3.73) 8.58 (3.07)  9.57 (3.50) 13.13 (4.77) 7.54 (3.50) 
Chest discomfort 5.13 (2.09) 3.71 (1.03) 7.00 (2.51)  9.83 (3.99) 7.33 (2.97) 4.38 (1.78) 




6.4.10 Sensitivity Measures 
In the proposed sensitivity analyses, I planned to restrict the analysis by MNWS ratings 
and change in nausea. Five participants (21%) experienced substantial withdrawal 
(MNWS > 9) in the placebo condition and six (25%) experienced substantial withdrawal 
in the nicotine condition. Four participants (17%) experienced substantial changes in 
nausea rating pre- to post-spray in the nicotine condition (increase in ratings of 20 
points or more) and no participants experienced substantial changes pre- to post-spray 
in the placebo condition. 
6.5 Discussion 
Over a three-month recruitment period, 24 participants completed the pilot study. The 
study retention rate was high (92%) when excluding those who could not complete the 
study due to COVID-19 restrictions. The amended study procedures increased the rate 
of enrolment (5 participants completed the study within six weeks prior to the changes, 
and 19 participants completed the study within seven weeks following the changes). The 
quality of data collected for the main outcome was good, however, the data quality for 
the secondary outcome (satiety) was moderate, and access to data collected via the 
Mandometer was limited due to COVID-19 restrictions. The data should be sufficient to 
support my planned main analysis once the pre-determined sample size has been 
achieved, and with some minor amendments (i.e., introducing a pen and paper or 
computerised rating of satiety) the data should also be sufficient to support my 
secondary analysis. 
Due to the small sample size and limited statistical power of this pilot study, the results 
described in this Chapter cannot be used to infer a statistical difference between the 
placebo and nicotine conditions. Although I discuss the pattern of results in relation to 
my hypotheses here, it is important to highlight that the specific estimates (mean 
differences and confidence intervals) reported could change in size and direction when 
the sample size increases (Button et al., 2013). The observed direction of the effects of 
nicotine administration on self-selected portion size and food consumption are in 
contrast to my hypotheses; participants actually served themselves slightly larger 




compared with placebo administration. The observed direction of the effect of nicotine 
administration on satiety was also not in line with my hypothesis; participants reported 
feeling less satiated on average over the course of the study meal following nicotine 
administration compared with placebo administration. The pattern of these results 
supports previous evidence suggesting nicotine increases caloric intake among smokers 
(Perkins et al., 1992). However, the observed direction of effect of nicotine 
administration on consumption rate was in line with my hypothesis; consumption rate 
decreased following nicotine administration, with participants consuming slightly less 
food per minute compared with the placebo administration. Additionally, the pattern of 
results for the subjective ratings are in line with a nicotine-induced reduction in 
appetite; mean subjective ratings of hunger decreased on average following nicotine 
administration whereas mean ratings of hunger increased following placebo 
administration. The pattern of these results supports previous evidence suggesting 
nicotine decreases caloric intake among smokers (Perkins et al., 1991). 
Although the patterns reported warrant further investigation, I cannot draw any clear 
conclusions from the current findings without conducting inferential statistics which 
would be inappropriate with such a small sample size (Button et al., 2013). With a 
sample size of 24, I only have 38% power to detect an effect of dz = 0.35. Consequently, 
it is unlikely that small effects of nicotine on self-selected portion size, food 
consumption, or consumption rate would be detected as a result of conducting my 
planned inferential statistics. When testing can safely resume, I plan to complete testing 
with a further 88 participants and conduct the full planned analysis with sufficient 
power. If I find that the results are in line with my hypotheses when the full sample size 
has been achieved, I will conclude that nicotine appears to reduce appetite among 
non-dependent smokers and this could explain the observed relationship between 
smoking and lower BMI (Audrain-McGovern & Benowitz, 2011). If the data do not 
support my hypotheses, I will conclude that this relationship may not be due to a 
nicotine-induced reduction in appetite and food consumption.  
A further limitation of the study is that the satiety measure was limited by substantial 
missing data due to participants not completing the questions when prompted. When 
the study recommences, this will be addressed by introducing clearer instructions 




rating which participants will complete directly before and after meal consumption. The 
study was also limited by the inaccessibility of data from the Mandometer due to 
COVID-19 restrictions. When these data are accessible, I will contact the data team and 
arrange for the raw data to be sent to the research team at regular intervals so that this 
issue can be avoided in the event of another disruption. 
Even with the current limitations of the study, some strengths of the study are still 
evident. The patterns in subjective ratings suggest that the dose of nicotine 
administration was adequate to result in a biological response, with higher ratings of 
nicotine-related side effects on average in the nicotine compared with the placebo 
condition – particularly for nausea, dizziness and light-headedness which are common 
side effects of nicotine administration (as stated on the Boots NicAssist information 
leaflet). In both the placebo and nicotine condition, 75% of participants accurately 
guessed which spray had been administered, but the mean rating of confidence in their 
guess (on a scale of 0 [not at all confident] to 10 [extremely confident]) was only 5.5. 
Therefore, the participants were adequately blinded given the uncertainty of their 
judgement. Average ratings of discomfort which could have impacted food consumption 
appeared to be low in both conditions. However, there may be some differences in 
mouth discomfort which may have an impact on eating behaviour – this should be 
explored when sufficient data is available. As participants reported more mouth 
discomfort but also consumed more food following nicotine administration compared 
with placebo administration, it does not appear that mouth discomfort induced by the 
nicotine spray reduced food intake. 
6.6 Chapter Summary 
In summary, the results show a pattern of reduced consumption rate but increased 
self-selected portion size and food consumption following nicotine administration 
compared with placebo administration. Therefore, the relationship between nicotine 
and BMI may not be as straightforward as previously assumed; the relationship may be 
a result of factors aside from, or in addition to, nicotine-induced reductions in food 
consumption. However, no clear conclusions can be drawn until inferential statistics are 




Chapter 7 Discussion 
7.1 Summary  
The aims of this thesis were three-fold, namely to: 
1. Identify which young adults are more likely to use e-cigarettes by describing the 
demographics and profiles of young e-cigarette users in a UK sample. 
2. Explore why young adults use e-cigarettes, including the subjective reasons 
given by vapers, and the genetic factors influencing vaping. 
3. Investigate the potential consequences of e-cigarette use on smoking behaviour 
and health outcomes. 
I highlighted the need to address these aims in Chapter 2, showing that young people 
who have never smoked before are being exposed to vaping which could lead to 
negative consequences such as smoking initiation. I addressed my first aim in Chapter 3 
and found substantial differences in demographic, behavioural and lifestyle factors 
between young adults who had ever and never vaped, as well as differences between 
those who were former and current vapers. I addressed my second aim in Chapters 3 
and 4, identifying reasons for using e-cigarettes among a sample of UK young adults who 
had both ever smoked and ever vaped, and exploring whether there is a shared genetic 
predisposition to smoking and e-cigarette use. I addressed my third aim in Chapters 2, 3, 
5 and 6, investigating whether e-cigarette use could lead to smoking initiation, 
continued smoking, continued vaping and smoking-related health outcomes. In this 
Chapter, I discuss the findings of each of my thesis chapters in relation to my aims, the 
conclusions and implications of the thesis, as well as the strengths, limitations and 
potential future directions of the work. 
7.1.1 Which Young Adults Are More Likely to Use E-cigarettes? 
In Chapter 2, I explored the association between e-cigarette use among non-smokers 
and later smoking in a systematic review and meta-analysis. While reviewing studies 
which explored this association, I identified a substantial number of non-smoking 
e-cigarette users. As e-cigarettes are only a form of harm reduction to smokers (Kimber, 




adults are most likely to vape. In Chapter 3, I identified multiple factors which were 
associated with ever using e-cigarettes in a cohort of young adults in the UK: young 
adults who are male, of lower socioeconomic position at birth, who have poorer mental 
health, who engage in other risky behaviour, and who smoke are more likely to have 
ever vaped. Current vapers were more likely to have lower parental socioeconomic 
position at birth, report anxiety and have smoked by the age of 23 years but were less 
likely to be hazardous or harmful alcohol users than former vapers. 
 
7.1.2 Why Do Young Adults Use E-cigarettes? 
After identifying which individuals are more likely to vape, it is important to understand 
why they vape. In Chapter 3, I found that the most common reason given for vaping by 
23 years old was out of curiosity (51%), the second most common reason was to quit 
smoking (32%) and third was vaping to cut down their smoking (23%). This is in contrast 
to older adults in the UK who are most likely to use an e-cigarette to quit smoking 
(Action on Smoking and Health, 2019a). 
In addition to the subjective reasons given for vaping, my results indicate that vapers 
may be genetically predisposed to smoking as well as e-cigarette use. In Chapter 4, I 
found evidence to suggest that there is a potential shared genetic predisposition to 
smoking initiation and e-cigarette use; I observed associations of a similar magnitude 
between smoking initiation polygenic risk scores and both self-reported smoking 
initiation and ever e-cigarette use. Given the strong correlation between the two 
behaviours, this is not necessarily surprising, and the association found could be due to 
smoking directly impacting e-cigarette use – a logical assumption given that 32% of 
young adults in this cohort stated that they have used e-cigarettes to quit smoking (as 
found in Chapter 3) and 46% used e-cigarettes for any smoking-related reason.  
However, I also observed associations with smoking initiation polygenic risk scores and 
risk-taking and impulsivity, even when using the genome-wide significant p-value 
threshold for the inclusion of genetic variants within the polygenic risk scores. This 
indicates that there could be horizontal pleiotropic effects (i.e., the genetic variants in 




smoking). Furthermore, I observed similar associations among never smokers. Rather 
than specifically predicting smoking or nicotine use, the smoking initiation polygenic risk 
scores may be capturing a broader risk-taking phenotype. If young adults are genetically 
predisposed to risk-taking (including smoking and e-cigarette use) this could explain why 
e-cigarette use appears to act as a gateway to smoking among young people (as found in 
Chapter 2).  
7.1.3 What Are the Consequences of Using E-cigarettes? 
In Chapter 2, I provided an update to a previous meta-analysis (Soneji, Barrington-
Trimis, Wills, Leventhal, et al., 2017) by identifying 17 studies (11 studies in addition to 
those found by Soneji and colleagues) which explored the association between 
e-cigarette use among non-smokers and later smoking. By meta-analysing the results of 
these studies, I found a strong association between e-cigarette use and later smoking, 
whereby non-smokers who had vaped were 3 times more likely to subsequently ever 
smoke. Subgrouping and stratification of the results (e.g., stratification by risk of bias) 
revealed some slight differences between groups, but consistently indicated a strong 
positive association. 
The results could suggest that e-cigarettes act as a gateway to smoking; however, I also 
identified some clear limitations of the included studies. First, there was a lack of 
biochemical verification of smoking or vaping status, meaning the estimates could suffer 
from measurement error and reverse causality. Second, some of the included studies 
lacked appropriate and adequate adjustment for potential confounding beyond basic 
demographic factors. Third, nicotine content was only accounted for in one study, 
despite often being implicated as the mechanism by which e-cigarettes act as a gateway 
to smoking (Bell & Keane, 2014). Although the majority of studies met three out of four 
pre-selected Bradford-Hill causality criteria, the criteria I used were relatively relaxed, 
and other (non-causal) explanations for the association between e-cigarette use and 
later smoking (e.g., a common liability) cannot be ruled out. Reviewing these studies 
highlighted a substantial number of non-smoking e-cigarette users who are potentially 
at greater risk of smoking and other poor health outcomes.  
In Chapter 3, different reasons for vaping were associated with the likelihood of 




out of curiosity was associated with lower likelihood of vaping at 24 years and was 
associated with continued smoking at 24 years among those who smoked just prior to 
vaping. However, vaping out of curiosity was also associated with an increased 
likelihood of using neither product compared with being a current smoker at 24 years 
among the full sample, and there was no clear association between vaping out of 
curiosity and current smoking at 24 years among individuals who did not regularly 
smoke just prior to vaping. Therefore, vaping out of curiosity does not appear to 
encourage continued vaping or smoking uptake among non-current smokers, but does 
not support smoking cessation either. Vaping to quit smoking at 23 years was associated 
with higher likelihood of vaping at 24 years and lower likelihood of smoking at 24 years 
(among those who were smoking just prior to vaping) compared to those not vaping to 
quit. Similarly, vaping to cut down smoking was associated with continued vaping at 24 
years, but in contrast, was associated with continued smoking at 24 years (among those 
who smoked just prior to vaping). Therefore, I concluded that e-cigarette use alone may 
not lead to discontinued smoking unless e-cigarettes are used with the intention to quit 
smoking.  
In Chapter 5, I found little evidence of a direct effect of cotinine on smoking-related 
health outcomes. This implies that the other constituents of tobacco smoke (aside from 
nicotine) are the cause of the selected smoking-related poor health outcomes. Although 
there may have been some weak instrument bias affecting the estimates of the direct 
effect of cotinine, this suggests that nicotine use (e.g., via e-cigarettes) may not lead to 
poor health outcomes associated with smoking.  
I further explored the relationship between nicotine exposure and health in Chapter 6 
but did not present any inferential statistics. Instead, I outlined the planned analyses for 
an experimental exploration of the effects of nicotine administration on eating 
topography which was disrupted by the COVID-19 pandemic. I presented descriptive 
statistics for the data collected to date. Although I cannot draw any conclusions at this 
stage (and the magnitude and direction of the estimates may be subject to change when 
the study is complete), the pattern of results are in the same direction as only one out of 
four of my hypotheses. In line with my hypotheses, participants consumed their meals 
slower following nicotine administration compared with placebo administration. In 




were less full after meal consumption following nicotine administration compared with 
placebo administration.  
7.2 Conclusions and Implications 
The results provide further evidence to contribute to the debate on whether 
e-cigarettes act as a gateway to smoking or could be a result of a shared liability. The 
results also provide novel evidence regarding the potential health implications of using 
nicotine without exposure to tobacco smoke (e.g., via e-cigarettes). 
7.2.1 The Gateway Effect and Common Liability Theory 
In Chapter 2, I found evidence of an association between e-cigarette use and later 
smoking which could be used to infer that e-cigarettes act as a gateway to smoking. 
However, I also highlighted the limitations present in the current literature. 
Consequently, I have refrained from concluding this association is due to a gateway 
effect. Furthermore, I found evidence to suggest that the strong association found 
between e-cigarette use and later smoking could be due to a shared liability (Chapters 3 
and 4). E-cigarette users share many demographic, behavioural and lifestyle 
characteristics with smokers (Chapter 3), and also share a genetic predisposition which 
may reflect a general predisposition to risk-taking (Chapter 4).  
There is a strong correlation between risk-taking and curiosity (Sagone & Caroli, 2013), 
and I found that curiosity was the most common reason for vaping among young adults 
in the UK who have both vaped and smoked at least once (Chapter 3). Nicotine addiction 
is a commonly cited explanation for why e-cigarettes may act as a gateway to smoking, 
yet the young adults who vaped out of curiosity did not appear to develop an addiction 
to nicotine (i.e., they did not seem to transition from non-current smoking/vaping to 
current smoking/vaping after trying e-cigarettes). These results could highlight a 
substantial group of ‘experimenters’ who try vaping and smoking but do not transition 
to current use. Given the majority of studies included in my meta-analysis (Chapter 2) 
explored the association between ever vaping and ever smoking, the results are likely to 
capture ‘experimenters’ who are curious about both vaping and smoking and are likely 
to take risks. Including these individuals in studies exploring the gateway hypothesis 




may inflate estimates of a gateway effect mediated by nicotine addiction as these 
‘experimenters’ do not appear to be addicted to nicotine. 
Ideally, I would have additionally explored the association between reasons for vaping 
and later vaping and smoking among those who had never smoked at 23 years, 
however, the sample was not appropriate to explore this; e-cigarettes only became 
available late in adolescence for this cohort whereas cigarettes were widely available 
throughout their adolescence, so the young adults had limited opportunity to 
experiment with e-cigarettes prior to smoking. As a result, I had insufficient power to 
stratify the data by never smokers at 23 years. Therefore, it is inappropriate to make 
direct conclusions regarding the gateway hypothesis based solely on the results of 
Chapter 3. However, triangulating the results and conclusions of Chapters 2, 3 and 4, 
shows some support for a shared liability between e-cigarette use and smoking.  
Of course, the two theories are not mutually exclusive, and it is possible that there is 
both a gateway effect and a shared liability influencing young adult e-cigarette use. I 
should also acknowledge that my own views and beliefs may have influenced my 
interpretation of these results (as I assumed the views and beliefs of other researchers 
may have impacted their conclusions regarding the gateway hypothesis in Chapter 2). 
7.2.2 Potential Health Consequences of E-cigarette Use 
In Chapter 2, I found a substantial number (10%) of young people who are non-smokers 
have ever vaped. To protect these young people from harm, it is vital to understand the 
health implications of nicotine use without exposure to tobacco smoke. In Chapter 5, I 
found no clear evidence to suggest that nicotine exposure without exposure to cigarette 
smoke results in smoking-related health outcomes. This suggests that nicotine use via 
vaping should not substantially expose non-smoking vapers to smoking-related health 
risks such as chronic obstructive pulmonary disease. 
Although I found limited evidence to suggest that long-term nicotine use results in 
smoking-related ill health (Chapter 5), this evidence is by no means sufficient to 
determine that e-cigarettes are safe for non-smokers. The instruments used as a proxy 
for cotinine levels were weak and nicotine is just one possible constituent of e-cigarette 




result in different and potentially harmful emissions (Behar et al., 2016). E-cigarettes 
could also pose risks which are not associated with smoking, such as EVALI (e-cigarette 
and vaping product use associated lung injury). Nevertheless, smokers expose 
themselves to many more chemicals and toxicants in tobacco smoke (Goniewicz et al., 
2014), thus switching completely from smoking to vaping should reduce their harm 
(Shahab, Goniewicz, et al., 2017).  
The data collected so far in the experimental study described in Chapter 6 are in line 
with the hypothesis that nicotine decreases food consumption rate but are not in line 
with the hypothesis that nicotine decreases food consumption or self-selected portion 
size. I cannot yet derive any clear conclusions from this data, as the sample size is 
smaller than calculated to achieve sufficient statistical power, but the methods appear 
to be robust enough to draw conclusions when the pre-determined sample size is 
achieved. If appetite is affected by nicotine exposure as hypothesised, nicotine 
containing e-cigarette use could be encouraged among smokers who have relapsed due 
to post-cessation weight gain (Mizes et al., 1998) to potentially increase the likelihood of 
a successful quit attempt. If appetite is not affected, further investigation will be needed 
to identify potential mechanisms through which nicotine exposure and BMI are related.  
7.3 Thesis Strengths  
7.3.1 Novel and Improved Methods 
A strength of this thesis is that I have extended previously used methods and used novel 
methods to address important questions regarding the factors influencing e-cigarette 
use and the possible consequences of their use.  
In Chapter 2, I updated a previous meta-analysis exploring whether e-cigarettes act as a 
gateway to smoking (Soneji, Barrington-Trimis, Wills, Leventhal, et al., 2017) by adding 
relevant search terms to the search criteria, providing further details of the included 
studies, and stratifying the data to explore sources of heterogeneity. The previous 
meta-analysis also appears to include an error; the authors stated that they included 
only studies reporting odds ratios, yet Miech and colleagues (2017) reported relative 
risk. When contacted, the corresponding author stated that the relative risk had been 




risk. The author did not respond to a request to share their equation for conversion. It is 
possible that an odds ratio and relative risk would be similar if the outcome is rare 
(Davies, Crombie, & Tavakoli, 1998), but in my conversion the estimate was not 
equivalent to the relative risk reported. Including a relative risk in a meta-analysis with 
odds ratios would be an issue for the interpretation of the combined estimate as 
interpreting relative risks as odds ratios will understate the effect (Davies et al., 1998). 
Therefore, I have provided an update to the previous meta-analysis with which the 
combined estimate can be more easily interpreted. 
In Chapter 3, I explored why young adults in the UK use e-cigarettes. Young adults are an 
understudied population – particularly in the UK – because they are often included in 
studies with older adults, assuming that the young adults and older adults share the 
same reasons for vaping. I have shown that this is not the case; the most common 
reason for vaping among young adults (23 years old) in the UK was out of curiosity, 
whereas among adults in Great Britain (18+ years old) the most common reason is to 
quit smoking (Action on Smoking and Health, 2019a).  
In Chapter 4, I extended the methods of Allegrini and colleagues (2019) by using 
updated smoking initiation polygenic risk scores. The updated scores were created using 
the summary results of a larger genome-wide association study with greater statistical 
power to detect significant genetic variants (Liu et al., 2019). As a result, the scores I 
used should explain more variance in smoking initiation. My method was also novel as I 
included negative control outcomes to explore potential horizontal pleiotropy and 
shared liability. 
In Chapter 5, I employed a novel method to explore the potential health effects of 
nicotine use without exposure to cigarette smoke. To my knowledge, this is the first 
study to have used multivariable Mendelian randomisation to investigate and separate 
these effects. Without novel methods such as multivariable Mendelian randomisation, it 
would be decades before these effects would be observed, and the observed measures 
would likely be biased by confounding factors. Applying this novel multivariable 
Mendelian randomisation approach to other complex behaviours could be useful to 




In Chapter 6, I used novel methods to explore the effects of nicotine on appetite by 
recruiting non-dependent smokers. Previous studies (Perkins et al., 1992; Perkins et al., 
1991) have recruited non-smokers (who may experience adverse effects due to being 
naïve to nicotine) and daily smokers (who may experience withdrawal symptoms which 
could affect their appetite). Non-dependent smokers have been excluded from previous 
studies but exploring the effects among individuals who are unlikely to experience 
nicotine withdrawal or adverse effects due to naivety to nicotine could help to explain 
the role of nicotine in lowering BMI among smokers. 
7.3.2 Sample Size and Statistical Power 
A second strength of this thesis is that I have used relatively large sample sizes, which 
increases statistical power to detect true effects (Button et al., 2013). I have described 
the largest meta-analysis to date which explores whether e-cigarette use acts as a 
gateway to smoking, including 17 studies with sample sizes ranging from 347 to 39,718 
(Chapter 2). I have also utilised large, prospective cohorts with rich data (the Avon 
Longitudinal Study of Parents and Children [N = 412 to 6,702] and UK Biobank [N = 
337,010]) and used summary genetic data from GSCAN (Liu et al., 2019), a large-scale 
genome-wide association study with a sample size of 337,334 (Chapters 3, 4, and 5). 
Furthermore, using the Avon Longitudinal Study of Parents and Children data set, I was 
able to access a large sample of young adults which allowed me to investigate my 
research questions among an understudied subgroup of individuals. However, large 
sample sizes are required for genetic studies and so I may still have been underpowered 
to detect effects in Chapters 4 and 5. 
I also calculated the appropriate sample size to achieve 90% power to detect a 
substantial effect in the experiment described in Chapter 6. However, as this sample size 
has not yet been achieved, I was not able to report any inferential statistics and so I 
cannot be confident in the magnitude or direction of the effects found thus far.  
7.3.3 Causal Inference and Strength of Evidence 
A third strength of this thesis is that I have used a range of methods which are 
considered to contribute strong evidence of causation and aid consideration of possible 




consideration of whether the relationship between smoking initiation polygenic risk 
scores and e-cigarette use is causal (i.e., the genetic variants influence e-cigarette use 
only through smoking). By including negative controls relating to risk-taking in childhood 
(before the vast majority of participants engaged in smoking), I was able to show that 
there could be an underlying risk-taking phenotype which cannot be a result of smoking 
(as smoking had not occurred at this age) and which could also influence e-cigarette use.  
Traditionally, randomised controlled trials and meta-analyses are stated to be the 
strongest forms of evidence (Haapasalo, 2016). Mendelian randomisation is akin to a 
randomised controlled trial due to the random assortment of genetic variants at 
conception (Nitsch et al., 2006; Swanson et al., 2017). Although I have included strong 
methods in this thesis (i.e., meta-analyses and Mendelian randomisation), such methods 
can still be limited by bias and error. By triangulating these methods and drawing similar 
conclusions regarding the aims of my thesis, I provide stronger support for my 
conclusions than if I had presented the evidence from any of my individual studies alone 
(Munafo & Davey Smith, 2018). 
7.4 Thesis Limitations  
7.4.1 Risk of Bias, Measurement Error and Reverse Causality 
The first limitation of this thesis is that risk of bias, measurement error and potential 
reverse causality may have influenced some of my findings. Including studies of low 
quality (i.e., studies with greater potential for bias) in meta-analyses can lead to an issue 
referred to as ‘garbage in, garbage out’ whereby the results of the meta-analysis are also 
biased (Sharpe, 1997). Although I assessed and stratified by risk of bias in my 
meta-analysis in Chapter 2, the criteria which I used to determine the quality of the 
studies was relatively liberal as there were so few studies which met stricter criteria for 
high quality, as highlighted in a recent review focussing on adolescents (Chan et al., 
2020). For example, using a star-based rating system, I awarded a star to studies which 
had used self-reports to demonstrate that the outcome of interest preceded the 
exposure, but smoking status is sometimes misreported by young people (Khouja, 
Munafò, et al., 2020), so the outcome of interest may not have preceded the exposure 




determine the order of exposure and outcome (thereby removing some measurement 
error and limiting potential reverse causality), no stars would have been awarded for 
this criterion. Consequently, all of the studies would have been rated poor/fair quality 
and no studies would have been rated as good quality. Although it is possible to 
biochemically verify whether non-current smokers are currently vaping (by verifying 
nicotine exposure without carbon monoxide exposure), it is not currently possible to 
biochemically verify that a person has ever vaped but never smoked. However, this may 
be possible in the near future with advancing methods such as DNA methylation 
(Richmond et al., 2018), therefore more research using stronger emerging methods is 
needed. 
Measurement error and reverse causality may also have affected the results of Chapter 
3, as the young adults retrospectively-recalled their reasons for using e-cigarettes. This 
may lead to recall bias; for example, if an individual used an e-cigarette to quit smoking 
but failed to quit, they may be less likely to recall that they used an e-cigarette to quit. 
Ideally, I would have measured reasons for use just prior to vaping for the first time but 
this may also influence my results. For example, I could recruit individuals who intend to 
vape but have not yet tried vaping, but this would exclude individuals who try 
e-cigarettes on an impulse which could substantially reduce the proportion of vapers 
who vaped out of curiosity included in the study.  
7.4.2 Data Availability and Weak-Instrument Bias 
The second limitation of this thesis is that my results may have been restricted by the 
data which was available to me. For example, ALSPAC is a rich source of data, but may 
not be appropriate for studying the gateway effect given the context of the cohort (i.e., 
the young adults were exposed to cigarettes but not e-cigarettes in their youth). 
Due to only one small GWAS of cotinine being available (and no GWAS of e-cigarette 
use) my results may also have been influenced by weak-instrument bias. In Chapter 5, 
the conditional F-statistic for multivariable Mendelian randomisation indicated that 
there may be weak-instrument bias in the multivariable Mendelian randomisation 
analysis of the direct effect of nicotine. However, I was able to investigate the effect of 
nicotine by observing differences (or lack thereof) between univariable and 




evidence of weak-instrument bias in the analysis of the direct effect of smoking 
heaviness, a difference between the direct and total effects provides some evidence of 
an indirect effect via the other exposure(s) accounted for in the multivariable Mendelian 
randomisation analyses (i.e., nicotine). Therefore, comparing the univariable and 
multivariable Mendelian randomisation analyses of smoking heaviness and 
smoking-related health outcomes allowed me to make cautious inferences about the 
potential direct effects of nicotine on smoking-related health outcomes. 
7.4.3 Horizontal Pleiotropy and Collider Bias 
Aside from weak instrument bias, Mendelian randomisation studies can also be biased 
when the assumptions of Mendelian randomisation are violated. For example, results 
will be biased when the genetic variants included in a model are not valid because they 
exert horizontally pleiotropic effects (i.e., when one genetic variant affects more than 
one different phenotype) (Davies et al., 2018). Conditioning or stratifying on a collider 
can also bias the results of Mendelian randomisation (Davies et al., 2018) and 
observational studies (Munafò et al., 2018). The third limitation of this thesis is that 
horizontal pleiotropy and collider bias may have occurred. 
In Chapter 4, I found evidence to suggest that the genetic variants used to create the 
smoking initiation polygenic risk scores could have been horizontally pleiotropic as they 
were not only associated with smoking and e-cigarette use, but also with risk-taking, 
impulsivity and socioeconomic position at birth. Pleiotropy robust methods such as 
MR-Egger have been developed to address issues of pleiotropy, but MR-Egger allows for 
pleiotropy only if the InSIDE (Instrument Strength Independent of Direct Effect) 
assumption is held. These associations demonstrate a violation of the InSIDE 
assumption, so even pleiotropy robust methods, such as MR-Egger, may not be 
appropriate when conducting Mendelian randomisation studies of smoking initiation. In 
Chapter 5, I instead conducted univariable and multivariable Mendelian randomisation 
analyses of smoking heaviness but there was also evidence of horizontal pleiotropy in 
these analyses (as indicated by the MR-Egger intercept, Cochran’s Q statistic, and effects 
observed among never smokers).  
The effects seen among never smokers may alternatively be due to stratifying on the 




(i.e., never, ever, former and current smoking), which is likely to be impacted by the 
number of cigarettes an individual is predisposed to smoke per day, and health status. 
The smoking heaviness genetic variant rs16969968-rs1051730 has previously been 
suggested to be positively associated with smoking status (i.e., ever versus never 
smoking) in younger age groups but negatively associated with smoking status in older 
age groups – smokers with the heavier smoking genetic predisposition have a higher 
mortality rate and are therefore less likely to survive into older adulthood (Taylor & 
Munafò, 2014). Diagnosis of a smoking-related disease could also lead smokers to quit 
smoking; health concern is a particularly strong motivation to quit smoking among those 
with a diagnosed disease (Buczkowski, Marcinowicz, Czachowski, & Piszczek, 2014). As 
both the exposure and outcome could influence smoking status, smoking status is a 
collider and thus stratifying by it could induce collider bias. Similarly, selection into UK 
Biobank may have introduced collider bias as participants are less likely to smoke than 
the general population and the mortality rate is also lower (Munafò et al., 2018). 
Consequently, the Mendelian randomisation results reported in Chapter 5 may be 
subject to bias whereby associations are negatively biased (i.e., results may indicate 
stronger evidence that increased smoking heaviness causes poor health than the true 
effect). 
The analysis in Chapter 4 may also have been subject to collider bias. If both smoking 
initiation polygenic risk scores and unmeasured confounders influence smoking 
initiation (i.e., ever versus never smoking), then smoking initiation is a collider in this 
analysis. Thus conditioning on smoking initiation (i.e., restricting the analysis to never 
smokers) as I have in this analysis could induce bias (Paternoster et al., 2017) which 
could lead to biased associations in either direction depending on the direction of the 
effect of the unmeasured confounders.  
7.5 Future Directions 
Given the limitations I have outlined, further research is needed to develop our 
understanding of the factors influencing youth and young adult e-cigarette use and the 




First, the evidence base exploring whether e-cigarette use acts as a gateway to smoking 
is rapidly expanding meaning that my systematic review and meta-analysis could soon 
be out of date. Consequently, frequent updates of this review are necessary and should 
take into account advances and developments in the field. For instance, if more studies 
account for the nicotine content and frequency of exposure, include biochemical 
verification and adjust more appropriately for confounders, the results of the 
meta-analysis may differ from the findings presented in Chapter 2. Stricter criteria could 
also be used to determine the quality of studies, in which case subsequent stratification 
may result in different findings. However, if future studies also fail to take these factors 
into account, the results of future meta-analyses are likely to result in similar 
conclusions as the evidence of an association between e-cigarette use and later smoking 
appears to be robust. 
Second, with new and emerging data, the procedures described in this thesis could be 
replicated in other relevant populations or adapted to more thoroughly explore the 
research questions. For example, the Millennium cohort is a prospective birth cohort 
study which released genetic data in Autumn 2020 – the young people in this study were 
exposed equally to e-cigarettes and cigarettes in youth and thus would be an 
appropriate population to explore whether smoking initiation polygenic risk scores 
predict e-cigarette use among never-smoking youth. Replicating the findings of Chapter 
4 in this cohort (or other similar cohorts) could provide further support to my conclusion 
that the presumed gateway effect is better explained as a shared liability. Additionally, 
with the greater availability of cohorts with genetic and phenotypic data, a 
genome-wide association study of e-cigarette use may become available which could be 
used to directly compare the genetic influences on vaping with the genetic influences on 
smoking (furthering the findings of Chapter 4) and explore causal effects of e-cigarette 
use (furthering the findings of Chapters 2 and 5). Following on from my PhD, I plan to 
form a consortium aimed at collating genetic and phenotypic data relating to e-cigarette 
use from a range of cohorts to facilitate a genome-wide association study of e-cigarette 
use. 
Third, I plan to resume recruitment for the study exploring the effect of nicotine on 
eating behaviour (described in Chapter 6) and will continue collecting data until the 




procedure in order to meet new government guidelines for safety during (or after) the 
COVID-19 pandemic. During the initial recruitment phase (pre-pandemic), the methods 
were refined in order to maximise recruitment, drop-out rates were moderate, and the 
data (bar data measured using the Mandometer) were of good quality, thus I am 
confident that with a sufficient sample size the data will be adequate to proceed with 
my planned analyses. If the results support my hypotheses (i.e., nicotine administration 
decreases food consumption, self-selected portion size and consumption rate compared 
with placebo) I will conclude that nicotine appears to reduce appetite among 
non-dependent smokers and this could explain the observed relationship between 
smoking and lower BMI. If the data do not support my hypotheses, I will conclude that 
this relationship may not be due to a nicotine-induced reduction in appetite and food 
consumption.  
7.6 Public Health and Policy Implications 
Despite the limitations of this thesis, my findings have substantial implications for policy 
and public health strategies relating to e-cigarettes, particularly for strategies aimed at 
reducing harm to youth and young adults. The findings in Chapter 2 do not provide 
strong support for the gateway hypothesis yet the combined findings of Chapters 2, 3 
and 4 provide strong support for a shared liability between vaping and smoking, 
therefore, strict policies (e.g., bans) which prevent e-cigarette use in order to reduce the 
risk of smoking initiation among youth and young adults are unlikely to be effective. In 
fact, they may have the opposite effect; if young people are predisposed to both vaping 
and smoking but only cigarettes are available, this could increase their likelihood of 
smoking because it is the only option available to them.  
Given the strong positive association that I reported between e-cigarette use among 
never-smokers and later smoking in Chapter 2, researchers and policymakers alike are 
interested in what may attract non-smokers to e-cigarettes in order to make them 
unattractive. Frequently, attractive flavours and packaging have been identified as 
potential factors which could be attracting young non-smokers, and as a result, 
restrictions have been placed on flavour availability and packaging in some countries 
(Klein, Chaiton, Kundu, & Schwartz, 2020). However, there is limited evidence of the 




limited evidence of the impact that flavour restrictions would have on current smokers 
and vapers. Some evidence suggests that some vapers would relapse to smoking and 
some would create their own flavours or source their e-liquids from unregulated/illegal 
sources, which can have lethal consequences such as E-cigarette and Vaping Associated 
Lung Injury (Action on Smoking and Health, 2020; Heinzerling et al., 2020). Thus, 
restrictions on flavours may actually put current vapers at risk and given that the 
association found between vaping and later smoking in Chapter 2 may not be causal, 
such restrictions may not protect non-smokers or vapers. 
Furthermore, restrictive policies may prevent and discourage adult smokers from 
accessing an effective smoking cessation tool and hamper smoking cessation attempts. 
The evidence I presented in Chapter 5 suggests that consuming nicotine without tobacco 
smoke (e.g., via e-cigarettes rather than cigarettes) is likely to reduce the risk of 
developing smoking-related diseases. Therefore, policies should encourage smokers to 
switch from tobacco cigarettes to e-cigarettes. Additionally, restrictions placed on 
nicotine contents (such as the 20 mg/ml restriction in the UK) should be carefully 
considered to ensure that heavy smokers have access to a less harmful nicotine 
replacement which is sufficient for their needs. 
The results I have presented suggest that policies which encourage smokers to switch to 
e-cigarettes should be adopted over those that discourage use. Ideally, policy should 
encourage smokers to vape while simultaneously restricting non-smokers’ access to 
both cigarettes and e-cigarettes.  
7.7 Thesis Conclusion 
In this thesis I aimed to explore who uses e-cigarettes, why, and what the potential 
consequences of e-cigarette use could be, particularly among young adults. I highlighted 
the need to address these aims, showing that young people who have never smoked 
before are being exposed to vaping, which may act as a gateway to smoking. I found 
substantial differences in demographic, behavioural and lifestyle factors between young 
adults who had ever and never vaped, as well as differences between those who were 
former and current vapers. Specifically, vapers were more likely to be male, of lower 




behaviours, and smoke. I also identified curiosity as the most popular reason for using 
e-cigarettes (followed by use to quit smoking) among a sample of UK young adults who 
had both ever smoked and ever vaped. Vaping out of curiosity did not appear to change 
an individual’s smoking or vaping status (i.e., individuals were unlikely to become 
current vapers and smokers continued to smoke) whereas vaping to quit smoking was 
associated with continued vaping and discontinued smoking. I also showed that 
e-cigarette use may be influenced by a genetic predisposition to risk-taking. Finally, I 
showed that nicotine exposure (without exposure to cigarette smoke) does not appear 
to cause smoking-related ill health.  
Using a variety of methods, I have shown that the shared liability hypothesis may explain 
the relationship between e-cigarette use among non-smokers and later smoking, and 
that nicotine use without exposure to tobacco smoke (e.g., via e-cigarettes ) is unlikely 
to cause smoking-related ill health. However, further research is required to support 
these findings using emerging datasets which will allow for greater exploration of the 
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List of Abbreviations 
Abbreviation Description 
ACR Assumed control risk 
ADHD Attention deficit hyperactivity disorder 
ALSPAC Avon longitudinal study of parents and children 
ANDS Alternative nicotine delivery system 
ANOVA Analysis of variance 
ASH Action on Smoking and Health 
AUDIT Alcohol use disorders identification test 
BMI Body mass index 
BRCA1 Breast cancer type 1 gene 
BRCA2 Breast cancer type 2 gene 
CD Conduct disorder 
CDC Centre for disease control and prevention 
CHD Coronary heart disease 
CHRNA Cholinergic receptor 
CI Confidence interval 
CIS-r Computerised interview schedule - revised 
CO Carbon monoxide 
COPD Chronic obstructive pulmonary disease 
COVID-19 Coronavirus disease 
CPD Cigarettes per day 
DAWBA Development and wellbeing assessment 
DEBQ Dutch eating behaviour questionnaire 
DNA Deoxyribonucleic acid 
DSM Diagnostic and statistical manual of mental disorders 
ENDS Electronic nicotine delivery system 
EU European union 
EVALI E-cigarette and vaping associated lung injury 
FEV-1 Forced expiratory volume in 1 second 
FTND Fagerström test of nicotine dependence 
FVC Forced vital capacity 
GAD Generalised anxiety disorder 
GN Genetic variants as proxies for nicotine  
GRADE Grading of recommendations assessment, development and evaluation 
GS Genetic variants as proxies for smoking heaviness  
GSCAN Genome-wide association study & sequencing consortium of alcohol and 
nicotine use  
GSN Genetic variants as proxies for nicotine and smoking heaviness 
GWAS Genome-wide association study  
GX Genetic variants as proxies for the exposure 
HR Heart rate 
ICD International statistical classification of diseases and related health problems 
ID Identification 
IEU Integrative epidemiology unit 
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ITC International Tobacco Control 
IVW Inverse variance weighted 
LD Linkage disequilibrium 
LSD Lysergic acid diethylamide 
MAF Minor allele frequency 
MeSH Medical subject headings 
MHRA Medicines and healthcare products regulatory agency  
MNWS Minnesota nicotine withdrawal scale 
MOOSE Meta-analyses of observational studies in epidemiology 
MR Mendelian randomisation 
MRC Medical research council 
MVMR Multivariable Mendelian randomisation 
NHS National health service 
NIH National institute of health 
NOS Newcastle-Ottawa scale 
NRT Nicotine replacement therapy 
ODD Oppositional defiant disorder 
OPCS Office of population censuses and surveys  
OR Odds ratio 
OSF Open science framework 
POMC Pro-opiomelanocortin gene 
PRISMA Preferred reporting items for systematic reviews and meta-analyses 
PRS Polygenic risk score 
QC Quality check 
RCT Randomised controlled trial 
RDA Rebuildable dripping atomiser 
REC Research ethics committee 
RR Risk ratio 
RRR Relative risk ratio 
SD Standard deviation 
SDQ Strengths and difficulties questionnaire 
SE Standard error 
SEP Socioeconomic position 
SES Socioeconomic status 
SIMEX Simulation extrapolation 
SNP Single nucleotide polymorphism 
TAG Tobacco and alcohol genetics consortium 
TARG Tobacco and alcohol research group 
THC Tetrahydrocannabinol 
UK United Kingdom 
US United States  
USA United States of America 
USB Universal serial bus 
VAS Visual analogue scale 






Appendix 1. Systematic search strategy. 
Search dates 
Search 1 completed: 12/02/18 
Search 2 completed: 09/11/18 
Search 3 completed: 24/11/18 
 
Pubmed search terms 
(Tobacco Use[mesh] OR Tobacco[mesh] OR Tobacco use disorder[mesh] OR Tobacco 
Products[mesh] OR Cigar*[tiab] OR Tobacco[tiab] OR Smok*[tiab]) AND (Electronic 
Cigarettes[mesh] OR (Nebulizers and Vaporizers[mesh] AND (Tobacco[mesh] OR 
Tobacco[tiab] OR Nicotine[mesh] OR Nicotine[tiab])) OR Electronic Cigarette*[tiab] OR 
E-Cig*[tiab] OR Electronic Nicotine Delivery System*[tiab] OR Vape[tiab] OR Vaping[tiab] 











































Appendix 2. Newcastle-Ottawa Quality Assessment Form for Cohort Studies. 
Note: A study can be given a maximum of one star for each numbered item within the Selection and 
Outcome categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Representativeness of the exposed cohort 
a) Truly representative of the average non-smoker who has used an e-cigarette in the community 
(one star) 
b) Somewhat representative of the average non-smoker who has used an e-cigarette in the 
community (one star) 
c) Selected group e.g., nurses, volunteers 
d) No description of the derivation of the cohort 
 
2) Selection of the non-exposed cohort 
a) Drawn from the same community as the exposed cohort (one star) 
b) Drawn from a different source 
c) No description of the derivation of the non-exposed cohort 
 
3) Ascertainment of exposure 
a) Secure record (e.g., stop smoking service record) (one star) 
b) Structured interview (one star) 
c) Written self-report 
d) No description 
e) Other 
 
4) Demonstration that outcome of interest was not present at start of study 




1) Comparability of cohorts on the basis of the design or analysis controlled for confounders 
a) The study controls for age (one star) 
b) Study controls for additional factors (e.g., sex and SES) (one star) 
c) Study controls for A and B (two stars) 
d) Cohorts are not comparable on the basis of the design or analysis controlled for confounders 
 
Outcome 
1) Assessment of outcome 
a) Independent blind assessment (one star) 
b) Record linkage (one star) 
c) Self-report 
d) No description 
e) Other 
 
2) Was follow-up long enough for outcomes to occur 







3) Adequacy of follow-up of cohorts 
a) Complete follow up- all subject accounted for (one star) 
b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to 30% or 
description of those lost suggested no different from those followed (one star) 
c) Follow up rate less than 70% and no description of those lost 
d) No statement 
 
Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and poor): 
 
Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 
stars in outcome/exposure domain 
 
Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in 
outcome/exposure domain 
 

















Auf et al. 
(2018) 
39,718 14.5  
(12-19) 
N/A Ever-vapers Ever smoking Cross-
sectional 
USA 24 Age, race/ethnicity, gender, peer 
influence, household e-cigarette use and 
household use of outcome product 
Barrington-
Trimis et al. 
(2018) 
6,258 N/A  
(grade 9-12) 




Longitudinal USA 6-18 Gender, race/ethnicity, baseline grade in 
high school and study (random effect for 
school) 




N/A Ever-vapers Ever smoking Longitudinal UK 12 Sex, age, ethnicity, and school 
Conner et al. 
(2018) 
1,726 13.18  
(13-14) 
48% Ever-vapers Ever smoking Longitudinal UK 12 Sex, family smoking, friends’ smoking, 
intentions, attitudes, norms, perceived 
behavioural control, self-efficacy, and free 
school meals 
East et al. 
(2018) 
1,152 N/A  
(11-18) 
46% Ever-vapers Ever smoking Longitudinal UK 4-6 Age, gender, school performance, problem 
behaviour, monthly alcohol use, smoking 
susceptibility, e-cigarette susceptibility, 
some friends smoke, some friends use e-
cigarettes, at least one parent smokes, at 
least one parent uses e-cigarettes, 
sibling(s) smoke, sibling(s) use e-cigarettes 

















47% Ever-vapers Recent 
smoking 
Longitudinal USA 18 Age, sex, race/ethnicity, parental 
education, family living situation, family 
history of smoking, peer smoking, 
depressive symptoms, impulsivity, use of 
non–nicotine or tobacco substances, 
delinquent behaviour, susceptibility to 
smoking, and smoking outcome 
expectancies 
Loukas et al. 
(2018) 
2,558 19.71  
(18-25) 
33% Ever-vapers Ever smoking Longitudinal USA 20 Sex, age, race, type of college attended, 
susceptibility to smoking, family-of-origin 
tobacco use, friend cigarette use, and 
other tobacco use 
Lozano et al. 
(2017) 
4,695 N/A  
(11-13+) 
48% Ever-vapers Ever smoking Longitudinal Mexico 18 Age, sex, parental education, parent 
smoker, sibling smoker, smoking among 
close friends, sensation seeking, trial of 
alcohol, trial of drugs, and internet 
tobacco product advertising 
Miech et al. 
(2017) 




Ever smoking Longitudinal USA 12 Sex, race, parental education, baseline 
levels of marijuana use and binge drinking. 
Morgenstern 
et al. (2018) 
4,163 15.61  
(14-18) 
N/A Ever-vapers Ever smoking Longitudinal Germany 6 Sex, age, federal state, school type, 
migration background, school leaving 
qualification of parents, SES, sensation 
seeking, impulsivity, anxiety sensitivity, 
hopelessness, extraversion, agreeableness, 
conscientiousness, neuroticism, openness, 
alcohol ever, binge drinking ever, cannabis 
ever, other illegal drugs ever and 
participation in the “Keep a Clear Head” 
program. 




46% Ever-vapers Ever smoking Longitudinal USA 12 Sex, age, race/ethnicity, maternal 




parental smoking, and smoking among 
close friends 




39% Ever-vapers Ever smoking Longitudinal USA 12 Age, sex, race, ethnicity, education level, 
self-esteem, sensation seeking, 
rebelliousness, yearly household income, 
living situation and relationship status 









Longitudinal USA 12 Sex, age, race/ethnicity, depression, 
anxiety, negative urgency, positive 
urgency, lack of premeditation, lack of 
perseverance, sensation seeking, stressful 
life events, peer deviance, and other 
tobacco use 




52% Ever-vapers Ever smoking Longitudinal Netherlan
ds 
6 Age, sex, educational attainment and 
composite score of smoking propensity 
Watkins et al. 
(2018) 
10,348 14.3  
(12-17) 





Longitudinal USA 12 Sex, age, race/ethnicity, parental 
educational, urban residence, sensation 
seeking, alcohol use, living with tobacco 
user, frequency of noticing of tobacco 
warnings, receptivity to tobacco 
advertising, and season 




47% Ever-vapers Ever smoking Longitudinal USA 12 Age, sex, race/ethnicity, family structure, 
parental education, parental support, 
parental monitoring, sensation seeking, 
rebelliousness, and clustering within 
school 
 




Appendix 4. E-cigarette questionnaire items and possible responses. 
Variable Question Answer 
Vaped as a 
smoking 
cessation aid 
Have you ever used [an e-
cigarette] to help you stop 
smoking? 
Tick box response 
Ever use Have you ever used/vaped 
an electronic cigarette (e-




Age of use How old were you when 
you first used an electronic 
cigarette or other vaping 
device? 
Free response 
Current use Do you currently use/vape 
electronic cigarettes or 





How often did you 
use/have you used 
electronic 
cigarettes/vaping devices? 
At least once a day 
At least once a week  
At least once a month 
Less than once a month 
Duration of 
use 
How long did you use/have 
you used electronic 
cigarettes/vaping devices 
for? 
Less than 1 month 
1-3 months 
4-6 months 
7 months to 1 year 
1-2 years 
More than 2 years 
Device type What type of electronic 
cigarette/vaping device do 
you use most often/have 
you used in the past? 
A disposable electronic cigarette or vaping device (non-
rechargeable) 
An electronic cigarette or vaping device that uses 
replaceable pre-filled cartridges (rechargeable) 
An electronic cigarette or vaping device with a tank that 
you refill with liquids (rechargeable) 
A modular system that you refill with liquids (you use 
your own combination of separate devices: batteries, 
atomizers etc.) 
Rebuildable dripping atomiser (RDA) 
Other (e.g. e-pipe, e-cigar) 
Reasons for 
use 
What are/were your 
reasons for using electronic 
cigarettes/vaping devices? 
Please cross all that apply. 
To help me quit smoking 
To help me cut down on the number of cigarettes I 
smoke 
To help me with cravings in situations where I cannot 
smoke e.g. travel, indoors 
Pleasure 
Curiosity 








Did you smoke tobacco 
regularly just before you 









Appendix 5. Details of imputed variables. 








Regression model used to 
predict missing data in this 
variable 
Outcome variable    
Use status Categorical 
(4) 
0 (0%) N/A 
Exposure variables    
To quit Binary 0 (0%) N/A 
To cut down Binary 0 (0%) N/A 
To curb cravings Binary 0 (0%) N/A 
For pleasure Binary 0 (0%) N/A 
Curiosity Binary 0 (0%) N/A 
Friends used them Binary 0 (0%) N/A 
Covariates    
Sex Binary 0 (0%) N/A 
Parental SEP at birth Binary 75 (44%) Logistic regression 
Ethnicity Binary 62 (9%) Logistic regression 
Age at 23+ questionnaire completion Continuous 7 (1%) Linear regression 
Auxiliary variables (i.e., variables not 
included in the analysis model)  
   
Type of device used Categorical 
(3) 
0 (0%) N/A 
Maternal smoking in pregnancy Binary 46 (7%) Logistic regression 
BMI Continuous 121 (18%) Linear regression 
Cannabis use Binary 207 (31%) Logistic regression 
Other drug use Binary  Logistic regression 
AUDIT score Continuous 222 (33%) Linear regression 
Ever smoked at age 20 Binary 202 (30%) Logistic regression 
Gambling problems Binary 228 (34%) Logistic regression 
Condom use Binary 298 (45%) Logistic regression 
Anxiety Continuous 256 (38%) Linear regression 
Depressed mood Binary 262 (39%) Logistic regression 
Employment and education status Binary 266 (40%) Logistic regression 
Parenthood status Binary 251 (38%) Logistic regression 
Ever smoked by 17 years Binary 189 (28%) Logistic regression 
Ever smoked by 18 years Binary 308 (46%) Logistic regression 
Ever smoked by 20 years Binary 202 (30%) Logistic regression 
Ever smoked by 21 years Binary 259 (39%) Logistic regression 
Ever smoked by 22 years Binary 143 (21%) Logistic regression 
Current smoker at 18 years  Binary 366 (55%) Logistic regression 
Current smoker at 21 years Binary 276 (41%) Logistic regression 
Current smoker at 22 years Binary 143 (21%) Logistic regression 
Ever used an e-cigarette by 22 years Binary 145 (22%) Logistic regression 
Parental SEP at 8 months Binary 397 (59%) Logistic regression 
Parental SEP at 2 years Binary 376 (56%) Logistic regression 




Parental SEP at 4 years Binary 374 (56%) Logistic regression 
Paternal ethnic group Binary 94 (14%) Logistic regression 
Maternal ethnic group Binary 156 (23%) Logistic regression 
Paternal ethnic group (reported by mother) Binary 210 (31%) Logistic regression 
Number of cigarettes mother smoked per 
day (32 weeks gestation) 
Continuous 106 (16%) Linear regression 
Age YP completed 21+ questionnaire Continuous 248 (37%) Linear regression 
21+ completion date based on date received Binary 248 (37%) Logistic regression 
Age YP completed 22+ questionnaire Continuous 140 (21%) Linear regression 
22+ completion date based on date received Binary 140 (21%) Logistic regression 
BMI at 8 Continuous 381 (57%) Linear regression 
BMI at 16 Continuous 312 (47%) Linear regression 
YP tried cannabis by 15 years Binary 198 (30%) Logistic regression 
YP tried cannabis by 16 years Binary 187 (28%) Logistic regression 
YP tried cannabis by 17 years Binary 272 (41%) Logistic regression 
YP tried cannabis by 18 years Binary 308 (46%) Logistic regression 
YP tried cannabis by 22 years Binary 145 (22%) Logistic regression 
Tried other drugs by 16 since 15 - aerosols Binary 200 (30%) Logistic regression 
Tried other drugs by 16 since 15 - gas Binary 200 (30%) Logistic regression 
Tried other drugs by 16 since 15 - glue Binary 198 (30%) Logistic regression 
Tried other drugs by 16 since 15 - solvents Binary 202 (30%) Logistic regression 
Tried other drugs by 16 since 15 - poppers Binary 191 (29%) Logistic regression 
Tried other drugs by 16 since 15 - 
amphetamines 
Binary 190 (28%) Logistic regression 
Tried other drugs by 16 since 15 - ecstasy Binary 188 (28%) Logistic regression 
Tried other drugs by 16 since 15 - LSD Binary 191 (29%) Logistic regression 
Tried other drugs by 16 since 15 - magic 
mushrooms 
Binary 190 (28%) Logistic regression 
Tried other drugs by 16 since 15 - cocaine Binary 191 (29%) Logistic regression 
Tried other drugs by 16 since 15 - crack Binary 192 (29%) Logistic regression 
Tried other drugs by 16 since 15 - heroin Binary 193 (29%) Logistic regression 
Tried other drugs by 16 since 15 - ketamine Binary 191 (29%) Logistic regression 
Tried other drugs by 16 since 15 - steroids Binary 192 (29%) Logistic regression 
Number of illicit drugs used by 22 years Binary 168 (25%) Logistic regression 
Ever drank alcohol by 16 years Binary 189 (28%) Logistic regression 
Ever drank alcohol by 17 years  266 (40%)  
AUDIT score at 17 years Continuous 272 (41%)) Linear regression 
Ever drank alcohol by 18 years Binary 307 (46%) Logistic regression 
Ever drank alcohol by 20 years Binary 200 (30%) Logistic regression 
Ever drank alcohol by 22 years Binary 144 (22%) Logistic regression 
AUDIT score at 22 years Binary 158 (24%) Logistic regression 
Alcohol dependence (DSM-4) Binary 159 (24%) Logistic regression 
Alcohol abuse (DSM-4) Binary 152 (23%) Logistic regression 
Gambled by 18 years Binary 290 (43%) Logistic regression 
Had sexual intercourse in last year at 15 
years 
Binary 492 (74%) Logistic regression 
Used condom when last had sex at 15 years Binary 564 (84%) Logistic regression 
Had sexual intercourse in last year at 23 
years 




Used condom when last had sex at 23 years Categorical 
(3) 
18 (3%) Multinomial logistic 
regression 
Total CIS-r score at 18 years Continuous 231 (35%) Linear regression 
Anxiety score at 17 years Continuous 231 (35%) Linear regression 
YP been sad/miserable/tearful Binary 192 (29%) Logistic regression 
YP been sad/miserable/tearful for 3+ hours 
regularly 
Binary 504 (75%) Logistic regression 
Depression score at 17 years Continuous 231 (35%) Linear regression 
YP in full time education at 16 years Binary 190 (28%) Logistic regression 
YP working part time at 16 years Binary 186 (28%) Logistic regression 
YP working full time at 16 years Binary 186 (28%) Logistic regression 
YP in full time education or employment at 
20 years 
Binary 208 (31%) Logistic regression 
YP become a parent by 16 years Binary 196 (29%) Logistic regression 
YP become a parent by 20 years Binary 195 (29%) Logistic regression 
YP = young person; BMI = body mass index; AUDIT = alcohol use disorder identification test; CIS-r = 





Appendix 6. Associations between reasons for vaping by 23 years and current vaping at 24 years 
among ever vapers and ever smokers. 
 Unadjusted (n=668)  Adjusted (n=578) 
Reason for vaping by 23 years 
 
OR 95% CI p-value  OR 95% CI p-value 
To quit smoking 3.43 2.24, 5.23 <.001  3.97 2.50, 6.30 <.001 
To cut down  2.80 1.82, 4.31 <.001  3.10 1.95, 4.93 <.001 
To curb cravings  4.34 2.58, 7.29 <.001  4.95 2.82, 8.68 <.001 
Pleasure 3.20 2.02, 5.07 <.001  3.08 1.86, 5.10 <.001 
Curiosity 0.42 0.27, 0.65 <.001  0.39 0.24, 0.62 <.001 
Friends used them 0.62 0.36, 1.07 .084  0.51 0.28, 0.94 .031 
 
Note: The analyses were restricted to individuals who ever smoked and ever vaped. Adjusted 
analyses adjusted for demographic factors (sex, ethnicity, socioeconomic position, and age in 






Appendix 7. Associations between reasons for vaping by 23 years and current smoking at 24 years 
among ever vapers and regular smokers prior to vaping. 
 Unadjusted (n=412)  Adjusted (n=360) 
Reason for vaping by 23 years 
 
OR 95% CI p-value  OR 95% CI p-value 
To quit smoking 0.49 0.32, 0.77 .002  0.48 0.30, 0.77 .003 
To cut down  1.68 1.06, 2.65 .027  1.61 0.98, 2.64 .058 
To curb cravings  0.91 0.52, 1.60 .744  0.85 0.46, 1.58 .614 
Pleasure 0.92 0.50, 1.70 .797  0.75 0.39, 1.43 .378 
Curiosity 1.68 1.06, 2.65 .027  1.72 1.04, 2.84 .034 
Friends used them 1.76 0.94, 3.30 .077  1.74 0.91, 3.33 .092 
 
Note: The analyses were restricted to individuals who ever smoked and had smoked regularly just 
before they started vaping. Adjusted analyses adjusted for demographic factors (sex, ethnicity, 




Appendix 8. List of SNPs included in analyses 





Cotinine MR  
Included in 
CPD MR 
Included in MVMR 
main analysis 
Included in MVMR 
supplementary analysis 
rs10851907 15 78915864 Cotinine  
 
Yes No Yes Yes 
rs77107237 4 69746647 Cotinine  
 
Yes No Yes Yes 
rs57064725 15 78540694 Cotinine   
 
No No No No 
rs4887074 15 78952110 Cotinine   
 
Yes No Yes No 
rs74386627 15 79099986 Cotinine   
 
Yes No Yes No 
rs7971121 12 129977245 Cotinine   
 
Yes No Yes No 
rs2814672 6 63134804 Cotinine   
 
Yes No Yes No 
rs76474922 15 78884553 Cotinine   
 
Yes No Yes No 
rs11745112 5 685849 Cotinine   
 
Yes No Yes No 
rs1813379 16 84437335 Cotinine   
 
Yes No Yes No 
rs10744625 12 3868168 Cotinine   
 
Yes No Yes No 
rs11264100 1 35591626 Cigarettes 
per day 
rs2971426 No Yes Yes Yes 
rs2072659 1 154548521 Cigarettes 
per day 
 
No Yes Yes Yes 
rs34973462 1 175993820 Cigarettes 
per day 
 
No Yes Yes Yes 
rs7599488 2 60718347 Cigarettes 
per day 
 
No Yes Yes Yes 
rs78408772 2 62710608 Cigarettes 
per day 
 
No Yes Yes Yes 
rs10204824 2 148372720 Cigarettes 
per day 
 
No Yes Yes Yes 
rs2084533 3 16872929 Cigarettes 
per day 
 




rs7431710 3 48935583 Cigarettes 
per day 
rs11705737 No Yes Yes Yes 
rs2236951 3 50421081 Cigarettes 
per day 
 
No Yes Yes Yes 
rs699165 3 136224697 Cigarettes 
per day 
 
No Yes Yes Yes 
rs28813180 3 158083918 Cigarettes 
per day 
 
No Yes Yes Yes 
rs1024323 4 3006043 Cigarettes 
per day 
 
No Yes Yes Yes 
rs11940255 4 67086288 Cigarettes 
per day 
 
No Yes Yes Yes 
rs10454798 4 67980830 Cigarettes 
per day 
 
No Yes Yes Yes 
rs7766641 6 26184102 Cigarettes 
per day 
 
No Yes Yes Yes 
rs215600 7 32333642 Cigarettes 
per day 
 
No Yes Yes Yes 
rs62447179 7 50339609 Cigarettes 
per day 
 
No Yes Yes Yes 
rs2741351 8 27418040 Cigarettes 
per day 
 
No Yes Yes Yes 
rs73229090 8 27442127 Cigarettes 
per day 
 
No Yes Yes Yes 
rs13253502 8 42442018 Cigarettes 
per day 
 
No Yes Yes Yes 
rs4236926 8 42578059 Cigarettes 
per day 
 
No Yes Yes Yes 
rs790564 8 64604218 Cigarettes 
per day 
 




rs75596189 9 136468701 Cigarettes 
per day 
 
No Yes Yes Yes 
rs3025383 9 136502369 Cigarettes 
per day 
 
No Yes Yes Yes 
rs7951365 11 16377044 Cigarettes 
per day 
 
No Yes Yes Yes 
rs10742683 11 43667625 Cigarettes 
per day 
 
No Yes Yes Yes 
rs113001570 11 46737412 Cigarettes 
per day 
rs77920005 No Yes Yes Yes 
rs7125588 11 113436072 Cigarettes 
per day 
 
No Yes Yes Yes 
rs11846838 14 104184737 Cigarettes 
per day 
 
No Yes Yes Yes 
rs1115019 15 57141231 Cigarettes 
per day 
 
No Yes Yes Yes 
rs632811 15 59155050 Cigarettes 
per day 
 
No Yes Yes Yes 
rs182317 15 89943601 Cigarettes 
per day 
 
No Yes Yes Yes 
rs1592485 16 52093549 Cigarettes 
per day 
 
No Yes Yes Yes 
rs12924872 16 69552215 Cigarettes 
per day 
 
No Yes Yes Yes 
rs258321 16 89756473 Cigarettes 
per day 
 
No Yes Yes Yes 
rs4144686 18 53251725 Cigarettes 
per day 
 
No Yes Yes Yes 
rs4485470 18 62125063 Cigarettes 
per day 
 




rs59208569 19 4044424 Cigarettes 
per day 
 
No Yes Yes Yes 
rs143200968 19 41338847 Cigarettes 
per day 
 
No Yes Yes Yes 
rs56113850 19 41353107 Cigarettes 
per day 
 
No Yes Yes Yes 
rs6078373 20 11863500 Cigarettes 
per day 
 
No Yes Yes Yes 
rs1737894 20 31054702 Cigarettes 
per day 
 
No Yes Yes Yes 
rs2273500 20 61986949 Cigarettes 
per day 
 
No Yes Yes Yes 
rs7281463 21 40520783 Cigarettes 
per day 
 
No Yes Yes Yes 
rs8192726 19 41354496 Cigarettes 
per day 
rs76112798 No Yes No No 
rs8040868 15 78911181 Cigarettes 
per day 
 
No Yes No No 
rs3743063 15 79065171 Cigarettes 
per day 
 
No Yes No No 
rs28681284 15 78908565 Cigarettes 
per day 
 
No Yes No No 
rs10519203 15 78814046 Cigarettes 
per day 
 
No Yes No No 
rs12438181 15 78812098 Cigarettes 
per day 
 
No Yes No No 
rs28438420 15 78836288 Cigarettes 
per day 
 
No Yes No No 
rs146009840 15 78906177 Cigarettes 
per day 
 




rs72740955 15 78849779 Cigarettes 
per day 
 
No Yes No No 
rs4886550 15 78243579 Cigarettes 
per day 
 





Appendix 9. Tests of the weighted regression dilution (I2GX), instrument validity and 
heterogeneity among ever smokers in MR analyses. 
Note: Cotinine (5×10-6) refers to MR analysis in which cotinine SNPs were selected for 
inclusion based on a threshold of p < 5 × 10-6. Cotinine (5x10-8) refers to MR analysis in 
which cotinine SNPs were selected for inclusion based on a threshold of p < 5×10-8. CPD 
= cigarettes per day. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease; mF = mean F-statistic. mF tests for instrument validity. The 









Exposure Outcome Q  I2GX (weighted) mF 
Cotinine (5x10-6) BMI 22.00 0.743 30.67 
 COPD 22.03 0.793  
 FEV-1 27.71 0.747  
 FVC 10.27 0.747  
 CHD 23.60 0.742  
 Heart Rate 16.47 0.743  
Cotinine (5x10-8) BMI 8.02 0.573 61.29 
 COPD 13.93 0.629  
 FEV-1 3.83 0.577  
 FVC 0.23 0.577  
 CHD 2.10 0.585  
 Heart Rate 5.58 0.573  
CPD  BMI 270.37 0.965 68.44 
 COPD 144.80 0.965  
 FEV-1 258.10 0.965  
 FVC 184.00 0.965  
 CHD 138.82 0.965  




Appendix 10. Tests of the weighted regression dilution (I2GX), instrument validity and 
heterogeneity among current smokers in MR analyses. 
 
Note: Cotinine (5x10-6) refers to MR analysis in which cotinine SNPs were selected for 
inclusion based on a threshold of p < 5×10-6. Cotinine (5x10-8) refers to MR analysis in 
which cotinine SNPs were selected for inclusion based on a threshold of p < 5×10-8. CPD 
= cigarettes per day. BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; FEV-1 = forced expiratory volume in 1 second; FVC = forced vital capacity; CHD = 
chronic heart disease. mF = mean F-statistic. The Cochran Q statistic tests for instrument 
strength and validity in the two sample summary data setting. mF tests for instrument 
validity. 
  
Exposure Outcome Q  I2GX (weighted) mF 
Cotinine (5x10-6) BMI 41.22 0.760 30.67 
 COPD 19.91 0.847  
 FEV-1 12.39 0.766  
 FVC 2.29 0.766  
 CHD 13.16 0.733  
 Heart Rate 16.60 0.757  
Cotinine (5x10-8) BMI 19.10 0.531 61.29 
 COPD 14.09 0.702  
 FEV-1 4.58 0.517  
 FVC 0.24 0.516  
 CHD 3.27 0.557  
 Heart Rate 4.42 0.530  
CPD  BMI 217.21 0.965 68.44 
 COPD 99.42 0.965  
 FEV-1 177.36 0.965  
 FVC 114.84 0.965  
 CHD 76.32 0.965  




Appendix 11. Univariable Mendelian randomisation analysis of cotinine and 
smoking-related health outcomes among ever and current smokers (n = 3 SNPs). 
Health  
outcome 
MR method Ever smokers  Current smokers 
 Effect 95% CI p-value  Effect 95% CI p-value 
BMI IVW -0.08 -0.31, 0.14 0.469  -0.78 -1.52, -0.04 0.039 
 MR-Egger (SIMEX) 0.25 -11.79, 12.29 0.967  -1.58 -43.76, 40.59 0.941 
 W. median  -0.13 -0.26, 0.00 0.045  -1.04 -1.36, -0.71 <0.001 
 W. mode -0.16 -0.32, 0.00 0.057  -1.05 -1.40, -0.70 <0.001 
COPD IVW 0.54 -0.24, 1.33 0.175  0.64 -0.83, 2.10 0.393 
 MR-Egger (SIMEX) -2.76 -34.00, 28.48 0.863  -4.43 -47.27, 38.42 0.840 
 W. median  0.56 0.18, 0.94 0.004  0.75 0.07, 1.43 0.030 
 W. mode 0.46 -0.12, 1.05 0.121  0.80 -0.22, 1.83 0.124 
FEV-1 IVW -0.07 -0.10, -0.04 <0.001  -0.14 -0.22, -0.07 <0.001 
 MR-Egger (SIMEX) -0.03 -1.48, 1.42 0.970  -0.14 -2.85, 2.57 0.918 
 W. median  -0.08 -0.10, -0.05 <0.001  -0.17 -0.23, -0.11 <0.001 
 W. mode -0.08 -0.11, -0.05 <0.001  -0.17 -0.25, -0.09 <0.001 
FVC IVW -0.05 -0.07, -0.02 <0.001  -0.10 -0.16, -0.04 <0.001 
 MR-Egger (SIMEX) -0.02 -0.40, 0.36 0.918  -0.15 -1.37, 1.07 0.810 
 W. median  -0.05 -0.08, -0.02 0.001  -0.11 -0.18, -0.04 0.001 
 W. mode -0.05 -0.08, -0.01 0.008  -0.11 -0.19, -0.03 0.008 
CHD IVW 0.02 -0.06, 0.10 0.628  0.07 -0.14, 0.27 0.519 
 MR-Egger (SIMEX) 0.22 -2.86, 3.30 0.888  0.58 -7.84, 8.99 0.893 
 W. median  0.04 -0.05, 0.12 0.379  0.12 -0.06, 0.30 0.203 
 W. mode 0.05 -0.06, 0.15 0.393  0.14 -0.09, 0.37 0.226 
Heart  IVW 0.52 0.05, 0.98 0.030  1.52 0.62, 2.43 <0.001 
rate MR-Egger (SIMEX) -1.20 -7.87, 5.46 0.723  -1.37 -14.19, 11.45 0.834 
 W. median  0.54 0.19, 0.89 0.003  1.60 0.81, 2.39 <0.001 
 W. mode 0.53 0.06, 1.00 0.026  1.64 0.62, 2.66 0.002 
Note: Single nucleotide polymorphisms (SNPs) identified as conditionally independently 
associated with cotinine in a GWAS were selected for inclusion. BMI = body mass index; 
COPD = chronic obstructive pulmonary disease; FEV-1 = forced expiratory volume in 1 
second; FVC = forced vital capacity; CHD = chronic heart disease; IVW = inverse variance 
weighted; W. median = weighted median; W. mode = weighted mode. Effects are betas 
for continuous variables (BMI, FEV-1, FVC and heart rate) and log odds ratios for binary 





Appendix 12. MR-Egger test of directional pleiotropy among ever smokers for cotinine (p 
< 5x10-8). 
 Ever smokers  Current smokers 
Outcome Intercept 95% CI p-value  Intercept 95% CI p-value 
BMI -0.06 -2.85, 2.73 0.967  0.21 -9.34, 9.75 0.966 
COPD 0.67 -6.34, 7.67 0.852  1.00 -8.53, 10.53 0.837 
FEV-1 -0.01 -0.34, 0.32 0.961  0.00 -0.64, 0.65 0.993 
FVC -0.01 -0.10, 0.08 0.899  0.01 -0.28, 0.30 0.942 
CHD -0.05 -0.74, 0.65 0.895  -0.12 -2.04, 1.80 0.904 
Heart Rate 0.35 -0.91, 1.60 0.588  0.58 -1.83, 2.99 0.638 
Note: Cotinine (5x10-8) refers to MR analysis in which cotinine SNPs were selected for 
inclusion based on a threshold of p < 5×10-8. BMI = body mass index; COPD = chronic 
obstructive pulmonary disease; FEV-1 = forced expiratory volume in 1 second; FVC = 




Appendix 13. Univariable and multivariable Mendelian randomisation Egger analysis of 
cotinine and smoking heaviness (cigarettes per day) and smoking-related health 






Appendix 14. Univariable and multivariable Mendelian randomisation Egger analysis of 
cotinine and smoking heaviness (cigarettes per day) and smoking-related health 






Appendix 15. Multivariable Mendelian randomisation analysis of cotinine and cigarettes 
per day (CPD) and smoking-related health outcomes among ever, current, former and 
never smokers (n = 46 SNPs). 
  Cotinine  CPD  
Outcome Smoking  
Status 
Effect 95% CI p-value   Effect 95% CI p-value Q 
BMI Ever -0.02 -0.34, 0.30 0.897  0.10 -0.56, 0.75 0.770 251.33 
 Current -0.01 -0.45, 0.43 0.964  -1.61 -2.52, -0.71 <0.001 103.67 
 Former 0.01 -0.31, 0.33 0.952  0.59 -0.07, 1.26 0.077 201.42 
 Never -0.07 -0.35, 0.21 0.612  0.97 0.39, 1.54 0.001 225.98 
COPD Ever 0.17 -0.20, 0.54 0.357  2.23 1.48, 2.98 <0.001 44.81 
 Current -0.22 -0.80, 0.35 0.439  3.95 2.79, 5.12 <0.001 33.67 
 Former 0.29 -0.18, 0.77 0.220  1.46 0.49, 2.44 0.004 52.94 
 Never 0.36 -0.30, 1.03 0.277  -1.69 -3.05, -0.33 0.016 39.79 
FEV-1 Ever -0.02 -0.06, 0.02 0.429  -0.22 -0.30, -0.14 <0.001 100.76 
 Current -0.05 -0.13, 0.03 0.201  -0.35 -0.51, -0.19 <0.001 75.89 
 Former 0.00 -0.04, 0.04 0.848  -0.19 -0.27, -0.10 <0.001 92.31 
 Never 0.01 -0.03, 0.04 0.733  -0.04 -0.11, 0.03 0.275 92.47 
FVC Ever 0.00 -0.06, 0.05 0.907  -0.21 -0.32, -0.10 <0.001 121.64 
 Current -0.05 -0.15, 0.05 0.302  -0.25 -0.45, -0.05 0.014 78.73 
 Former 0.01 -0.05, 0.06 0.779  -0.20 -0.31, -0.08 0.001 110.34 
 Never 0.01 -0.04, 0.05 0.802  -0.05 -0.15, 0.04 0.270 114.94 
CHD Ever -0.05 -0.19, 0.08 0.431  0.36 0.08, 0.63 0.013 100.41 
 Current 0.01 -0.20, 0.22 0.947  0.29 -0.14, 0.72 0.177 53.53 
 Former -0.07 -0.22, 0.08 0.360  0.37 0.06, 0.69 0.021 99.73 
 Never -0.13 -0.24, -0.02 0.023  0.09 -0.14, 0.31 0.437 44.97 
Heart  Ever 0.28 -0.25, 0.81 0.289  1.71 0.64, 2.79 0.002 104.04 
rate Current 1.04 0.22, 1.85 0.014  3.08 1.41, 4.74 <0.001 51.07 
 Former -0.04 -0.61, 0.53 0.890  1.31 0.14, 2.48 0.029 103.47 
 Never 0.03 -0.53, 0.59 0.917  -0.09 -1.24, 1.06 0.875 158.66 
 
Note: A p-threshold of 5×10-8 was used to determine the single nucleotide 
polymorphisms (SNPs) associated with cigarettes per day (CPD) and cotinine. BMI = body 
mass index; COPD = chronic obstructive pulmonary disease; FEV-1 = forced expiratory 
volume in 1 second; FVC = forced vital capacity; CHD = chronic heart disease. Effects are 
betas for continuous variables (BMI, FEV-1, FVC and HR) and log odds ratios for binary 
outcomes (COPD and CHD). The Cochran Q statistic tests for instrument strength and 






Appendix 16. Contraindications for nicotine or placebo use. 




Diagnosed and medicated asthma attacks 
Stomach ulcers 
Liver or kidney disease 
Overactive thyroid gland 
Diabetes 
Prone to allergic reactions*  
Prone to seizures 
Taking medication (excluding the contraceptive pill) 
